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1.1. Vascular remodelling 
The vascular system is not a static vessel’s network, but rather constantly changing to adapt 
to the body’s and tissue’s needs and maintain vascular homeostasis. In response to short-
term alterations in hemodynamic forces exerted by the flowing blood or to humoral factors, 
especially oxygen, vessels adjust blood flow and flow distribution, regulating lumen 
diameters through vasoconstriction or vasodilation. However, when these alterations 
become longstanding, the vasculature responds by modifying its basal structure, changing 
the vascular network through the generation (angiogenesis) or elimination of vessels 
(pruning), and/or by remodelling the vessel’s wall (Zakrzewicz, Secomb et al. 2002).  
Vascular remodelling processes can result in increased (outward remodelling) or decreased 
lumen diameters (inward remodelling) and can develop in both physiological and 
pathological situations.  Involved mechanisms are fibrosis, hyperplasia of the intima and 
media layers, changes in the extracellular matrix (ECM) and in case of pathological 
remodelling, endothelial dysfunction and/or arterial calcification (van Varik, Rennenberg et 
al. 2012). By switching to a synthetic phenotype, smooth muscle cells (SMCs) play a crucial 
role in some of these mechanisms. By migrating and proliferating in the intima they 
contribute to intimal thickening and by releasing elastolytic enzymes and synthesizing new 
matrix components, to the restructuring of the ECM (Doran, Meller et al. 2008, van Varik, 
Rennenberg et al. 2012). 
In pathological remodelling, damage of the endothelium (endothelial dysfunction) occurring 
during angioplasty or the formation of atherosclerotic plaques often derive in inward 
remodelling that can result in stenosis of the vessel followed by ischemia in the downstream 
tissues (Patel, Waltham et al. 2010). Interestingly, to counterbalance ischemic damage in 
obstructive vascular diseases, vasculature spontaneously develops a physiological adaptive 
response: the outward remodelling of collateral arteries or arteriogenesis. 
Arteriogenesis happens near the obstruction site and defines the growth of arterial 
anastomosis, or collateral arteries, bypassing the obstructed artery. The redirected blood 
from a feeding artery into the collaterals increases the hemodynamic forces that drive their 
development into physiological bypasses. Grown collateral arteries can indeed restore 30 to 
40 % of the blood perfusion (Schaper 2009). Hence, therapeutic arteriogenesis represents 
the only option to mitigate ischemic symptoms of an obstructed artery.  
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To better understand arteriogenic remodelling, a basic knowledge of the structure and 
function of an artery wall is required and will be introduced next. 
1.1.1. Artery wall 
Vessels are composed of up to three different tissue layers or tunics, that from the vessel 
lumen to the outside are called tunica intima, media and adventitia (Figure 1.1). While 
capillaries are composed of a tunica intima solely, arteries and veins possess all three layers.  
Figure 1.1: Schematic representation of an artery wall 
Artery wall composed of the three tunics: intima, media and adventitia. The intima is formed usually 
by a single-cell lining of endothelial cells (ECs) and a basement membrane underneath. The media 
is composed of several layers of smooth muscle cells (SMCs) embedded in elastin sheets with 
collagen fibers and thin layers of proteoglycan-rich extracellular matrix (ECM). The adventitia is 
composed of fibroblasts in collagen-rich ECM. The interna elastic lamina (IEL) and the externa 
elastic lamina (EEL) separate the intima from the media and the media from the adventitia, 
respectively. Modified from (Hammes 2015). 
The intima, or endothelium, is a single-cell lining of endothelial cells (ECs) covering the 
internal vessel surface, with a basement membrane underneath, constituted by connective 
tissue and elastin and collagen fibers. The tunica media is formed by one or more concentric 
layers of SMCs supported by elastin sheets with collagen fibers and thin layers of 
proteoglycan-rich ECM in-between. Finally, the outer adventitia is a layer of connective 
tissue composed of collagen-rich ECM and fibroblasts that holds the vessel in the tissue 
surrounding. In conductive arteries, between the intima and the media and between the 
media and the adventitia are located the internal and external elastic laminae (IEL and EEL), 





ECs not only act as a transport barrier between the blood and the rest of the vessel, they 
regulate the equilibrium between thrombosis and haemostasis by separating their 
anticoagulant luminal surface with the strongly thrombogenic macromolecules of the 
basement membrane underneath (Félétou 2011). ECs also exert important functions in the 
control of lumen diameter, leukocytes trafficking and wound healing (Félétou 2011).  
Due to blood flow, ECs are exposed to hemodynamical forces, one perpendicular to the wall 
- the blood pressure - and the other being parallel to the wall, and representing a frictional 
force at the surface of the endothelium, the fluid shear stress (FSS) (Davies 1995). Changes 
in FSS are sensed by ECs and are mechanotransduced via activation of cell membrane 
proteins, mechanosensitive ion channels, focal adhesion and integrins, G-protein linked 
receptors and/or mitogen-activated protein kinase (MAPK) signalling (Davies 1995). One 
of the most important physiological consequences of FSS changes sensed by ECs is the 
regulation of lumen diameter by the secretion of relaxing and contractile factors acting on 
the SMC layer underneath (Davies 1995). However, in response to long-term changes in 
FSS the endothelium initiates arterial remodelling processes (Resnick, Yahav et al. 2003). 
Hence, while decreased blood flow and FSS lead to inward remodelling, increased flow and 
FSS results in enlargement of the lumen diameters as happens during arteriogenesis 
(Resnick, Yahav et al. 2003, Schaper and Scholz 2003). 
 SMCs 
The principal function of differentiated SMCs is the regulation of lumen diameter and blood 
flow through vasoconstriction and vasodilation, in part in response to endothelial-released 
relaxing and contracting factors, or by sensing circumferential wall stress (CWS) (Jacobsen 
and Holstein-Rathlou 2012). CWS is directly proportional to the intravascular pressure and 
inversely proportional to wall thickness. Long-term changes in CWS can also induce 
vascular remodelling processes to preserve vascular homeostasis. To increased CWS, the 
media responds by thickening and vice versa (Jacobsen and Holstein-Rathlou 2012). SMCs 
retained plasticity allow them to dedifferentiate into a synthetic, high proliferative 
phenotype in response to a variety of environmental cues (Owens, Kumar et al. 2004). 
Proliferative SMCs are strongly involved in arterial remodelling by contributing to the 
thickening of the intima and restructuring of the ECM. Due to their pleiotropic functions, 
proliferative SMCs are targets for treatments of coronary artery disease as well as targets in 
therapeutic arteriogenesis (Grundmann, Piek et al. 2007, Stefanini and Holmes 2013) . 
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 Function of vessels wall 
The function of the vessel will determine the composition of its wall. Near the heart, elastic 
arteries are characterized by big lumen diameters and thick tunica intima with a substantial 
IEL and several sheets of SMCs layers in the tunica media. Their high elasticity helps 
stabilize blood pressure oscillations from pumping. Elastic arteries branch into muscular 
arteries, with lower percentage of elastic fibers but thicker tunica media and play an 
important role in vasoconstriction.  
Arteries branch to arterioles of around 30 µm of diameter which walls are much thinner, 
with a tunica media of one or two SMC layers. SMCs in arterioles are slightly contracted, 
leading to a basal arteriolar vasoconstriction, called vascular tone, regulated under neural 
and chemical control (Jackson 2000). Hence, arterioles are referred to as resistance vessels 
since they considerably slow down blood flow causing a rise in blood pressure. 
Arterioles eventually end into small capillaries. Through the thin capillary walls composed 
solely of an intima layer, gases, nutrients and metabolites are exchanged between blood and 
tissue. Finally, the less-oxygenated blood is returned to the heart from capillaries via venules 
and veins.  
1.1.2. Collateral circulation 
Arterioles occasionally end into a conductive artery without capillary branching in-between, 
building so arterio-arteriolar anastomoses. These arterioles are called collateral arteries and 
can be found in both the heart and the peripheral circulation. 
The existence of a collateral circulation is known since the 18th century (Ziegler, Distasi et 
al. 2010). Repetitively during history, cardiologists have described the existence of such 
anastomoses in the heart bypassing obstructed arteries and correlating with better outcomes. 
Due to low resolution techniques unmasking small arterioles, the origin and formation of 
these grown collateral arteries have been for long subject of debate. Were they formed de 
novo or were they growing from pre-existing arteriolar anastomoses? In the 1960’s, by using 
more sensitive techniques, Fulton and Baroldi concurrently demonstrated in post-mortem 
heart angiograms that collaterals had developed from pre-existing arteriolar connections 
(Baroldi, Mantero et al. 1956, Fulton 1963). In fact, collateral arteries are nowadays well 
characterized (Faber, Chilian et al. 2014). 
Histologic- and morphologically, there is no difference between an arteriole and a collateral 
artery at rest. Like arterioles, collaterals are composed of a tunica intima, a prominent IEL, 
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a tunica media with one or two layers of SMCs and a tunica adventitia (Scholz, 
Ziegelhoeffer et al. 2002). Their diameters vary depending on the species, in mice, they are 
usually smaller than 50 µm (Ziegler, Distasi et al. 2010). Even so, resting collateral arteries 
can be distinguished from normal arterioles in that blood enters the collaterals from the two 
anastomotic ends simultaneously and is drained from branches localized along the collateral 
length. A pulsatile collateral flow prevents haemostatic thrombosis and results in almost no 
net flow near the midpoint of the collateral. It is thought that collaterals optimize regional 
metabolic control of oxygen delivery in healthy tissues and serve as scaffolds for delivery 
of blood flow to parenchymal tissue between adjacent artery trees (Faber, Chilian et al. 
2014). 
1.1.3. Arteriogenesis 
Since the identification of arteriogenesis as a remodelling process occurring in pre-existent 
arteriolar anastomoses and differing from angiogenesis - the sprouting or splitting of pre-
existing capillaries - (Schaper, De Brabander et al. 1971), extensive research has been 
performed in the field. Several in vivo models, especially the femoral artery ligation (FAL) 
model have considerably contributed to identify underlying molecular mechanisms and 
cellular players (Limbourg, Korff et al. 2009, Schaper 2009).   
Following the obstruction of a feeding artery, a pressure gradient is established between the 
prestenotic high-pressure bed and the poststenotic low-pressure bed, leading to a rise in 
blood flow and flow velocity through the collaterals (Fig 1.2, A and B) (Pipp, Boehm et al. 
2004). As a consequence, FSS, a force proportional to the flow velocity and exerted onto 
ECs rises and is mechanotransduced by the endothelium into diverse biochemical signalling 
pathways initiating the arteriogenic process (Schaper and Scholz 2003). Collateral 
vasodilation occurs and is mediated by nitric oxide (NO), prostacyclin and endothelium-
derived hyperpolarization factor (EDHF) (Unthank, Nixon et al. 1996, Schaper and Scholz 
2003, Troidl, Troidl et al. 2009). However, since FSS is inversely proportional to the cube 
of the radius, small increases in lumen diameter due to vasodilation and arterial remodelling 
lead to a substantial drop of its value. Hence, other mechanisms contribute to further arterial 
remodelling such as an increase in CWS and the recruitment of perivascular cells (Schaper 
and Scholz 2003).  
An early FSS-induced upregulation of endothelial adhesion molecules, such as Intercellular 
adhesion molecule 1 (ICAM-1) and Vascular cell adhesion molecule 1 (VCAM-1) as well 
as vascular endothelial growth factor (VEGF-A) participate in the recruitment of leukocytes, 
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principally monocytes (Scholz, Ito et al. 2000). Besides macrophages, a role of mast cells 
which degranulate around growing collateral arteries further supports leukocytes 
recruitment and cell proliferation by releasing growth factors (GFs) and cytokines (Chillo, 
Kleinert et al. 2016). Platelets activation also mediates leukocyte recruitment by facilitating 
leukocytes adhesion to the activated endothelium (Chandraratne, von Bruehl et al. 2015). 
Monocyte chemoattractant protein 1 (MCP-1) chemotaxis gradient generated by SMCs 
upon increase in CWT and stretch further guides monocytes towards the vessel’s wall 
(Demicheva, Hecker et al. 2008) (Fig 1.2, B). 
Figure 1.2: Arteriogenesis 
A. Pre-existing collateral arteries as arterio-arteriolar anastomosis. B. In the presence of an arterial 
obstruction, the formation of a pressure gradient in the extremes of the collateral arteries establishes 
an increased blood flow from a supplying artery. Blood flow is accompanied by a rise in FSS sensed 
by the EC layer, inducing a vasodilation first, followed by recruitment of monocytes. C. Collateral 
arteries grow in diameter and length and act as physiological bypasses restoring blood perfusion of 
the downstream tissue and palliating so ischemic-damage. Modified from (Schirmer, van Nooijen 
et al. 2009). 
Macrophages and mast cells orchestrate then collateral growth by secreting GFs and matrix 
proteases, inducing proliferation of ECs and SMCs and degrading the IEL and basal 
membrane to provide room for the proliferating cells (Arras, Ito et al. 1998, Heil, 
Eitenmuller et al. 2006, Schaper 2009, Chillo, Kleinert et al. 2016). Recently, we 
demonstrate a role of vascular arginase in recruitment of M2 macrophages through the 
regulation of Icam-1 expression in collateral arteries (Lasch, Caballero-Martinez et al. 
2016). M2 macrophages localize within the adventitial space of growing collaterals where 
they might be involved in matrix rebuilding and new space formation for the growing 
collateral (Troidl, Jung et al. 2013). Depending on the species, collateral arteries can 
increase their diameter 2 to 20-fold and their tissue mass up to 50-fold. The grow in diameter 
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and in length gives mature collaterals their characteristic tortuosity (Schaper 2009) (Fig 1.2, 
C). As collateral vessels mature, SMCs re-synthesize the wall matrix building the platform 
for the grown collateral vessel. Matrix proteins also contribute to the re-differentiation of 
SMCs, that finally rearrange into circulatory layers and establish cell-to-cell contacts 
(Schaper 2009). 
1.2. Epidemiology of cardiovascular diseases (CVDs)  
1.2.1. CVDs and atherosclerosis 
Cardiovascular diseases (CVDs) constitute the major cause of mortality worldwide (WHO 
2015). Indeed, in 2015, the World Health Organisation (WHO) estimated that annually 17.7 
million people die from CVDs, representing 31 % of all global death. 
The most common disorders are coronary heart disease (CHD), cerebrovascular disease and 
peripheral artery disease (PAD), diseases affecting arteries supplying heart muscle, the brain 
or arms and legs, respectively. 
The main cause of CVDs is atherosclerosis, a chronical arterial disease characterized by 
lipid deposition and oxidation at the luminal layer of the vascular vessels that can cause the 
narrowing of the vessels to even stenosis or to thrombotic events. The disease is influenced 
by unmodified factors such as hyperlipidaemia diseases or genetic susceptibility (genetic 
history), but also by life habits such as smoking, physical inactivity, obesity, diabetes 
mellitus and hypertension (Herrington, Lacey et al. 2016).  
The severity of the symptomatology will depend on localization and sequential events of 
the plaque. The lipid deposits are phagocytosed by macrophages that transform into foam 
cells. In an advanced stage, these accumulations develop into fibroatheromas characterized 
by the disruption of the intimal structure, an enrichment in collagen-rich fibrous tissue and 
apoptosis and necrosis of the underlying macrophages and SMCs layers (Bentzon, Otsuka 
et al. 2014). The slow narrowing of a coronary artery usually leads to stable angina pectoris. 
While if the narrowing occurs in a leg artery, it generates intermittent arterial claudication 
mostly during exercise. This relatively slow reduction of the vessel lumen occurs due to the 
growth of the fibrous tissue forming the fibrotic cap or to an aberrant proliferation of SMCs 
leading to neointima hyperplasia (Bentzon, Otsuka et al. 2014). However, a more dramatic 
situation appears when the rupture of the fibrotic cap or the exposure of the highly 
haemorrhagic necrotic core leads to thrombus formation, that can suddenly partially or even 
totally obstruct the affected artery or a nearby artery (Bentzon, Otsuka et al. 2014). 
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Thrombotic obstruction of a supplying brain artery can lead to ischemic stroke, while the 
obstruction of a coronary artery can cause myocardial infarction or even heart failure. In 
PAD, thrombotic obstruction can lead to rest pain and even gangrene and amputation 
(Ziegler, Distasi et al. 2010). 
1.2.2. Current treatments for atherosclerotic-driven CVDs 
In high-income countries, mortality rates for CVDs have decreased in the last decades due 
to changes in health habits - such as smoking cessation, healthy diet and exercise activity -
and treatment improvements (Herrington, Lacey et al. 2016).  
Besides vasodilators and anti-thrombotic drug treatments, physicians have developed two 
different revascularization strategies to free obstructed arteries in CVDs: angioplasty and 
bypass surgery. Angioplasty is a nonsurgical procedure used to open an artery at the site of 
an atherosclerotic plaque, whereby a balloon with or without stent is introduced through a 
catheter and inflated at the obstructed site. Stents contribute to stabilize artery wall and the 
new generation of drug-eluding stents (DES), releasing anticoagulant or intimal growth 
inhibitors, has proven to significantly reduce the risk of thrombus formation and in-stent 
restenosis (Haas, Lloyd et al. 2012). An alternative to angioplasty is bypass surgery, usually 
preferred in patients with several atherosclerotic arteries. This technique consists in the 
implantation of vessel grafts circumventing the obstructed zone of the affected artery. The 
efficacy and safety of coronary bypass surgery and coronary angioplasty with DES 
deployment have been compared by several randomized trials, showing no clear advantages 
for the one over the other (Al Ali, Franck et al. 2014, Fanari, Weiss et al. 2015).  
However, revascularization therapies are not always recommended in patients with CHDs 
as they do not always result in clear survival benefits over medical therapy alone (Fox, 
Garcia et al. 2006). Hence, while revascularization improves survival in acute coronary 
syndromes, no prognostic benefits have been observed with coronary angioplasty in stable 
coronary artery disease usually performed to relieve symptomatic (Degen, Millenaar et al. 
2014, Al-Lamee, Thompson et al. 2018). Patients with high-procedure morbidity and 
mortality, with a non-significant coronary stenosis (with less than 50 %) or with mild or 
with no symptoms of ischemia, are usually treated with medical therapy alone (Fox, Garcia 
et al. 2006). However, all these patients may benefit from another therapeutic option, the 




1.2.3. Limitations of physiological arteriogenesis 
Atherosclerosis-driven CVDs, sometimes remain asymptomatic due to the development of 
collateral arteries into physiological bypasses. In CHDs, numerous studies demonstrate a 
protective role of good versus poor coronary collateralization (Meier, Schirmer et al. 2013). 
Patients with a good collateralization tend to have smaller infarcts, improved ventricular 
function, fewer future cardiovascular events and improved survival (Berry, Balachandran et 
al. 2007, Meier, Hemingway et al. 2012). 
Nevertheless, only a third of patients with hemodynamically significant atherosclerotic 
lesions still develop sufficiently grown coronary collaterals as to prevent signs of 
myocardial ischemia (Meier, Schirmer et al. 2013). Similarly, limitations of collateral 
growth are found in PAD patients too (Murrant 2008). Heterogeneity in the arteriogenic 
response against cardiovascular obstruction can be explained by the existence of both 
inherited and risk factors. Studies in a mice model for arteriogenesis have identified genetic 
differences between mouse strains as well as aging as factors influencing collateral density 
during embryonic development (collaterogenesis) and/or collateral growth in adulthood 
(Scholz, Ziegelhoeffer et al. 2002, Chalothorn and Faber 2010, Epstein, Lassance-Soares et 
al. 2012). Several genetic determinants have been identified in patients with CHD too, 
principally through analysis of monocytes transcriptomes (Chittenden, Sherman et al. 2006, 
Schirmer, Fledderus et al. 2008, Meier, Antonov et al. 2009, de Marchi 2014). In addition, 
factors known to induce atherosclerosis such as hypercholesterolemia, hypertension, 
hyperglycemia or obesity, could at the same time hamper collateral artery growth (de Groot, 
Pasterkamp et al. 2009).  
Besides the above-mentioned factors, arteriogenesis also displays physiological limitations. 
Typically, only 30 to 40 % of functional blood flow can be restored by grown coronary and 
peripheral collaterals, respectively (Schaper 2009). This growth arrest has been explained 
by the rapid decrease in FSS, once the diameter of the collateral lumen increases as a 
consequence of the outward remodelling (Schaper 2009). Indeed, the study of Pipp et al 
with the arteriovenous shunt model, resulting into a constant raised FSS and in an impressive 
collateral artery growth demonstrated that anatomical restraints can be transcended. Hence, 
therapeutic stimulation of collateral growth may improve the formation of a strong collateral 




1.2.4. Therapeutic arteriogenesis 
Several strategies have been followed to induce arteriogenic growth in patients 
(Hakimzadeh, Verberne et al. 2014). One has been the induction of increased shear stress 
in collaterals by means of physical exercise (Haas, Lloyd et al. 2012, Mobius-Winkler, 
Uhlemann et al. 2016). However, this kind of therapy is not suitable in patients with end-
stage obstructive arterial disease who are unable to perform exercise training. 
Another strategy has been based on the versatile role of monocytes recruited to the growing 
collaterals, fomenting vascular cell proliferation and matrix remodelling through the release 
of GFs and matrix degradation enzymes (Fung and Helisch 2012). Several compounds 
targeting monocytes recruitment and/or activation have been carried out in experimental 
settings with relative success. Despite the promising outcomes of such therapies, large 
randomized clinical trials have failed to show clear beneficial effects (Hakimzadeh, 
Verberne et al. 2014). 
SMCs have also been targets in arteriogenesis by promoting their proliferation with GFs 
such as Fibroblast growth factor 2 (FGF-2) (Yang, Deschenes et al. 1996, Rissanen, 
Markkanen et al. 2003, de Paula, Flores-Nascimento et al. 2009). While in preclinical 
studies, FGF-2 could improve arteriogenesis, in a clinical trial, the beneficial effects in CHD 
patients were limited (Simons, Annex et al. 2002). Probably the time point of FGF 
administration is likely to be critical, as expression of the FGF-receptors is induced during 
a brief time window in the early phase of arteriogenesis (Deindl, Hoefer et al. 2003). 
Besides GFs, several potassium (K+) channels have been involved in SMCs phenotypic 
modulation and proliferation. Hence, K+ channel inhibitors have been used to target SMCs 
proliferation in intima hyperplasia following angioplasty or allograft vasculopathy (Tharp, 
Wamhoff et al. 2008, Chen, Lam et al. 2013, Cidad, Novensa et al. 2014). The 
characterization of K+ channels involved in arteriogenic SMC proliferation might open new 




1.3. SMCs in arteriogenesis 
SMCs play a crucial role in arteriogenesis, not only as a principal cellular component of the 
vessel wall but also as a source of chemokines, proteolytic enzymes and new ECM 
components (Schaper 2009). To accomplish these new tasks, SMCs undergo a 
dedifferentiation process toward a synthetic/high-proliferative phenotype (Owens, Kumar 
et al. 2004). 
1.3.1. SMC phenotypic modulation  
SMCs differentiate during embryogenesis in cells with a clear function, the regulation of 
the vascular tone. SMC-specific contractile and contractile-associated proteins allow a fast 
modulation of cell morphology, that in a synchronized manner leads to changes in the lumen 
diameter of the vessels (Owens, Kumar et al. 2004). The expression regulation of SMC 
contractile genes is complex and involves both transcription factors (TFs) and 
transcriptional coactivators. SMCs contractile proteins have highly conserved CArG cis-
element in their promoter recognized by the TF serum response factor (SRF). SRF however 
is not exclusive of the SMC lineage, since it also regulates the expression of cardiac- and 
skeletal-specific genes and early response and structural genes (Mack 2011). Specificity is 
achieved by Myocardin and Myocardin related transcription factors (MRTF) A and B, a 
family of transcriptional coactivators considered as the master regulators of the SMC 
lineage. The binding of Myocardin or MRTFs and additional coactivators to SRF regulates 
the SRF-dependent transcription of important SMC effector proteins like α-smooth muscle 
actin (α-SMA), smooth muscle myosin heavy chain (SMMHC), or smooth muscle 22 alpha 
(SM22-α) among others (Yoshida, Sinha et al. 2003, Wang and Olson 2004, Wang, Wang 
et al. 2004, Mack 2011).In adulthood however, diverse stimuli such as GFs, several matrix 
components or matrix degradation products secreted during vascular growth or vascular 
injury stimulate SMC phenotypic modulation (PM) toward a proliferative phenotype 
(Owens, Kumar et al. 2004, Mack 2011). Receptor tyrosine kinase (RTK) engagement and 
subsequent activation of the MAPK signalling pathway results in the phosphorylation of 
Myocardin and its consequent release from DNA binding. SRF is then recruited to a member 
of the ternary complex factor (TCF) family that recognizes E26 transformation-specific 
(Ets) box sequences in the promoters of early growth genes. So Myocardin and TCF 




1.3.2. Factors inducing SMC proliferation in arteriogenesis 
GFs and their signalling through RTKs are strong SMCs mitogenic factors during 
arteriogenesis too. In a rabbit FAL model, Deindl et al. reported a strong expression of 
fibroblast growth factor receptor 1 (FGFR-1) in growing collateral arteries as early as 3h 
after FAL, mostly restricted to SMCs. Moreover, treatment with polyanethole-sulfonic acid 
(PAS), that blocks the binding of FGFR-1 with fibroblast growth factors (FGFs), resulted 
in poorer collateral artery growth (Deindl, Hoefer et al. 2003).  
FGF-2 is the most relevant FGF in SMC proliferation. Monocytes, which adhere to the 
activated endothelium as early as 12h post ligation, strongly express FGF-2 (Arras, Ito et al. 
1998, Scholz, Ito et al. 2000, Deindl, Hoefer et al. 2003). Mast cells are another source of 
FGF-2 as well as of platelet-derived growth factor ß (PDGF-BB), another strong SMC-
mitogenic GF (Chillo, Kleinert et al. 2016). Consistently, application of FGF-2 following 
coronary artery stenosis boosted collateral artery growth in the canine heart and resulted in 
higher blood flow recovery after FAL (Lazarous, Scheinowitz et al. 1995, Yang, Deschenes 
et al. 1996). Interestingly, the combined administration of FGF-2 and PDGF-BB as well as 
transfer of both genes has been beneficial in promoting angiogenesis and arteriogenesis in 
the FAL model (Cao, Brakenhielm et al. 2003, de Paula, Flores-Nascimento et al. 2009). 
Moreover, FGF-2 induces platelet-derived growth factor receptor PDGFR-α and -ß 
expression and together enhance stabilization of collateral arteries (Kano, Morishita et al. 
2005). Nonetheless, since deletion of FGF-2 in mice did not affect collateral growth in the 
FAL model (Sullivan, Doetschman et al. 2002), other FGFs might have similar functions, 
such as FGF-4 (Rissanen, Markkanen et al. 2003).  
The relevance of RTK engagement and MAPK activation during arteriogenesis is reflected 
by the upregulation and activation of the MAPK members extracellular-signal regulated 
kinases 1 and 2 (ERK-1 and -2) (Eitenmuller, Volger et al. 2006). ERK activation in turn 
leads to an upregulation of the pro-arteriogenic TF early growth response 1 (EGR-1) 
expression. The role of EGR-1 in arteriogenesis has been studied in Egr1 knockout mice 
undergoing FAL. Interestingly, EGR-1 deficiency leads to lower hind-limb perfusion 
recovery and poorer arteriogenesis, partially due to an inhibition of SMCs PM and 
proliferation (Pagel, Ziegelhoeffer et al. 2012). 
Besides GFs, the matrix surrounding SMCs also regulates SMC phenotype. Hence, the 
proteolytic cleavage of the IEL and the basement membrane by matrix metalloproteinases 
(MMPs), release collagen I, fibronectin (FN) and elastin-derived peptides, which are 
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inducers of SMC PM and proliferation (Mochizuki, Brassart et al. 2002, Schaper 2009, 
Mack 2011). Collagen I and FN signal through integrin receptors and the nonreceptor 
tyrosine kinase focal adhesion kinase (FAK) leading to activation of the MAPK and Rho A 
signalling pathways regulating migration and proliferation of collateral SMCs (Eitenmuller, 
Volger et al. 2006, Mack 2011).  
1.3.3. SMCs and matrix remodelling 
In early arteriogenesis, SMCs, together with recruited monocytes, secrete MMPs and 
contribute to the disruption of the basement membrane that facilitate their migration and 
proliferation, as well as the fragmentation of the IEL that enable the vascular wall to expand 
and enlarge (Cai, Kocsis et al. 2004). As the collateral vessels grow and the final diameter 
is attained, SMCs reconstitute the IEL producing ECM, collagen and elastin (Schaper and 
Scholz 2003). Moreover, collagen IV and laminin regulate SMCs differentiation towards a 
contractile phenotype (Mack 2011). 
1.4. K+ channels and cell proliferation 
SMC PM and proliferation have not only been correlated with changes in the expression of 
contractile proteins and early growth genes, but also with changes in the composition of K+ 
channels (Cidad, Moreno-Dominguez et al. 2010). Moreover, in vivo and in vitro blockade 
of several K+ channels inhibit SMC proliferation (see below).  
K+ channels are transmembrane proteins that specifically conduct K+ ions across the 
membrane down their electrochemical gradient. They play an important role in cellular 
processes such as cell proliferation, cell volume regulation, hormone secretion and 
formation of action potentials in excitable cells (MacKinnon 2003).  
1.4.1. Membrane potential 
Due to their hydrophobic interior, cell membranes are non-permeable to ions. Through ion 
channels and ion pumps, cells control the permeation of the membrane to each type of ions 
and create ion gradients across it. This way, cells generate in an energy invested process a 
voltage called membrane potential (MP), that facilitates the transport of nutrients and 
proteins or generates electrical driving forces for the movement of ions, crucial e.g. during 
action potentials in excitable cells (Wright 2004).  
While K+ ions are concentrated in the interior of the cell, in the extracellular space are more 
abundant Na+, Cl- and Ca2+ ions. The membrane is relatively permeable to K+ ions and 
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almost no permeable to Cl- and Na+ ions. The high membrane permeability to K+ which 
leads to the constant efflux of positive charges through them, strongly influence the MP 
which is near the equilibrium potential for K+, -84 mV (Wright 2004). Permeability is 
conferred by the amount of leakage channels expressed by the cell, a type of channels 
characterized by being always open.  
Besides leakage channels, there are other channels that can be in a closed or opened state, 
the voltage- and ligands-gated ion channels. Gating of these channels can change very 
quickly the MP through the movement of ions towards their electro-chemical gradients. For 
example, an influx of Ca2+ or Na+ leads to depolarisation of the membrane while K+ ions 
efflux through K+ channels leads to membrane hyperpolarisation.  
1.4.2. Structure and types of K+ channels 
The structure of K+ channels can be divided in two parts: a pore-forming structure, 
responsible for the transportation of K+ ions, and a regulatory part which senses diverse 
stimuli and regulate the pore-forming structure.  
The pore-forming structure is a tetrameric structure of four identical protein subunits, called 
α-subunits. Depending on the K+ channel type, this α-subunit is a transmembrane protein 
containing two, four or six α-helices, that arrange around the central ion-conducting pore 
(Kuang, Purhonen et al. 2015). All identified K+ channels belong to a unique protein family, 
that conserve a segment in their protein sequence called K+ signature sequence, TVGYG. 
This segment constitutes a structural element called selectivity filter (SF), responsible for 
the discrimination between K+ and Na+ ions, allowing only the transportation of K+ ions 
with a selectivity over Na+ of more than 1000. Furthermore, K+ ions are conducted very 
efficiently at rates approaching the diffusion limit (MacKinnon 2003, Kuang, Purhonen et 
al. 2015). 
Ion flux rates through the channels are tightly regulated by gating and/or inactivation of the 
pore-forming structure. There are mainly two mechanisms of K+ channel gating: by voltage 
or by ligand binding. Voltage-gated K+ channels (KV) are opened by energetically coupling 
changes in the membrane electric field with a conformational change in a voltage sensor 
domain of the channel (MacKinnon 2003). The other K+ channels are ligand opened, by 
which opening of the pore is energetically coupled to the binding of a ligand. This ligand 
can be an ion, phospholipids or a binding protein in inwardly rectifying K+ channels (Kir); 
ions, pH, lipids and regulatory proteins in tandem pore domain K+ channels (K2P) or cAMP, 
Ca2+ and NADP in ligand-activated K+ channels (Kligand) (Kuang, Purhonen et al. 2015). 
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K+ channel gating is also modulated by auxiliary subunits that form heteromultimeric 
complexes with Kv α-subunits. Auxiliary subunits also regulate channel assembly and exit 
from the endoplasmic reticulum (ER) and trafficking to and from the cell membrane (Pongs 
and Schwarz 2010). 
1.4.3. Mechanisms of K+ channel-mediated cell proliferation 
One of the most important functions assigned to K+ channels is the regulation of cell cycle 
progression and cell proliferation. Hence, blockade of K+ channels with broad spectrum-
blockers inhibits cell proliferation. Moreover, expression or activity of several K+ channels 
change during cell cycle (Blackiston, McLaughlin et al. 2009). 
In eukaryotes, cell division can be divided in four different phases: a first growth phase 
(G1), a DNA replication phase (S), a second growth phase (G2) and a cell division phase or 
mitosis (M). Correct progression through cell cycle is controlled by several mechanisms to 
assure completion of one phase before proceeding to the next. One of these mechanisms 
controls changes in MP during transitions: depolarization towards G0/G1 and membrane 
hyperpolarizations during the G1/S and G2/M transitions (Pardo 2004, Urrego, Tomczak et 
al. 2014). K+ channels gating results in efflux of K+ ions and creates an electrical gradient 
that derives in membrane hyperpolarization. Membrane hyperpolarization in turn regulates 
cell cycle progression through 3 different mechanisms. Through activation of Cl- ion 
channels involved in cell volume regulation, through changes in membrane potential 
themselves and through the generation of a driving-force for Ca2+ entry. Ca2+ ions act as 
second messengers and activate important signalling pathways involved in cell division (see 
Fig 1.3) (Cartin, Lounsbury et al. 2000, Urrego, Tomczak et al. 2014). 
Interestingly, as shown in Figure 1.3, besides K+-current dependent mechanisms, non-
canonical, permeation-independent mechanisms of cell progression have been described for 
several K+ channels. It has been shown that not only broad-spectrum K+ channels inhibitors 
but also channel specific blockers can inhibit cell proliferation. This denotes that specific 
channels and not only a general change in K+ current are involved in cell-cycle-regulation 
through specific actions of the channel itself. Indeed, the channels éther-a-gogo (eag), 
voltage-gated K+ channels KV1.10 and KV1.3 and the Ca2+-gated K+ channel KCa3.1, among 
others, are still able to influence proliferation even in the absence of K+ permeation (Pardo 
2004, Millership, Devor et al. 2011, Cidad, Jimenez-Perez et al. 2012). K+ channels may act 
as scaffold proteins and activate signalling pathways following channel gating. Moreover, 
K+ channel activity is highly regulated by intracellular auxiliary subunits that act as scaffold 
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proteins too (Sole, Roura-Ferrer et al. 2009, Pongs and Schwarz 2010). The signalling 
cascades and interaction partners involved are now starting to be identified. 
Figure 1.3: K+ channels and their mechanisms of cell proliferation 
K+ channels have different mechanisms to regulate cell cycle progression and cell proliferation. 
Besides permeation-dependent mechanisms, K+ channels can act as scaffold proteins activating 
downstream signalling cascades. Modified from (Urrego, Tomczak et al. 2014). 
1.4.4. K+ channels in SMC proliferation 
Several in vitro and in vivo studies report changes in ion transport and ion channel 
configuration during SMC PM and proliferation in different contexts (Neylon, Lang et al. 
1999, Miguel-Velado, Moreno-Dominguez et al. 2005, Beech and Cheong 2006, Beech 
2007, Cidad, Moreno-Dominguez et al. 2010). This evidence a function of several K+ 
channels in the induction and control of the cell division in SMCs too.  
While the expression of channels involved in the SMC contraction such as Ca2+-gated K+ 
channel KCa1.1 (BKCa), CaV1.2, and several KV1 channels is repressed in proliferating 
SMCs, two K+ channels, the voltage-gated K+ channel KV1.3 and the Ca2+-gated K+ channel 
KCa3.1, among others, have been repeatedly found upregulated in proliferative SMCs in 
vitro and in neointima hyperplasia models. Moreover, their specific blockade could hinder 




 Role of KV1.3 in SMC proliferation 
In SMCs, an upregulation of KV1.3 has been detected in cultured SMCs compared to fresh 
isolated ones and in in vivo pathological situations characterized by endothelial dysfunction 
and neointima hyperplasia (Cidad, Moreno-Dominguez et al. 2010, Cheong, Li et al. 2011). 
Furthermore, small interference RNA (siRNA)-mediated KV1.3 downregulation as well as 
treatment with two specific KV1.3 channel blockers, Margatoxin and PAP-1 (Garcia-Calvo, 
Leonard et al. 1993, Schmitz, Sankaranarayanan et al. 2005), resulted in an inhibition of 
SMC migration and proliferation in vitro (Cidad, Moreno-Dominguez et al. 2010). 
Contrarily, transfection of human embryonic kidney cells (HEK-293) with KV1.3 together 
with the auxiliary subunit KVß2, resulted in an increased proliferation that was reverted by 
treatment with Margatoxin or PAP-1 (Cidad, Jimenez-Perez et al. 2012).  
In cultured organ segments of saphenous veins with induced intima hyperplasia, KV1.3 
blockade with Margatoxin or correolide compound C, another KV1.3-specific channel 
blocker (Felix, Bugianesi et al. 1999), reduced SMC proliferation too (Cheong, Li et al. 
2011).  
The mechanisms of KV1.3-mediated cell proliferation are still unclear. KV1.3 blockade with 
Margatoxin or correolide compound C resulted in partial inhibition of K+ efflux in 
depolarized proliferating SMCs and to a significant suppression of Ca2+ entry under 
blockade with Margatoxin. So, KV1.3-mediated hyperpolarization could influence Ca2+ 
entry and Ca2+-dependent gene expression in proliferative SMCs (Cheong, Li et al. 2011). 
In contrast, Cidad et al. observed that Margatoxin-mediated inhibition of SMC proliferation 
could not be reverted by high concentrations of K+ in the medium and hypothesized that 
KV1.3 could exert its role through permeation-independent mechanisms and independent on 
Ca2+ entry (Cidad, Moreno-Dominguez et al. 2010). Indeed, a non-conducting voltage-
sensitive KV1.3 channel mutant showed similar pro-proliferative effects than the wild type 
KV1.3 channel in transfection experiments on HEK-293 cells. Hence, a conformational 
change of the channel driven by membrane depolarization was sufficient to activate 




 The role of KCa3.1 in SMC proliferation 
Similar to KV1.3, several in vitro reports stated an upregulation of KCa3.1 in SMC of 
different origins too, following stimulation with RTK ligands such as epidermal growth 
factor (EGF), PDGF-BB or tumor growth factor-ß (TGF-ß) (Neylon, Lang et al. 1999, 
Kohler, Wulff et al. 2003, Si, Grgic et al. 2006, Tharp, Wamhoff et al. 2006, Shepherd, 
Duffy et al. 2007, Toyama, Wulff et al. 2008, Bi, Toyama et al. 2013). In vivo, KCa3.1 
expression is induced in several models of intima hyperplasia (Kohler, Wulff et al. 2003, 
Tharp, Wamhoff et al. 2008) . 
The role of the KCa3.1 channel in SMC proliferation has also been evidenced through 
channel blockade with the specific blocker TRAM-34 (Wulff, Miller et al. 2000). Bi et al 
demonstrated that PDGF-BB-induced SMC proliferation in vitro is mediated by KCa3.1 
since treatment with TRAM-34 or downregulation of the channel via siRNA reverted this 
effect (Bi, Toyama et al. 2013). Moreover, in vivo blockade of KCa3.1 with TRAM-34 could 
reduce neointima hyperplasia in a balloon catheter injury rat model of the carotid artery 
(Kohler, Wulff et al. 2003). Similarly, in a porcine model of postangioplasty restenosis, 
coating the balloon with TRAM-34 prevented KCa3.1 induction and significantly reduced 
intima hyperplasia 14 and 28 days post-surgery (Tharp, Wamhoff et al. 2008). Toyama et 
al also reported an inhibition of SMCs proliferation in Apolipoprotein E knockout mice, a 
genetic model of atherosclerosis, when mice were treated with TRAM-34 (Toyama, Wulff 
et al. 2008). 
KCa3.1-mediated SMC proliferation seems to involve Ca2+-mediated signalling but also 
non-permeation mechanisms. Hence, KCa3.1-blockade by TRAM-34 inhibits PDGF-BB 
induced rise in i[Ca2+], responsible for the expression of cyclins involved in cell 
proliferation and Ca2+-dependent TFs, such as cAMP response element-binding protein 
(CREB) (Bi, Toyama et al. 2013). In contrast, the transfection of HEK-293 cells with a 
KCa3.1 pore-mutant, unable neither to conduct K+ ions nor to promote Ca2+ entry, increased 
cell proliferation with respect to mock-transfected cells. Intriguingly, transfection with a 
non-functional trafficking mutant localized in a ring surrounding the nucleus also increased 
proliferation. Hence, not either its localization at the cell membrane was essential for its cell 
proliferation induction (Millership, Devor et al. 2011).  
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1.5. The voltage-gated K+ channel KV1.3 
The voltage-gated K+ channels (KV) constitute a family of K+ ion specific channels which 
are activated by changes in the voltage of the cell membrane, usually upon depolarization. 
It comprehends many different channels grouped in 12 subfamilies based on sequence 
homology of the hydrophobic transmembrane cores of the α-subunit (Gonzalez, Baez-Nieto 
et al. 2012). KV1.3 belongs to the delayed rectifier, shaker subfamily of KV channels 
characterized by a slow inactivation of the channel in the presence of a maintained 
membrane depolarization. KV1.3 is ubiquitously expressed in mammals and can be found 
in both excitable and non-excitable cells (Blunck and Batulan 2012).   
1.5.1. Structure and gating of Kv1.3 
As a typical KV channel, KV1.3 is composed out of four α-subunits, each having six 
transmembrane α-helices, S1-S6, connected by five linker regions. Both the amino (NH2)- 
and carboxy (COOH)-termini are located intracellularly (Fig 1.4, A). The subunits 
tetramerize so that the α-helices S5-S6 of all the monomers co-assemble to the center of the 
structure to form the ion-conducting pore. Surrounding the central pore rearranged the 
voltage-sensing domains (VSD), each formed by the S1-S4 segments (Fig 1.4, B). On the 
extracellular entrance of the pore, the S5-S6 linker forms a membrane re-entering small 
helix (P-loop) that contains the selectivity filter (SF) (Fig 1.4, C) (Blunck and Batulan 
2012). K+ permeation through the channel is controlled by the SF gate and the S6 bundle 
crossing (BC) gate (Fig 1.4, C). Upon depolarization of the membrane potential, the VSD 
undergoes conformational change, which leads to the widening of the BC gate. In KV1.3, 
with a C-type inactivation, opening of the pore subsequently triggers closing of the SF gate 
preventing ions from passing through (Blunck and Batulan 2012). 
Other functional domains in KV1.3 channel have been described. The intracellular T1 
domain located at the NH2-terminus is responsible for its interaction with KVß-subunits that 
regulate channel gating (McCormack, McCormack et al. 1999, Gulbis, Zhou et al. 2000). 
Additionally, the tertiary topology of the COOH-terminus is responsible for the interaction 
with the auxiliary subunit potassium voltage-gated channel subfamily E member 4 
(KCNE4) that regulates KV1.3 endoplasmic reticulum (ER) retention and trafficking to the 




Figure 1.4: Structure of voltage-gated K+ channels 
A. Cartoon of an KV channel α-subunit composed of 6 transmembrane segments (S1-S6) and one P-
loop. In grey are represented the voltage-sensing domains (S1-S4) and in blue the 2 pore-forming 
domains (S5-S6). The amino and carboxy termini are intracellular. B. 3D structure of the KV1.2 
channel, viewed from the extracellular site. Four α-subunits forms a typical KV channel. One subunit 
is red. C. Side view of the pore region formed by the segments S5, S6 and the P-loop. The selectivity 
filter (SF) allows the passage of K+ ions. The bundle crossing (BC) of the S6 helices (BC gate) forms 
a barrier K+ ions. Taken from (Labro and Snyders 2012). 
1.5.2. Functions of KV1.3 
Its role as inducer of cell division has been reported in many different cell types pointing to 
a conserved role of the channel in the process. Kv1.3 role in cell proliferation was first 
observed in T cells where it plays an important role in T-cell-receptor signalling-mediated 
proliferation (Cahalan and Chandy 2009). By now its mitogenic role has been observed in 
several other cell types such as oligodendrocytes (Chittajallu, Chen et al. 2002), microglia 
(Kotecha and Schlichter 1999), ECs (Erdogan, Schaefer et al. 2005) and SMCs (Cidad, 
Moreno-Dominguez et al. 2010, Cheong, Li et al. 2011, Cidad, Jimenez-Perez et al. 2012, 
Tian, Yue et al. 2013, Cidad, Novensa et al. 2014). 
The characterization of KV1.3 knockout mice has revealed a role of KV1.3 in olfactory 
sensing, insulin metabolism and control of body weight. KV1.3 plays a key role in the 
establishment of a membrane potential in the neurons of the olfactory bulb. It also 
participates in the structure of the olfactory bulb glomeruli and modulates the capacity to 
detect odorant molecules by changing the expression of scaffold proteins involved in 
downstream signalling pathways (Fadool, Tucker et al. 2004). Interestingly, channel activity 
is inhibited by insulin through activation of RTKs (Fadool, Tucker et al. 2000). KV1.3 
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deletion in mice subjected to high-fat diet results in lower body weight but normal basal 
activity. Since the channel is expressed in the hypothalamus, a region of the brain regulated 
by insulin that control adaptive thermogenesis, a role of KV1.3 in thermogenesis has been 
postulated (Xu, Koni et al. 2003). 
Besides its localization at the cell membrane, KV1.3 has also been localized at the 
mitochondrial membrane, where it plays an important role in the regulation of the 
mitochondrial membrane potential ΔΨm. Inhibition of the channel through membrane-
permeable specific blockers (Psora-4, PAP-1, correolide compound C) or through binding 
to Bcl-2-associated X protein (Bax) leads to hyperpolarisation of the membrane with 
subsequent radical oxygen species (ROS) production, cytochrome c release and finally 
apoptosis (Gulbins, Sassi et al. 2010, Leanza, Henry et al. 2012). Hence, KV1.3 channel has 
been identified as a target for anti-tumour therapies (Leanza, Venturini et al. 2015). 
1.6. The Ca2+-gated K+ channel KCa3.1 
Ca2+-gated K+ channels (KCa) are a family of K+ channels activated by a rise in intracellular 
Ca2+ concentrations (i[Ca2+]). Their activation leads to K+ efflux and to repolarization or 
even hyperpolarization of the membrane. There are three subfamilies of Ca2+-gated K+ 
channels: big conductance KCa1.1 channel, also known as BKCa, intermediate conductance 
KCa3.1 channel (or IKCa), and small conductance SKCa channels KCa2.1, KCa2.2 and KCa2.3. 
The intermediate conductance KCa3.1 channel is expressed in both excitable and non-
excitable cells.  
1.6.1. Structure and gating of KCa3.1 
KCa3.1 is composed out of four α-subunits rearranged into a central pore. Each α-subunits 
is a transmembrane protein with six transmembrane domains (Fig 1.5). The selectivity filter 
and the central pore are formed by the extracellular loop between the fifth and sixth 
transmembrane domains. Both the NH2- and COOH-termini are intracellular. Gating of the 
channel is induced by a rise in i[Ca2+], which is sensed by the binding of Calmodulin (CaM) 
to the Calmodulin binding domain (CaMBD) at the COOH-terminus of the channel. The 
COOH-terminus localizes just after the channel pore and it interacts with CaM even in the 
absence of Ca2+. The Ca2+-dependent binding of CaM to the channel involves the 
CaMBD2A and CaMBD2B (Morales, Garneau et al. 2013). Each α-subunit must interact 
with CaM to get activated (Gueguinou, Chantome et al. 2014).  
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Figure 1.5: Structure of the Ca2+-gated K+ channel KCa3.1 
Cartoon of the KCa3.1 α-subunit, organized in six transmembrane segments (S1-S6) plus a pore 
region between S5 and S6. The channel Ca2+ sensitivity is conferred by Calmodulin (CaM), with the 
CaM C-lobe constitutively bound to the CaM binding domain 1 (CaMBD1). The Ca2+-dependent 
binding of CaM to the channel also involves the CaMBD2A and CaMBD2B. Modified from 
(Morales, Garneau et al. 2013). 
The exact molecular mechanism of KCa3.1 gating through Ca2+-CaM is not well known and 
there is no high-resolution 3D-structure crystallized for KCa3.1 yet. However, structural 
information from the crystallization of the rat KCa2.2–CaMBD in the presence of Ca2+ led 
to a proposed model where Ca2+ binding to CaM induces its conformational change that 
drives the interaction of the NH2-terminus of a subunit with the COOH-terminus of an 
adjacent channel subunit. This, in turn, induces a conformational change in the S6 
transmembrane segments leading finally to the opening of the channel pore (Fig 1.6) 
(Morales, Garneau et al. 2013).  
Figure 1.6: Model of KCa3.1 channel gating 
CaM-binding to the COOH-terminus confers channel sensitivity to Ca2+. Ca2+-binding to CaM 
induces a conformational change in the S6 segment leading to the opening of the pore. Adapted from 
(Ledoux, Werner et al. 2006) 
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1.6.2. Functions of KCa3.1 channel  
As well as KV1.3, KCa3.1 has been involved in induction of cell proliferation not only in 
SMCs (Kohler, Wulff et al. 2003, Shepherd, Duffy et al. 2007, Tharp, Wamhoff et al. 2008, 
Su, Wang et al. 2011, Bi, Toyama et al. 2013) but also in ECs, playing a role in angiogenesis 
(Grgic, Eichler et al. 2005, Yang, Li et al. 2013), in T cells (Ghanshani, Wulff et al. 2000), 
in cancer cells (Wang, Shen et al. 2007, Lallet-Daher, Roudbaraki et al. 2009, Yang, Liu et 
al. 2013) and in fibroblasts (Grgic, Kiss et al. 2009). 
Besides its effect on cell proliferation, KCa3.1 plays an important role in endothelium-
derived hyperpolarization factor (EDHF)-mediated vasodilation. As already mentioned, the 
endothelium regulates vascular tone by releasing vasodilator factors or transmitting 
electrical signals that induce the relaxation of the SMCs underneath. EDHF-mediated 
vasodilation is characterized by a hyperpolarization of the SMC membrane preceding 
relaxation. It is well accepted that EDHF depends to a large extent on the activation of the 
endothelial KCa2.3 and KCa3.1 K+ channels (Eichler, Wibawa et al. 2003, Feletou 2011). 
Even though both channels play a role in the process, their function cannot be substituted 
by each other. Indeed, KCa3.1 deficient mice have impaired EDHF-mediated vasodilation 
and increased blood pressure compare to wild type mice (Si, Heyken et al. 2006). The 
different subcellular localization could explain their specific functions. While KCa2.3 is 
confined in endothelial gap junctions, KCa3.1 localizes in endothelial projections towards 
the IEL, often associated with myoendothelial junctions (MEJ) (Feletou 2011). Following 
KCa3.1 activation, the accumulation of K+ ions in the intercellular space between ECs and 
SMCs could drive the activation of the K+-sensitive Kir2.1 channels and the Na+/K+ ATPase 
on the SMC membrane, leading to its hyperpolarization. Another explanation sustains that 
KCa3.1-mediated endothelial hyperpolarization is directly propagated to the SMC 
membrane through MEJ. This goes with the fact that both MEJ and EDHF-mediated 




1.7. Aim of the project 
SMCs play an important role in arteriogenic vascular remodelling. Besides proliferating and 
contributing to the enlargement and lengthening of collateral arteries, they secrete matrix 
degradation enzymes achieving place for migrating and new proliferating cells. Finally, they 
contribute to the synthesis of the new extracellular matrix and by differentiating into 
contractile cells to functional mature collateral arteries. Due to their pleiotropic functions, 
SMCs are an interesting target for therapeutic arteriogenesis. 
Several K+ channels have been involved in phenotypic modulation and proliferation of 
SMCs. The voltage-gated K+ channel KV1.3 and the Ca2+-gated K+ channel KCa3.1 are 
upregulated in cultured SMCs and in proliferating SMCs in in vivo models of neointima 
hyperplasia. However, their role in arteriogenesis has not been investigated so far. On the 
other hand, while several mechanisms have been described for K+ channel-mediated cell 
proliferation, it remains unclear how these channels orchestrate their mitogenic function. 
This study aimed to shed light on the role of KV1.3 and KCa3.1 in arteriogenic SMC 
proliferation focusing on the following points: 
• Characterization of KV1.3 and KCa3.1 expression and localization patterns in the 
FAL model of arteriogenesis 
• Effects of pharmacological KV1.3 and KCa3.1 channel blockade on arteriogenic 
SMCs proliferation in the FAL model 
• Role of the channels in the regulation of the RTK signalling pathway in 
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2. Materials and methods 
2.1. Materials 
Table 2.1. Consumables 
Consumable  Company 
Reaction 
tubes 
200 µl PCR tubes 
Eppendorf AG, Hamburg, 
Germany 
1.5 ml and 2 ml 
Eppendorf AG, Hamburg, 
Germany 
15 ml FALCON tubes 
Greiner Bio-One GmbH, 
Kremsmünster, Austria 
50 ml FALCON tubes 
Corning Inc., Corning, New 
York, USA 
Nunc CryoTubeTm 1.8 ml vials NuncTm, Roskilde, Denmark 
innuSPEED lysis tubes P Analytik Jena AG, Jena, Germany 
Tips 0.1-10 µl epT.I.P.S.® LoRetention 
filter tips 
Eppendorf AG, Hamburg, 
Germany 
0.1-10, 2-30, 10-100, 2-200 and 
100-1000 µl Diamond® filter tips 
Gilson Inc., Middleton, USA 
10, 100, 200, 1000 µl tips 
Eppendorf AG, Hamburg, 
Germany 
Combitips Advanced® 
Eppendorf AG, Hamburg, 
Germany 
Syringes 1 ml syringe Plastipak BD Biosciences, California, USA 
2 ml and 5 ml syringe, Discardit II BD Biosciences, California, USA 
10 ml Injekt syringes Braun, Melsungen, Germany 
Needles 24G and 30G Microlance 3 BD Biosciences, California, USA 
Slides and 
coverslips 
Thermo Scientific Superfrost plus 
slides 







Histosette I, Embedding Cassettes 
with LID, blue 
Simport, Beloeil, Quebec, Canada 
Cryomold® Standard 25 x 20 x 5 
mm 
Sakura Finetek., Tokyo, Japan 
Flasks 25, 75 and 175 cm2 Corning® TC-
treated surface treatment with vent 
cap 
Corning Inc., New York, USA 
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Well plates Costar® 12-, 24-, 96-well cell culture 
plates flat bottom with lid, tissue 
culture treated 
Corning Inc., New York, USA 
Costar® EIA/ RIA 96 well plate flat 
bottom, non-treated 
Corning Inc., New York, USA 
96 well Semi-Skirted qPCR Plates 4titude® Ltd., Wotton, UK 
Serological 
pipettes 
2 ml, 5 ml, 10 ml and 25 ml costar 
STRIPETTE 
Corning Inc., New York, USA 
PAGE gels 
PAGE 4-20 % gels (43230.01) 
SERVA Electrophoresis GmbH, 
Heidelberg, Germany 
Filter paper and 
Whatman GmbH, Dassel, 
Germany 
Nitrocellulose membrane (WB) 





Venofix Safety 25G Braun, Melsungen, Germany 
ETHICON 4-0 
Johnson&Johnson, New Jersey, 
USA 
VICRYL 6-0 
Johnson&Johnson, New Jersey, 
USA 
Silk Braided Suture 7/0 
Peasalls Sutures, Somerset, 
England 
Table 2.2. Devices 
Device Model Company 
Centrifuges Mikro 200R Andreas Hettich GmbH & 
Co.KG, Tuttlingen, Germany Rotina 420R 
Cryotome  Leica CM3050 S Research 
Cryostat 
Leica Biosystems, Wetzlar, 
Germany 
Dispenser Isoflurane Vapor 19.3 Abbott, Wiesbaden, Germany 
Embedding machine Tissue-Tek TEC 5 Sakura Finetek., Tokyo, Japan 
Hemocytometer 
Neubauer improved 




Analytik Jena AG, Jena, 
Germany 
Incubators 
CO2 Brutschrank C150 
BINDER GmbH, Tuttlingen, 
Germany 
Heating cabinet Heraeus, Hanau, Germany 
Laser Doppler 
Imaging moorLDI2-IR 
Moor Instruments Ltd., 
Millwey, Axminster, Devon, 
England 
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Microscopes Axioskop 40 and Axiocam 
105 color camera 
Carl Zeiss AG, Feldbach, 
Switzerland 
LEICA M60 and LEICA 
MC120 HD camera 
Leica Biosystems, Wetzlar, 
Germany 
Zeiss Axio Examiner.Z1 
Carl Zeiss AG, Feldbach, 
Switzerland 
Axio Imager 2 and Axiocam 
ICc 5 








Siemens AG, Munich 
Germany 
pH-Meter 
inoLab pH 720 




INTEGRA Biosciences Corp., 
Hudson, New Hampshire, 
USA 
Pipettes 0.1-10 µl Eppendorf Xplorer® 
plus 
Eppendorf AG, Hamburg, 
Germany 
1-10, 10-100, 20-200, 100-
1000 µl Eppendorf Research 
Eppendorf AG, Hamburg, 
Germany 
1-10, 10-100, 20-200, 100-
1000 µl Pipetman 
Gilson Inc., Middleton, USA 
Multipette Plus 
Eppendorf AG, Hamburg, 
Germany 
Power supply ECO-Power-Supply 300 V / 
700 mA 








ELISA reader Infinite F200 
Tecan Group Ltd., Männedorf, 
Switzerland 
NanoDrop 2000c 




LaminAir HBB 2448 
Heraeus Holding GmbH, 
Hanau, Germany 
Surgical instruments Adson Forceps Medical 
Fine Science Tools, 
Heidelberg, Germany 
Dumont #5, #7, #5/45 Forceps 
Inox 
Vannas Spring Scissor - 
Straight 
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Iris Scissors - Straight 11.5 cm 
Olsen-Hegar Needle Holder 
12 cm 
Thermocyclers Thermal Cycler 2720 
Life Technologies, Carlsbad, 




Eppendorf AG, Hamburg, 
Germany 
Tissue processor 
Shandon Citadel 1000 
Thermo Fischer Scientific, 
Waltham, Massachusetts, 
USA 
Vortexer IKA MS2 Minishaker 
Vortexer 
IKA®-Werke GmbH & Co. 
KG, Staufen, Germany 
Weighing machine 
CPA225D 
Sartorius AG, Göttingen, 
Germany 
Table 2.3. Buffers, cell culture media and solutions 
 Name Company 
Buffers Dulbecco’s phosphate buffered 
saline (DPBS) 
PAN BIOTECH, Aidenbach, Germany 
TRIzol Reagent 
Thermo Fisher Scientific Inc, Waltham, 
USA 
Laemmli Buffer 10x, for SDS-
PAGE 
SERVA Electrophoresis GmbH, 
Heidelberg, Germany 
Roti®-Load 1 protein loading 
buffer (4x) 
Carl Roth GmbH, Karlsruhe, Germany 
Media Dulbecco’s modified Eagle’s 
medium (DMEM) 
Thermo Fisher Scientific Inc, Waltham, 
USA 
Smooth muscle cell growth 
medium (SMCGM) 
Cell Biologics, Chicago, USA 
Solutions 
Acetic acid 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Aqua ad iniectabilia Braun, Melsungen, Germany 
Chloroform 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
70 %, 96 % and 99.8 % EtOH 
SAV Liquid Production GmbH, 
Flintsbach, Germany 
EtOH BioUltra, for molecular 
biology, ≥99.8% 




Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
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Gelatine, 2 % in PBS PAN BIOTECH, Aidenbach, Germany 
Giemsa - Solution for 
microscopy 
AppliChem, Darmstadt, Germany 
Isopropanol 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Mayer's Hämalaun AppliChem, Darmstadt, Germany 
Methanol AppliChem, Darmstadt, Germany 
Mythramycin A 




Thermo Fisher Scientific Inc, Waltham, 
USA 
Penicillin (10 000 units/ml )/ 
Streptomycin (10 mg/ml) 
solution 
PAN BIOTECH, Aidenbach, Germany 
Ponceau S solution  
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Super Signal West Femto 
Maximum Sensitivity Substrate 




Sakura Finetek., Tokyo, Japan 
Trypan blue solution 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Trypsin PAN BIOTECH, Aidenbach, Germany 
Xylene AppliChem, Darmstadt, Germany 
Others Foetal calf serum (FCS) PAN BIOTECH, Aidenbach, Germany 
 
Industrial Latex 
Chicago Latex Products, Crystal Lake, 
Illinois, USA 
Table 2.4. Chemicals 
Name Company 
Adenosine 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Agarose LE, analytical grade Promega GmbH, Mannheim, Germany 
Albumin from bovine serum Sigma-Aldrich, Steinheim, Germany 
Blotting Grade Blocker non Fat Dry 
Milk 
Bio-Rad Laboratories GmbH München, 
Germany 
5-Bromo-2’-deoxyuridine 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
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cOmplete ULTRA Tablets, Mini, 
EDTA-free EASYpack, protease 
inhibitor cocktail tablets 
Roche Diagnostics GmbH, Mannheim, 
Germany 
1,4-diamino-2,3-dicyano-1,4-bis[2-
aminophenylthio] butadiene (UO126) 
Cell Signaling Technology, Inc., Cambridge, 
USA 
4',6-diamidino-2-phenylindole (DAPI) 
Sigma Aldrich Chemie GmbH, Steinheim, 
Germany 
Ethylenediaminetetraacetate AppliChem GmbH, Darmstadt, Germany 
Glycine AppliChem, Darmstadt, Germany 
Hypo chloride acid Merck KGaA, Darmstadt, Germany 
Paraformaldehyde Merck KGaA, Darmstadt, Germany 
Paraplast Plus Tissue Embedding 
Medium 
Leica, Solms, Germany 
Phosphate 




Roche Diagnostics GmbH, Mannheim, 
Germany 
Potassium chloride Merck KGaA, Darmstadt, Germany 
Potassium Hydrogen phosphate Merck KGaA, Darmstadt, Germany 
Phenylmethylsulphonyl fluoride 
(PMSF) 
Calbiochem, La Jolla CA, USA 
Sodium chloride AppliChem, Darmstadt, Germany 
Sodium deoxycholate Sigma Aldrich GmbH, Seelze, Germany 
Sodium dodecyl sulfate Merck KGaA, Darmstadt, Germany 
Sodium hydrogen phosphate Merck KGaA, Darmstadt, Germany 
Sodium orthovanadate 
Sigma Aldrich Chemie GmbH, Steinheim, 
Germany 
Sucrose 
Sigma Aldrich Chemie GmbH, Munich, 
Germany 
Tris base AppliChem, Darmstadt, Germany 
Triton-X-100 
Sigma Aldrich Chemie GmbH, Steinheim, 
Germany 
Tween 20 AppliChem GmbH, Darmstadt, Germany 
 
Table 2.5. Drugs and substances administered to the mice 
Application  Brand name Active ingredient Company 
Analgesic 
Temgesic® Buprenorphine 
Reckitt Benckiser Healthcare 
(UK) Ltd., Slough, England 















































Bayer Vital GmbH, 
Leverkusen, Germany 
KV1.3 



















Bode Chemie GmbH, 
Hamburg, Germany 
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Table 2.6. Antibodies 
 Antigen Host  Conjugation Clone Company 
IHC/ 
ICC 
KV1.3 rabbit pAb no APC-101 
Alomone labs, 
Jerusalem, Israel 
KCa3.1 rabbit pAb no APC-064 
Alomone labs, 
Jerusalem, Israel 
α-SMA mouse mAb Cy3 1A4 
Sigma-Aldrich, 
Steinheim, Germany 
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Table 2.7. Primers 

















NM_007392.3 for: GAGCATCCGACACTGCTG 












































n factor Sp1 
(Sp1) 
NM_013672.2 for: ACAGGGTGCCAATGGCTGGC 
60 124 1.91 rev: 
GCCCACCAGAGACTGTGCGG 
Table 2.8. Kits 
Name Application Company 
BrdU In-situ detection kit 
Staining of 
proliferative cells 
BD Pharmingen, CA, USA 
BrdU proliferation assay Cell proliferation 
Roche Diagnostics GmbH, 
Germany 
PierceTM BCA protein assay 
kit 
Protein quantification 
Thermo Fischer Scientific, 
Waltham, USA 
Power Sybr green Real time PCR Life technologies 




cDNA synthesis Qiagen, Hilden, Germany 
Rneasy Kit RNA isolation Qiagen, Hilden, Germany 
RQ1 RNase-Free DNase 
DNase digestion of 
RNA 
Promega, Mannheim, Germany 
Table 2.9. Software, programs and websites 
Name Company 
AxioVision 4.8.2.0 Carl Zeiss AG, Feldbach, Switzerland 
AxioVision SE64 Rel. 4.9.1 Carl Zeiss AG, Feldbach, Switzerland 
Endnote® X4.01 Thomson Reuters, New York, USA 
GraphPad prism 6 GraphPad Software, California, USA 
i-control I.9 Tecan Group Ltd., Männedorf, Switzerland 
MatInspector Genomatix GmbH, Munich, Germany 
Microsoft Excel, Power point, 
Word 2007 
Microsoft Corporation, Redmond, USA 
moorLDI Version 5.3 Moor Instruments Ltd., Axminster, Devon, England 
Photoshop Microsoft Corporation, Redmond, USA 
StepOne Software v2.2.2 Life Technologies, Carlsbad, California, USA 
Wasabi software 
Hamamatsu PHOTONICS GmbH, Herrsching, 
Germany 
ZEN Blue Carl Zeiss AG, Feldbach, Switzerland 
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2.2. Murine model of femoral artery ligation 
2.2.1.  Animals 
C57BL/6J mice were purchased from Charles River and kept under 12 hours light/ night 
cycle with water and food ad libitum. Experiments were performed with 7 to 10 weeks old 
male mice. 
2.2.2. Drugs and channel blockers administration 
 Anaesthesia, antidote and analgesia 
Before the surgical procedure, mice were anesthetized with a mixture of 5 mg/kg 
Midazolam, 0.5 mg/kg Medetomidine and 0.05 mg/kg Fentanyl (MMF) injected 
subcutaneously. Just after the surgical procedure, anaesthesia effects were antagonized with 
an antidote consisting of a combination of 0.5 mg/kg Flumazenil, 1.2 mg/kg Naloxone and 
2.5 mg/kg Atipamezole (FNA), injected subcutaneously. 
To avoid pain, 1.2 mg/kg of Buprenorphine was injected subcutaneously immediately after 
surgery and 12 hours later. 
 Channel blockers 
For channel blockade experiments in vivo, the KV1.3 channel blocker 5-(4-
Phenoxybutoxy)psoralen (PAP-1) (Sigma) and the KCa3.1 channel blocker TRAM-34 
(Alomone labs) were dissolved in peanut oil and administered intraperitoneally at 40 mg/kg 
and 120 mg/kg per day, respectively. To maintain PAP-1 and TRAM-34 levels in blood as 
constant as possible, the doses were administered in two injections, one in the morning and 
another in the afternoon. Treatment started 4 hours before the surgical procedure and 
finished on day 6. 
2.2.3. Surgical procedure 
Once anaesthetized with MMF, mice were placed over a heated bench cover to control body 
temperature for the whole surgery. A veterinary ointment (Bepanthen®) was applied over 
the eyes to avoid desiccation. The skin of the upper thigh was first disinfected with 
Cutasept® and then shaved with a scalpel. A small skin incision on the right thigh was 
performed over the epigastric artery (Fig 2.1, A). A few millimetres downstream the 
epigastric artery, the femoral artery was dissected from the nerve, vein, fat and connective 
tissues (Fig 2.1, B). A thread was introduced surrounding the artery and tied off (Fig 2.1, C 
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and D). A contra-lateral sham operation on the left leg was performed as described above, 
except that the thread was let untied (Fig 2.1, E). Finally, the wound was closed with a 
surgical suture (Fig 2.1, F). To avoid pain, the analgesic Buprenorphine was injected 
subcutaneously immediately after surgery. 15 min after the first Buprenorphine injection, 
mice were waked up with the antidote, (FNA) injected subcutaneously. 
Figure 2.1: Surgical procedure of femoral artery ligation 
A. Upper right thigh of the mouse. Small skin incision over the bifurcation of the femoral artery and 
the epigastric artery. B. Ligation site proximal to the epigastric bifurcation free of fat and connective 
tissues. C. Silk surrounding the femoral artery. In D, silk tied off (occluded) and E let untied (sham). 
F. Skin incision is sutured. N: nerve, FA: femoral artery, FV: femoral vein, Ep: Epigastric artery. 
White scale bar: 5 mm, dark scale bar: 1 mm. 
2.2.4. Laser Doppler Imaging 
While ligation of the femoral artery on the right leg impairs perfusion of the hind-limb, in 
the sham-operated left leg, the perfusion remains intact. Hind-limb perfusion was 
established before surgery, immediately thereafter as well as three and seven days after FAL 
with a laser Doppler moorLDI2-IR (Moor Instruments Ltd). Results were expressed as the 
perfusion ratio of the occluded hind-limb relative to the sham-operated one. Basal 
measurements were performed as control, since no differences should be observed in the 
perfusion of both feet before surgery. Just after ligation, the occluded-to-sham hind-limb-
perfusion ratio was lower than 10 %. Mice showing higher perfusion ratios were discarded.  
Mice were either anaesthetized with MMF as described for surgery or were sedated by 
inhalation of 5 % isoflurane for 5 seconds following 1.5 % mixed with oxygen flowing at ~ 
2.5 l/min connected to a warm chamber (37 °C). Mice were led in a supine position and 
hind-limbs were fixed with double-band adhesive for an acclimatisation period of 10 min. 
Between the minutes 10 and 21, a measurement was performed each 3 minutes. During this 
period, occluded-to-sham ratios reach a maximum and then decrease. The maximal ratio 
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was selected for analysis. The setup parameters were the following: distance from Laser 
Doppler to warm plate: 20 cm, image dimension: 3.6x2.3 cm, Gain: DC 2, FLUX 0, CONC 
2; Background Threshold BK 65. For analysis, a region of interest of 0.55 mm2 was 
delimited per hand around the paws and perfusion was assessed with the moorLDI Version 
5.3 software (Moor Instruments Ltd.). 
2.2.5. Mouse tissue harvesting 
 Aortic catheterization and perfusion 
Before collecting thigh muscles for histology, mice were perfused with vasodilation and 
fixation buffers via an aortic catheterization, to allow maximal vasodilation of collateral 
arteries and tissue fixation. Likewise, for gene expression analysis, the perfusion per hand 
of 0.5 ml of latex facilitated the dissection of thigh collateral arteries. 
Mice were first anaesthetized with MMF. Skin was removed from the abdomen up to the 
thoracic cavity. Abdominal cavity was opened downstream the xiphoid process. To control 
bleeding, aorta and vena cava were clamped upstream the kidneys with a vascular clamp 
(Fig 2.2, A). Downstream to the kidney, the abdominal aorta was dissected from connective 
tissue and vena cava and was surrounded by a suture silk (Fig 2.2, B). A small cut was 
performed in the aorta and the point of a butterfly needle was introduced and fixed with the 
silk (Fig 2.2, C and D). The butterfly needle was first connected to an open syringe located 
at 1 meter over the bench and solution was let perfused to eliminate air bubbles before 
catheterization. Finally, solutions were let flow through the aorta by constant pressure after 
cutting the cava vein. 
For histology, 20 ml of vasodilation buffer, 0.1 % (w/v) adenosine and 0.5 % (w/v) bovine 
serum albumin (BSA) in phosphate-buffered saline (PBS), were perfused to allow maximal 
vasodilation of the collateral vessels. To fix the tissue for paraffin wax conservation, 20 ml 
of 4 % (w/v) paraformaldehyde (PFA) in PBS were perfused afterwards. For 
cryoconservation, tissue was fixed with 3 % PFA in PBS. All three buffers were freshly 
prepared and gently prewarmed to 37 °C. 
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Figure 2.2: Aortic catheterization for perfusion fixation and latex perfusion 
A. Open abdomen of the mouse showing the abdominal aorta (AAo), the inferior cava vein (ICV) 
and left kidney (Ki). Upstream of the kidney, AAo and ICV are clamped with a vascular clamp. B. 
Suture silk is placed surrounding the AAo and a small incision in AAo is realized. C. Introduction 
of a butterfly needle in the aorta through the aortic incision and fixation with silk. D. Perfusion, in 
this case with latex, used to make visible the vascular system like the collateral arteries subject of 
study. White scale bar: 5 mm, dark scale bar: 1 mm. 
 Processing of adductor samples for paraffin- and cryoconservation 
For paraffin conservation, thigh samples were collected immediately after perfusion fixation 
and placed in fixation solution allowing to fix for 12 h more at 4 °C. Samples were then 
washed with tap H2O for 30 min and immersed in 70 % ethanol for few hours to several 
days. Following dehydration in increasing concentrations of ethanol and xylene, samples 
were finally embedded in paraffin wax in a carousel-type tissue processor (see table 2.10). 
Adductors were then cut in the middle, crossing muscle fibres and collateral arteries, and 
embedded in paraffin wax with the cut face laying down. Samples were stored at room 
temperature (RT). 
Before cutting, thigh samples were cooled down by incubating them in a freezer to -20 °C. 
2 µm thick sections were placed over glass slides and let dry 24 h to 48 h at 37 °C in a warm 
chamber. Slides were then stored at RT or stained immediately. 
Table 2.10. Dehydration and paraffin embedding protocol 
Step 1-2 3-5 6-8 9-10 11-12 
Solution 70 % EtOH 96 % EtOH 
99.8 % 
EtOH 
Xylene Paraffin wax 
Time 2 x 60 min 3 x 60 min 3 x 60 min 2 x 90 min 2 x 90 min 
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For cryoconservation, following perfusion fixation, adductor samples were immersed first 
in 15 % sucrose (w/v) in PBS for 4 h at RT and then in 30 % sucrose (w/v) in PBS overnight 
at 4 °C. Sucrose should avoid the formation of crystals and protect cellular structure and 
tissue morphology during freezing. Adductor were cut in the middle as for paraffin 
conservation and embedded in OCT compound over cryomolds placed on dry ice and let 
freeze slowly. Samples were stored at -80 °C. 
Thigh samples were cut with a cryotome in 6 µm thick sections, that were placed over glass 
slides and stored at -80 °C.  
 Collateral arteries sampling for gene expression studies 
To avoid RNA degradation by endogenous ribonucleases, catheterization and sampling was 
performed as quick as possible. After latex perfusion, the skin of the upper tight was sprayed 
with Cutasept® to avoid the dispersion of hairs and then cut carefully. Using clean scissors, 
the two superficial collateral arteries were dissected from the Profunda artery to the femoral 
artery, collected in 1.5 ml RNases-free reaction tubes and quick-frozen on dry ice. Samples 
were immediately stored at -80 °C. 
2.3. Histology 
2.3.1. Giemsa staining and morphometric analysis 
Morphometric analysis was performed on collateral artery cross-sections stained with 
Giemsa’s solution. Giemsa’s solution is composed of a mixture of eosin, methylene blue 
and Azure B. Eosin is an acidic dye which binds to basic structures such as cytoplasm, 
proteins and collagen. Methylene blue and Azure B are basic dyes that bind to acidic 
structures such as nucleic acids. Paraffin sections stained with Giemsa’s solution in an acidic 
pH display blue nuclei and pink collagen fibres making possible the delimitation of the 
arterial wall. 
Sections were stained following the protocol described in table 2.11. Finally, sections were 
mounted over coverslips using Eukitt® quick-hardening mounting medium, let dry and 
stored at RT. Images of the collateral arteries were taken with a 40x oil immersion objective 
of an Axioskop 40 microscope equipped with an Axiocam 105 colour camera (Zeiss) and 
analysed with the AxioVision 4.8.2.0 software. 
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Table 2.11. Giemsa staining protocol of paraffin sections 
Step Time Temperature 
Immerse in xylene 20 min 
RT 
Hydrate in abs EtOH, 96 % EtOH, 70% EtOH 
5 min 
each 
Immerse in Giemsa’s solution 1 h 60 °C 
Wash with tap H20  
RT 
Immerse in 1 % acetic acid 3 s 
Dehydrate in 96 % EtOH and abs EtOH 15 s each 
Immerse in xylene 2x 5 min 
Cover with Eukitt® quick-hardening mounting medium and glass coverslips 
 
The inner and outer luminal circumferences were assessed as these two parameters are 
constant, independent on the vessel shape (Limbourg, Korff et al. 2009). The 
circumferences were then used to calculate the luminal diameter and the medial wall 
thickness. For this, collateral sections were assumed to be perfect circles. The following 
equations were used:  
 = × , 
where Co is outer circumference and D diameter, and 
 = × ,  
where A is vessel area and r the radius of the circumference. 
Medial thickness area was calculated then subtracting inner from outer vessel area, and wall 
thickness subtracting inner radius from outer radius. 
2.3.2. BrdU staining in paraffin sections 
Due to their distinct localization and morphology, ECs and SMCs can be very well identified 
in collateral artery cross-sections and their proliferation quantified in histological sections. 
ECs in growing collateral arteries have big round nuclei projected to the intraluminal space. 
SMCs are big cells immersed in the vessel media layer with round nuclei and can be easily 
differentiated from fibroblasts, localized in the adventitia layer. Compared to other cell 
proliferation markers expressed only during cell replication, bromodeoxyuridine (BrdU), a 
thymine analogue, is introduced into the deoxyribonucleic acid (DNA) during genome 
replication and remains in the genome after several cell divisions. This way, cells that have 
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replicated in the past will be BrdU positive too, increasing the sensitivity of the method 
respect to other cell proliferation markers. Together with the corresponding channel blocker, 
mice were given 50 mg/kg BrdU for five days starting just before surgery. BrdU (Sigma-
Aldrich) was dissolved in PBS à 12.5 mg/ml and sterile filtrated. 
Staining was performed using the BrdU detection kit (BD Pharmingen), based on exposition 
of BrdU antigen via antigen retrieval and further detection with an anti-BrdU antibody 
conjugated indirectly to a peroxidase enzyme. Oxidation of the chromogen 3,3'-
diaminobenzidine (DAB) by the peroxidase enzyme in the presence of hydrogen peroxide 
results in a brown alcohol soluble precipitate. See table 2.12. for a detailed protocol. 
Images were taken with a 40x oil immersion objective of an Axioskop 40 microscope 
equipped with an Axiocam 105 colour camera (Zeiss) and analysed with the AxioVision 
4.8.2.0 software. For the analysis of BrdU+ SMCs-to-total SMCs ratios, 50 SMCs were 
counted per mouse. For analysis of BrdU+ ECs-to-total ECs ratio, 150 ECs were counted 
per mouse. The average of BrdU+ cells-to-total cells of 3 mice was calculated and used as 
parameter for comparison between groups. 
Table 2.12. BrdU staining protocol of paraffin sections 
Step Time Temperature 
Immersion in xylene 2x 20 min 
RT 
Hydration in abs EtOH, 96 % EtOH, 70% EtOH 5 min each 
Destillated water 5 min 
7.5 % H2O2 5 min 
Destillated water 5 min 
Antigen retrieval buffer (ARB) 15 min 
800 watts microwave 
ARB refilled 15 min 
Cool down slowly in open jars 30-45 min 
RT 
 
Washing step with PBS 2x 5 min 
Incubation biotin conjugated- BrdU antibody 90 min 
Washing step with PBS 2x 5 min 
Peroxidase conjugated-streptavidin 30 min 
Washing step with PBS 2x 5 min 
Drop of DAB 3-4 min 
Washing step with tap water 10 min 
Counterstaining with Hämalaun solution 45 s 
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Washing step with tap water 5 min 
Dehydration in 96 % EtOH and abs EtOH 5 min each 
Immersion in xylene 5 min 
Cover with Eukitt® quick-hardening mounting medium and glass coverslips 
 
2.3.3. Fluorescence immunohistochemistry 
For fluorescence immunohistochemistry of collateral artery cross-sections, adductors were 
cryoconserved and cut as described above. Sections were let dry at RT for 15 min and then 
fixed in 2 % PFA for 3 min. After washing twice with PBS for 5 min, sections were 
permeabilized with 1 % tween 20 in PBS (PBST) for 20 min. Sections were then incubated 
with 1:100 rabbit anti-KV1.3 or rabbit anti-KCa3.1 antibodies (Alomone) in PBST overnight 
at 4 °C. After three washing steps with PBS, sections were incubated with 1:100 goat Alexa 
Fluor 488-conjugated anti-rabbit antibody, together with 1:100 Cy3-conjugated mouse anti-
α-SMA (Sigma) and 1:100 Alexa Fluor 647-conjugated rat anti-CD31 (cluster of 
differentiation 31) antibody in PBST for 1 h at RT. Sections were then washed three times 
for 5 to 10 min in PBS and imaging was performed immediately. Images were taken with a 
Zeiss Axio Examiner.Z1 microscope using a 60x water objective, equipped with a Colibri.2 
illumination system. 
Analysis of KV1.3 or KCa3.1 expression in α-SMA positive SMCs and CD31 positive ECs 
was performed with the ZEN Blue software (Zeiss). Briefly, the collateral artery section 
was delimited from the rest of the tissue. Positive α-SMA or CD31 areas were selected to 
create a mask of the SMC layer or endothelium respectively. Areas smaller than 10 µm2 
were not considered for calculations. Fluorescence intensity means for Alexa Fluor 488 
(KV1.3 and KCa3.1) in the selected masks were calculated and used as parameter for relative 
protein quantification. 
2.3.4. Fluorescence immunocytochemistry 
MArSMCs were stained for KV1.3 and KCa3.1 channels as well as for the SMC marker α-
SMA together with the nuclear dye 4',6-diamidino-2-phenylindole (DAPI).  
Cells were seeded à 5 x104/ per well of a 24 well plate over sterile and with 1 % collagen 
pre-coated coverslips. After let them growing for 2 more days in SMCGM, cells were 
washed with PBS and fixed with 2 % PFA in PBS for 3 min. Following two wash steps with 
PBS, cells were permeabilized with PBST for 20 min at RT. Cells were then incubated with 
1:100 diluted rabbit anti-KV1.3 or anti-KCa3.1 antibody in PBST overnight at 4 °C. After 
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washing three times with PBS, cells were incubated for 1 h at RT with a combination of 
Alexa Fluor 488-conjugated anti-rabbit secondary antibody and Cy3-conjugated anti α-
SMA antibody, both diluted 1:100 in PBST. After three washing steps, cells were incubated 
with the nuclear dye DAPI à 500 nmol/l for 20 min at RT and washed again with PBST. 
Finally, coverslips were washed with PBS and mounted with ProLong anti fade mounting 
medium (Invitrogen). 
Images were taken with a 40x objective of a Axio Imager 2 fluorescence microscope 
equipped with a fluorescence Axiocam ICc 5 camera and Axiocam ICc 5 software. 
2.4. Cell culture  
2.4.1. MArSMCs culture 
Cell isolation from mouse tissues often results in a mixture of cell populations. SMCs 
isolated from aorta and arteries are usually contaminated by fibroblasts, which grow faster 
and better than SMCs, overwhelming them after several passages. For this reason and to 
assure high quality standard and reproducible data, primary SMCs were purchased from 
Cell Biologics. Furthermore, since SMCs from different beds can have different phenotypes, 
special attention was done in choosing SMCs isolated from arteries and not from the aorta. 
In addition, cells were used in lower passages to avoid cell dedifferentiation.  
MArSMCs were cultured with SMC growth medium (SMCGM) (Cell Biologics) containing 
20 % foetal calf serum (FCS), Insulin and the growth factors FGF-2 (10 ng/µl) and EGF (5 
ng/µl). Cells were grown in collagen-coated flasks and medium was changed every other 
day.  
When cells reached 80 % confluence, they were splitted and used for experiments. Briefly, 
cells were washed with prewarmed Ca2+- and Mg2+-free PBS and loosed from the bottom 
of the flask with trypsin/ Ethylenediaminetetraacetic acid (EDTA) (1 ml in 25 cm2 flask, 2 
ml in 75 cm2 flask) for several minutes in a reaction controlled under the microscope. 
Reaction was stopped with 1:4 ml 10 % FCS Dulbecco's modified Eagle's medium 
(DMEM). After centrifugation à 2800 rpm (Rotina 420R) at RT for 5 min, cells were 
resuspended in SMCGM and either used for experiments or cultured further in coated flasks 
(1:4). 
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Figure 2.3: Light microscope image of MArSMCs after 2 passages 
2.4.2. MArSMCs counting and trypan blue exclusion 
Cell concentration of cell suspensions was determined with a Neubauer improved 
hemocytometer (Laboroptik) through staining with trypan blue solution (Sigma) allowing 
exclusion of dead cells (blue). 
2.4.3. BrdU proliferation assay 
To assess the effects of channel blockade on MArSMCs proliferation, the BrdU 
proliferation assay kit (ROCHE) was used, following manufacturer’s instructions. Briefly, 
MArSMCs were seeded in a 96 well plate à 1 x 104 cells/well in 100 µl SMCGM overnight. 
The next day, medium was replaced for starvation medium, DMEM containing 1 % FCS 
for 24 h. Cells were then stimulated with 10 % FCS in DMEM with or without the channel 
inhibitors PAP-1 or TRAM-34 together with 10 µM BrdU supplied by the kit. PAP-1 was 
diluted to 0.1, 1 and 5 µM while TRAM-34 was diluted to 10, 100 and 500 nM end 
concentrations. Negative control cells were stimulated with 2 % FCS medium. Cells were 
let grow for 3 days and then were fixed with 200 µl/well FixDenat buffer. After 30 min at 
RT, the solution was removed by flicking off and tapping. Then, 100 µl/well of anti-BrdU-
POD solution was added and incubated for 90 min at RT. The antibody conjugate was 
removed, and cells were washed 3 times with 200-300 µl Washing Solution. After removing 
the washing solution, 100 µl/well Substrate Solution was added and incubated for 5 to 30 
min at RT. Then reaction was stopped with 25 µl of 1 n/l H2SO4 for 1 min on a shaker at 30 
rpm. Finally, the absorbance at 450 nm was measured within 5 min after adding stop 
solution with an Infinite F200 ELISA reader (Tecan). The reference wavelength was set to 
620 nm. 
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2.4.4. MArSMCs samples collection for gene expression studies 
MArSMCs were seeded in a 12 well plate precoated with 1 % gelatine à 0.5 -1 x 106 
cells/well in 0.5 ml SMCGM overnight. For gene expression experiments with channel 
inhibitors, cells were serum starved for 24 h in DMEM containing 2 % FCS. Cells were then 
stimulated with 0.5 ml SMCGM/well with or without 1 µmol/l PAP-1 or 100 nmol/l TRAM-
34 for 6 h in a cell incubator at 37 °C and 5 % CO2. PAP-1 was first dissolved in Dimethyl 
sulfoxide (DMSO) à 1 mmol/l and TRAM-34 à 10 mmol/l. Both solutions were sterile 
filtrated with a 0.22 µm filter, aliquoted and stored à -20 °C. Stock solutions were fresh pre-
diluted in DMEM. DMSO end concentrations were lower than 0.1 %. Finally, cells were 
washed twice with ice cold PBS and lysed with 100 µl Trizol for RNA extraction. Sample 
were either stored at -20 °C or continued processing for RNA isolation. 
For gene expression studies with the Sp1-blocker Mithramycin A (MTM), MArSMCs were 
serum starved for 3 days in DMEM 0.5 % FCS. Cells were then stimulated with SMCGM 
with or without 200 nmol/l MTM for 6 h in a cell incubator. Finally, cells were washed 
twice with ice cold PBS and lysed with 100 µl TRIzol for RNA extraction. MTM was first 
dissolved in DMSO à 10 mM and was sterile filtrated with a 0.22 µm filter. Stock aliquots 
were stored at -20 °C.  
2.4.5. MArSMCs samples collection for western blot 
For western blot analysis, MArSMCs were seeded in 12 well plate precoated with 1 % 
gelatine à 0.8-1x106 cells/well in 1 ml SMCGM/well for several days, with daily medium 
changing. When confluence was reached, medium was changed to DMEM with 0.5 % FCS 
(starvation medium) for 3 days. Two hours before stimulation with SMCGM, MArSMCs 
were incubated with 10 µmol/l UO126, a Mitogen-activated protein kinase kinase 1/2 
(MEK1/2) inhibitor in starvation medium. UO126 was first resuspended in DMSO at a 
concentration of 10 mM and stock aliquots were stored at -20 °C. 30 min before stimulation, 
MArSMCs were incubated with the KV1.3 inhibitors PAP-1 and Margatoxin (MgTX) à 1 
µM and 100 nM respectively in starvation medium. MArSMCs were then stimulated with 
SMCGM for 5 min with or without UO126 and the channel inhibitors PAP-1 and 
Margatoxin. After two washing steps with ice cold PBS, cells were lysed with the 
corresponding lysis buffer. 
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2.5. Protein biochemistry 
2.5.1. Preparation of protein lysates 
After cell stimulation, cells were washed twice with ice cold PBS and lysed by scraping 
with 100 µl/well radio-immunoprecipitation assay (RIPA) buffer containing fresh added 
protease and phosphatase inhibitors (see Table 2.13.). Cell lysates were transferred to 1.5 
ml reaction tubes, incubated on ice for 30 min and vortexed each 10 min. Cell lysates were 
then centrifuged for 5 min à 10 000 g at 4 °C. Supernatants were transferred to new reaction 
tubes and pellets were discarded.  
Table 2.13. Composition of cell lysis buffer (RIPA) 
Component Concentration 
Tris/ HCl (pH 7.4) 50 mM 
NaCl 150 mM 
EDTA 1 mM 
Triton-X-100 1 % (v/v) 
Sodiumdeoxycholate 1 % (w/v) 
SDS (10 %) 0.1 % (v/v) 
Freshly added:  
Protease inhibitor cocktail 
(Roche) 
1 tablet /10 ml buffer 
PhosphoStop (Roche) 1 tablet /10 ml buffer 
Sodium orthovanadate 1 mM 
PMSF 0.5 mM 
2.5.1. Protein quantification 
Protein concentration of cell lysates was determined with the PierceTM bicinchoninic acid 
BCA protein assay kit with a standard curve ranging 0.125 mg/ml to 2 mg/ml bovine serum 
albumin supplied with the kit. 1:5 diluted samples and standards were pipetted in duplicates 
in a 96 well plate. Reaction buffer was freshly prepared by mixing 50 parts BCA Reagent 
A with 1 part BCA Reagent B. After 30 min of incubation à 37 °C, colorimetry was 
measured with the Infinite F200 ELISA reader (Tecan) à 562 nm. 
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2.5.2. Immunoblotting 
Changes in protein concentration as well as post-translational modifications in MArSMC 
lysates were assessed by western blot.10 µg cell lysates aliquots were reduced and denatured 
by adding Roti®-Load protein loading buffer (4x) (Carl Roth) and incubating à 95 °C for 5 
min. Samples were then chilled on ice for 5 min and stored at -80 °C until western blot was 
performed. 
MArSMCs lysates, containing 10 µg protein were thawed on ice, centrifuged, mixed by 
pipetting and loaded in a 4-20 % gradient Sodium dodecyl sulfate- polyacrylamide gel 
electrophoresis (SDS-PAGE) gel (Serva). Gel was placed before in an electrophorese 
chamber and covered with Laemmli running buffer (Serva) (see Table 2.14 for buffer 
composition). For future control of the size of the proteins of interest, the prestained protein 
marker PageRulerTM Prestained Protein (Thermo Fischer Scientific) with a band pattern of 
10 to 180 kDa was loaded in the first lane. Electrophorese chamber was then connected to 
a power supply and a current of 10 mA was first elicited for 10 min and then increased to 
20 mA for 1 h. 
From the gel, proteins were transferred to a nitrocellulose membrane to allow detection with 
specific antibodies. Briefly, filter paper and nitrocellulose membrane were first equilibrated 
in transfer buffer for 5 min (see Table 2.14 for buffer composition). In a blotting chamber, 
filter paper, membrane and gel were placed in the following order, from cathode to anode: 
filter paper, membrane, gel, filter paper. The presence of SDS in sample loading buffer 
charged the proteins negatively so that they move from the cathode to the anode in the 
presence of a current. A current of 44 mA was applied for 1 h. 
To control that transfer occurred successfully, the membrane was then stained with Ponceau 
solution for 30 s and washed with Tris-buffered saline containing 0.1 % Tween20 wash 
buffer (TBST). Additionally, the Ponceau stained membrane was scanned and used as 
evidence of equal loading. Before incubation with specific antibodies, the membrane was 
blocked for 1 h with 5 % dry milk in TBST in a shaker à 200 rpm. The membrane was then 
incubated overnight, either with the rabbit mAb anti-phospho-p44/42 MAPK (ERK-1/2) à 
1:2000 or with the rabbit mAb anti-p44/42 MAPK à 1:1000 in TBST with 5 % BSA at 4 °C 
with gentle shaking. After several washing steps under shaking, membrane was incubated 
with horseradish peroxidase (HRP)-conjugated goat anti-rabbit mAb, à 1:10000 in TBST 
with 5 % dry milk for 1 h at RT. Finally, HRP was detected with the luminol-based enhanced 
chemiluminescent substrate SuperSignal West Femto Substrate (Thermofischer) incubating 
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for 3-5 minutes and visualized in an ORCA system (Hamamatsu) and the Wasabi software 
(Hamamatsu). 
Table 2.14. Composition of running, transfer and wash buffers for western blot 
Running buffer:           Transfer buffer:  Wash buffer (TBST) 






 Tris  
Glycin 1.92 M  Glycin   NaCl  
SDS 1 %  SDS   HCl  
pH 8.4-8.9   Methanol   Tween20 0.1 % 
  pH 8.3   pH 7.5  
 
2.6. Real time Polymerase Chain Reaction 
2.6.1. RNA isolation 
RNA isolation was performed with TRIzol, a monophasic solution of phenol and guanidine 
isothiocyanate which maintains integrity of RNA while disrupting cells. MArSMCs were 
detached and lysed with 100 µl TRIzol reagent while collateral samples, around 15 mg 
tissue, were homogenised with 300 µl TRIzol in lysis tubes containing beads in a SpeedMill 
PLUS homogenizer (Analytic Jena). Addition of chloroform (1/5 volume of TRIzol) 
followed by centrifugation at 12.000 g for 15 min at 4 °C allowed the separation of the 
sample into an upper aqueous phase and an organic phase. The RNA-rich aqueous phase 
was then mixed with cold isopropanol (1/2 of TRIzol volume) and centrifuged at 12.000 g 
for 30 min at 4 °C to finally precipitate the RNA.  
To eliminate any rest of genomic DNA, RNA was digested with 1 unit of RQ1 RNase-Free 
DNase enzyme (Promega)/µg RNA at 37 °C for 30 min. RNA samples were then cleaned 
up from DNase and DNase buffer with the RNeasy MinElute Cleanup kit® from Qiagen 
following manual’s instructions. Briefly, samples were first mixed with buffer RLT, then 
with 100 % ethanol and transferred to spin columns (supplied by the kit). Spin columns 
were centrifuged to 14.000 g for 30 s at RT, washed twice with RPE buffer followed by 80 
% ethanol. Spin columns were let dry by centrifugation at full speed and RNA was finally 
eluted with 15-20 µl H2O.  
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RNA concentration was measured at a UV wavelength of 260 with a NanoDrop® 
spectrophotometer and calculated with the Beer-Lambert equation (solved for 
concentration): 
= /(Ɛ × ), 
where  is RNA concentration in molarity (n/L),  is UV absorbance in absorbance units 
(AU), Ɛ is extinction coefficient (liter/mol-cm) and  pathlength in cm. 
RNA purity was assessed analysing the ratios 260/230 and 260/280. While low 260/230 
ratios indicate contamination with guanidinium isothiocyanate, phenol and other buffer 
components, low 260/280 ratios reflect protein contamination. Samples were considered 
pure when the ratios 260/230 and 260/280 ranged from 1.8- to 2 and 2 to 2.2, respectively. 
RNA integrity was analysed in 1 % agarose gels. RNA samples were used when the 28s and 
18s ribosomal RNAs bands were visible and the upper 28s band was thicker than the 18s 
band. 
2.6.2. cDNA synthesis 
RNA samples were reverse transcribed to complementary DNA (cDNA) with the 
QuantiTect® Reverse Transcription kit from Qiagen, following manufacturer’s instructions. 
Briefly, 250 ng RNA was incubated with Wipeout buffer at 42 °C for 4 min to eliminate 
any rest of genomic DNA and chilled on ice for 5 min. Samples were mixed with reverse-
transcription master mix containing RT primer mix, a mixture of random and poly dT 
primers and reverse transcriptase and incubated for 30 min to 42 °C. Finally, reverse 
transcriptase was inactivated by incubating the samples at 95 °C for 3 min. Samples were 
diluted 1:5 and stored at -20 °C. 
2.6.3. Real time PCR 
Real time PCR was performed with the StepOne Plus PCR machine (Life technologies) and 
data were analysed with the ΔΔCt method, described elsewhere (Pfaffl 2001). 
Usually 2 µl of 1:5 diluted cDNA was amplified per well using the Power Sybr green kit 
(Life technologies). Forward and reverse primers (Eurofins GmbH) were mixed in a master 
mix à 5 µM each and used to a final concentration of 250-500 µM. Samples were run in 
triplicates and mean values were used for calculations. See Table 2.15. for running protocol.  
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PCR Melt curve 
Cycle (40x) 









58-64 °C * 95 °C 64 °C 
+ 0.7 °C/min 
until 95 °C 
Time 
10 min 15 s 1 min 15 s 1 min 
* Annealing temperature is primer-dependent. 
2.7. Statistics 
Results were analysed with the statistical software GraphPad Prism 6 (GraphPad Software, 
California, USA). For statistical comparison of two groups, data was first tested for 
normality. For normally distributed data, groups were compared with Student’s t test and 
for data not distributed normally by Rank Sum test. For the comparison of multiple groups, 
1-way or 2-way analysis of variance (ANOVA) followed by a Holm-Sidak Post Hoc test 
was carried out. The corresponding tests are indicated in the figure legends. All 
experimental values are displayed as mean ± standard error of the mean (SEM). Results 














3.1. KV1.3 and KCa3.1 localization and abundance pattern 
during arteriogenesis 
In order to investigate the role of the potassium channels KV1.3 and KCa3.1 in arteriogenesis, at 
first, their localization and expression patterns were characterized in collateral arteries, 
employing the murine model of FAL. Three different time points of collateral artery growth 
were analyzed: at baseline (sham), two days after FAL (2d), and seven days after FAL (7d). 
Two days after FAL, collateral arteries are characterized by a strong cellular proliferation rate 
while seven days after FAL they have already reached a low-proliferative state. Kv1.3 and 
KCa3.1 specific localization in SMCs and in ECs was assessed by immunofluorescence imaging 
through multi-staining with the SMC marker α-SMA and the EC marker CD31. Furthermore, 
fluorescence intensity measurements of the channels in SMCs and ECs allowed a relative 
quantification between time points. 
3.1.1. KV1.3 localization and abundance in collateral arteries 
Immunofluorescence imaging revealed KV1.3 expression in SMCs and ECs of collateral arteries 
at all time points analyzed, as demonstrated by co-localization with α-SMA and CD31 
respectively (Fig 3.1, A). Other vascular cells such as adventitial fibroblasts and perivascular 
inflammatory cells as well as skeletal muscle fibers were KV1.3+ too. However, as displayed in 
Figure 3.1, B, no changes in KV1.3 fluorescence intensity between the different time points 
analyzed were evident in neither SMCs nor ECs, indicating a constant protein abundance in 
these cells during arteriogenesis. Interestingly, KV1.3 staining intensities were stronger in ECs 
than in SMCs. 
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Figure 3.1: KV1.3 localization and abundance pattern in collateral arteries of wild type mice 
during arteriogenesis 
A. Immunofluorescence staining against KV1.3 (green) together with the SMC marker α-SMA (red) and 
the EC marker CD31 (blue) in cross-sections of collateral arteries in sham-operated hind-limb (sham) 
and collateral arteries 2 (2d) and 7 days (7d) after FAL. Lower line, negative control staining performed 
with anti-Kv1.3 antibody (Ab) pre-adsorbed with KV1.3 antigenic peptide. CA: collateral artery, SM: 
skeletal muscle, F: fibroblast, I: inflammatory cell. Scale bar 10 µm. B. Quantitative analysis of the 
fluorescence intensity mean values for KV1.3 in SMCs and ECs. Mean ± SEM, 1-way ANOVA and 










































3.1.2. KCa3.1 localization and abundance in collateral arteries 
KCa3.1 expression was more evident in collateral SMCs and ECs 2 days after FAL (Fig 3.2, A). 
Like KV1.3, KCa3.1 staining was also positive in fibroblasts, perivascular inflammatory cells 
and skeletal muscle. A comparison of KCa3.1-staining fluorescence intensities in SMCs, 
revealed a strong but still insignificant induction of KCa3.1 expression 2 days after FAL 
compared to resting collateral arteries (2407.53 ± 157.50 2d vs 1693.74 ± 251.07 sham) (Fig 
3.2, B). Interestingly, at day 7, KCa3.1 expression was significantly downregulated compared 
to 2 days after FAL (1238.51 ± 172.89 7d vs 2407.53 ± 157.50 2d), reaching even lower levels 
than in resting collateral arteries (1238.51 ± 172.89 7d vs 1693.74 ± 251.07 sham). In ECs, as 
in SMCs, KCa3.1 staining reached a peak 2 day after FAL (2433.64 ± 109.26 2d vs 1768.34 ± 
270.43) and its expression was significantly downregulated again 7 days after FAL (1300.53 ± 
202.36). KCa3.1 expression increased albeit not significantly during the proliferative phase of 
arteriogenesis in both SMCs and ECs. 
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Figure 3.2: KCa3.1 localization and abundance pattern in collateral arteries of wild type mice 
during arteriogenesis 
A. Immunofluorescence staining against KCa3.1 (green) together with the SMC marker α-SMA (red) 
and the EC marker CD31 (blue) in cross-sections of collateral arteries of sham-operated hind-limb and 
collateral arteries 2 (2d) and 7 days (7d) after FAL. Lower line, negative control staining performed with 
anti-KCa3.1 Ab pre-adsorbed with the KCa3.1 antigenic peptide. Scale bar 10 µm. B. Quantitative 
analysis of the fluorescence intensity mean values for KCa3.1 in SMCs and ECs. Mean ± SEM, 1-way 










































3.2. Effects of KV1.3 and KCa3.1 blockade on arteriogenesis 
To elucidate the role of KV1.3 and KCa3.1 in arteriogenesis, mice were treated with the KV1.3 
channel blocker PAP-1 (40 mg/kg per day) or with the KCa3.1 channel blocker TRAM-34 (120 
mg/kg per day), while control mice received vehicle only. Mice were subjected to femoral artery 
ligation and the effect of channel blockade on hind-limb perfusion recovery and collateral artery 
remodeling were assessed. 
3.2.1. Hind-limb perfusion recovery after FAL 
Blood perfusion of the hind-limb was monitored via laser Doppler imaging (LDI) and hind-
limb perfusion recovery was calculated as the ratio of perfusion of the occluded hind-limb to 
the perfusion of the sham-operated hind-limb.  
As displayed in Figure 3.3, treatment with the channel blockers had no effects on perfusion 
ratios at the baseline, showing values around 100 % in the 3 groups. Immediately after FAL, 
values decreased to less than 10 %, again independent on the treatment. At day 3, hind-limb 
perfusion ratio in control mice reached 42.5 ± 1.67 % and at day 7 already 89.17 ± 1.49 % (Fig 
3.3). While 3 days after FAL both treated groups displayed only an attenuated perfusion 
recovery respect to controls (33.33 ± 2.19 TRAM-34 and 33.50 ± 3.45 PAP-1), this reduction, 
however, became significant at day 7 (67.5 ± 4.67 % TRAM-34 and 75.5 ± 3.02 PAP-1). 
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Figure 3.3: Hind-limb perfusion recovery after femoral artery ligation 
A. Line plot displaying the ratio perfusion in occluded (occ) versus perfusion in sham hind-limb 
(occ/sham) of control, TRAM-34-treated and PAP-1-treated mice, before (basal), just after (after lig) 
and 3 and 7 days after FAL. B. Representative flux images. Mean ± SEM, 2-way ANOVA and Holm-
Sidak Post Hoc test, n=6 per group, * PAP-1 vs Con, # TRAM-34 vs Con. 
3.2.2. Morphometric analysis of collateral arteries 
To contrast the results on hind-limb perfusion recovery, the effects of channel blockade on 
collateral artery growth were investigated directly on collateral artery cross-sections seven days 
after FAL. The luminal and external perimeters of collateral arteries were measured in Giemsa 
stained cross-sections. Luminal diameter, medial area and medial thickness were then 
calculated using perfect circle formulas. 









































As noticed in the representative images of Figure 3.4, femoral artery ligation induced a strong 
collateral artery growth compared to resting collateral arteries of the sham-operated hind-limb 
in all three groups. Unexpectedly, while sections of collateral arteries of mice treated with the 
channel blockers compared to control collateral arteries suggested thinner collateral arteries, 
arterial lumen respect to resting collaterals appears as large as in control mice.  
Figure 3.4: Representative images of thigh muscle cross-sections seven days after femoral artery 
ligation 
Sections of thigh muscle in the occluded hind-limb (occ) and sham-operated hind-limb (sham) of 
control, TRAM-34-treated and PAP-1-treated mice were stained with Giemsa. Inner and outer arteriole 
circumference were measured to determine luminal diameter, medial thickness and medial area. CA: 
collateral artery, CV: collateral vein, N: nerve. Scale bar: 20 µm 
As expected, the luminal diameter of collateral arteries in occluded hind-limb of control mice 
increased significantly 1.61-fold with respect to those of collateral arteries in sham-operated 
hind-limb (44.33 ± 4.62 µm occ vs 27.54 ± 1.34 µm sham) (Fig 3.5, A). However, and in 
contrast to that what one would expect from the perfusion recovery data, the luminal diameter 
of collateral arteries of TRAM-34-treated and PAP-1-treated mice were significantly increased 
too with respect to their relatives in sham-operated hind-limb. In TRAM-34 treated mice, the 
increase in luminal diameter was found to be slightly larger than in control mice, reaching 2-
fold values respect to the contralateral collaterals (53.84 ±.2.92 µm occ vs 25.76 ± 2.19 µm 
sham). However, the raise in luminal diameter in TRAM-34 collateral arteries was not 
significant with respect to control arteries as shown after normalization of values to those in the 
respective sham-operated hind-limb (Fig 3.5, A, right). The enlargement in luminal diameter 
of collateral arteries in PAP-1-treated mice was similar to controls, with a 1.79-fold increase 

















Parallel to the results on luminal diameter, collateral artery medial area in the occluded hind-
limb of control mice experienced a significant 1.48-fold increase respect to their contralateral 
counterparts (27.43 ± 1.50 µm2 occ vs 18.50 ± 0.43 µm2 sham) (Fig 3.5, B). Interestingly, this 
increase was attenuated under treatment with TRAM-34 in collateral arteries of occluded hind-
limb and, with 1.2-fold increase, no more significant with respect to those in sham-operated 
hind-limb (23.40 ± 2.10 µm2 occ vs 19.14 ± 0.71 µm2 sham). However, this increase was almost 
inexistent in PAP-1-treated mice (21.77 ± 0.77 µm2 occ vs 20.35 ± 1.40 µm2 sham). 
Normalization of collateral medial area in occluded hind-limb with those in the sham-operated 
hind-limb revealed a significant reduction in PAP-1 treated mice respect to control mice. 
Analogous to arterial medial area, medial thickness of collateral arteries in the occluded hind-
limb of control mice significantly increased 1.52-fold when compared to those in sham-
operated hind-limb (4.46 ± 0.65 µm occ vs 2.94 ± 0.14 µm sham) (Fig 3.5, C). Again, media 
thickening under treatment with TRAM-34 was attenuated increasing only 1.24-fold (3.67 ± 
0.78 µm occ vs 2.96 ± 0.12 µm sham), while treatment with the KV1.3 blocker PAP-1 abolished 
media thickening in collateral arteries of occluded hind-limb versus their contralateral 
counterparts (3.41 ± 0.33 µm occ vs 3.24 ± 0.55 µm sham). Again, normalization with respect 
to medial thickness values in sham-operated hind-limb revealed a significant reduction in PAP-
1-treated mice compared to controls. 
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Figure 3.5: Morphometric analysis of collateral arteries seven days after femoral artery ligation 
A. On the left, box-and-whiskers graph representing the luminal diameter of collateral arteries in 
occluded and sham-operated hind-limb. On the right, after normalization to sham values and measured 
as percentages. B. Quantitative analysis of the collateral medial area of collateral arteries in occluded- 
and sham-operated hind-limb, before (left) and after normalization to values in sham-operated hind-limb 
(right). C. Quantitative analysis of the collateral medial thickness before (left) and after normalization 
to values in sham-operated hind-limb (right). One-way ANOVA and Holm-Sidak Post Hoc test, 






































































































































3.3. Effects of KV1.3 and KCa3.1 blockade on SMC proliferation 
in arteriogenesis 
The data on wall thickening alluded to an inhibition of SMC proliferation during arteriogenesis 
under channel blockade, particularly under KV1.3 blockade. In this chapter, the effects of 
channel blockade on SMC proliferation in vivo were investigated more specifically. Mice were 
treated with the proliferation cell marker BrdU and seven days after ligation, BrdU positive 
cells were quantified in collateral artery cross-sections. Additionally, these data were 
complemented with gene expression analysis of α-SMA, a SMC effector protein whose 
expression is strongly downregulated in proliferative SMCs. 
3.3.1. Analysis of collateral SMC and EC proliferation via BrdU 
staining 
To quantify SMC and EC proliferation in collateral arteries, immunohistochemical analysis of 
the proliferation marker BrdU was performed 7 days after FAL. Collateral artery transversal 
sections were stained against BrdU, followed by Haemalaun to counterstain tissue morphology. 
As exhibited in Figure 3.6, A, localization and distinctive morphology of SMCs and ECs at the 
vessel wall allowed an easy identification and quantification of both cell types, without cell 
specific staining. Since SMCs of collateral arteries in sham-operated hind-limb don’t 
proliferate, only collateral arteries in occluded hind-limb were examined and compared between 
groups. Results were calculated as the ratio of BrdU+ cell numbers to total cell numbers, 
normalized to control values and expressed as percentages.  
Quantification of BrdU+ SMCs in collateral arteries of TRAM-34-treated mice, seven days after 
occlusion, revealed that KCa3.1 blockade with TRAM-34 did not influence the number of BrdU+ 
SMCs with respect to the control group (Fig 3.6, B). On the contrary, KV1.3 blockade with 
PAP-1 resulted in a strong reduction of SMC proliferation, with 54.2 % decrease respect to 
control arteries (Fig 3.6, C). 
Interestingly, although statistically insignificant, both treatments slightly increased the numbers 
of BrdU+ ECs, with an increase of 38.78 % in the TRAM-34 group and 34.13 % in the PAP-1 
group above control values (Fig 3.6). The tendency to higher EC numbers under channel 
blockade supports morphometric analysis by which luminal diameters of collateral arteries were 
found to be as in controls in PAP-1 or even slightly higher in TRAM-34 collateral arteries on 
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occluded hind-limbs, seven days after ligation. However, both analysis contrast with perfusion 
data, by which PAP-1- and TRAM-34-treated mice recovered worse than control mice. 
Figure 3.6: Quantitative analysis of SMC and EC proliferation in collateral arteries seven days 
after femoral artery ligation via BrdU incorporation 
A. Representative image of BrdU immunohistochemical staining counterstained with Haemalaun. CA: 
collateral artery, CV: collateral vein, N: nerve. Black arrows: BrdU+ SMCs and black arrow’s head 
BrdU- SMC, red arrow: BrdU+ EC, red arrow’s head: BrdU- EC, asterisk: BrdU+ adventitial fibroblast. 
Scale bar: 20 µm. B. Bar plots representing the ratio BrdU+ SMCs-to-total SMC (left panel) and the ratio 
BrdU+ EC-to-total ECs (right panel) in TRAM-34-treated versus control mice. C. Bar plots representing 
the ratio BrdU+ SMCs-to-total SMCs (left panel) and the ratio BrdU+ ECs-to-total ECs (right panel) in 








































































































3.3.2. Analysis of aSma expression in collateral arteries 
Alpha smooth muscle actin (α-SMA) is a characteristic SMC effector protein and its expression 
is strongly repressed during SMC phenotypic modulation (PM) and in proliferative SMCs. To 
assess when SMC PM is induced following FAL, aSma expression was analyzed over time in 
collateral arteries of wild type mice via real time PCR. Results are expressed as the ratio 
between messenger RNA (mRNA) levels normalized to 18S rRNA in collateral arteries of 
occluded hind-limb and the mRNA levels in collateral arteries of sham-operated hind-limb. 
As displayed in Figure 3.7, aSma expression reached a depression point 12h after FAL, 
recovered 24h after ligation and from 36h on was even upregulated. Repression of aSma 
expression 12h after FAL indicated that at this time point phenotypic modulation towards 
proliferative SMCs probably occur. 
Figure 3.7: aSma expression profiling during arteriogenesis in wild type mice 
Bar graph displaying aSma expression pattern represented as the ratios of mRNA levels measured by 
real time PCR normalized to 18S rRNA in collateral arteries of occluded to collateral arteries of sham-
operated hind-limb of wild type mice at several time points after FAL. One-way ANOVA and Holm-
Sidak Post Hoc test, n=3-5. # p<0.05 refers to 12h occ vs 12h sham. 
To analyze the role of KV1.3 and KCa3.1 in phenotypic modulation induction, mice were treated 
with the corresponding blockers and the expression of aSma was assessed 12h after FAL. 
Again, aSma mRNA levels in control mice were downregulated in collateral arteries 12h after 
ligation respect to their contralateral counterparts. The same downregulation was evident under 
treatment with the KCa3.1 blocker TRAM-34 (0.867 ± 0.06 TRAM-34 vs 0.886 ± 0.04 Con) 
(Fig 3.8, B). However, KV1.3 blockade with PAP-1 resulted in an upregulation of aSma 
expression in collateral arteries of occluded hind-limb compared to those of the sham-operated 
hind-limb. Compared to controls this upregulation was statistically significant (1.366 ± 0.03 
PAP-1 vs 0.886 ± 0.04 Con).  






























Figure 3.8: aSma expression in collateral arteries 12h after femoral artery ligation  
Bar graph representing aSma expression in TRAM-34-treated, PAP-1-treated and control mice collateral 
arteries 12h after FAL. One-way ANOVA and Holm-Sidak Post Hoc test, ** p<0.01, n=3 per group. 
3.4. Effects of KV1.3 and KCa3.1 blockade on MArSMCs 
proliferation in vitro 
The role of KV1.3 and KCa3.1 K+ channels on SMC proliferation was investigated further on 
primary mouse artery SMCs (MArSMCs) in vitro.  
3.4.1. KV1.3 and KCa3.1 subcellular localization in MArSMCs 
First, a qualitative analysis of KV1.3 and KCa3.1 expression in MArSMCs with special attention 
on their cellular localization was performed via immunofluorescence imaging. 
As exposed in Figure 3.9, MArSMCs cultured in vitro with SMC growth medium (SMCGM) 
expressed both KV1.3 and KCa3.1 channels. Interestingly, immunofluorescence staining 
revealed a strong localization of both channels around and in the nuclei of MArSMCs together 





























Figure 3.9: KV1.3 and KCa3.1 subcellular localization in MArSMCs 
MArSMCs were immunostained against KV1.3 (upper line) and KCa3.1 (middle line) (green), together 
with the SMC marker α-SMA (red). Nuclei were stained with DAPI (blue). C. Negative control (lower 
line) staining performed without primary antibody. Scale bar 40 µm. 
3.4.2. Analysis of MArSMCs proliferation via BrdU assay 
To investigate the effects of KV1.3 and KCa3.1 blockade on MArSMCs proliferation, cells were 
cultured under increasing doses of TRAM-34 (10, 100, 500 nM) and PAP-1 (0.1, 1 and 5 µM) 
and cell proliferation was quantified via a BrdU incorporation assay.  
MArSMC proliferation was indeed inhibited in the presence of both channel blockers TRAM-
34 and PAP-1 (Fig 3.10). 100 nM TRAM-34 significantly reduced MArSMC proliferation 
0.26-fold compared to control cells (73.70 ± 10.23 100 nM TRAM-34 vs 100 ± 17.13 pos Con). 
Moreover, PAP-1 inhibition of MArSMC proliferation was found to be dose-dependent and 
significant at 1 µM PAP-1, with a 0.27-fold reduction compared to control cells stimulated with 
10 % FCS only (73.33± 8.24 1 µM PAP-1). Furthermore, cells treated with 1 µM PAP-1 or 
with 100 nM TRAM-34 displayed similar proliferation rates as negative control cells 
maintained in starvation medium with 0.27-fold reduction (73.06 ± 16.73 2% FCS), reflecting 
decreased proliferation but not cell death. Furthermore, toxicity and cell viability were assessed 
with a trypan blue staining (data not shown). 
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Figure 3.10: Assessment of MArSMC proliferation via BrdU incorporation 
Bar graph displaying BrdU incorporation values expressed as percentage to positive control: MArSMCs 
stimulated with 10 % FCS. Together with 10 % FCS stimulation, MArSMCs were cultured under 
increasing doses of TRAM-34: 10 to 500 nM or PAP-1: 100 nM to 5 µM. Negative control: MArSMCs 
cultured in 2 % FCS. One-way ANOVA and Holm-Sidak Post Hoc test, *p<0.05, n=3. 
3.5. Effects of KV1.3 and KCa3.1 blockade on Fgfr1 and Pdgfrb 
expression 
3.5.1. Fgfr1 and Pdgfrb expression in MArSMCs under TRAM-34 
and PAP-1 
RTK signalling plays an important role in SMC proliferation, activating the cell division 
machinery. Furthermore, FGFR-1 and PDGFR-ß signalling are important stimulators of 
arteriogenic SMC proliferation. To investigate the role of KV1.3 on Fgfr1 and Pdgfrb 
expression regulation in SMCs, experiments were performed in cultured MArSMCs. Cells were 
stimulated with SMCGM containing 2 RTK ligands: FGF-2 and EGF after 24h serum-
starvation. 
Stimulation with SMCGM did not induce Fgfr1 and Pdgfrb expression in cultured MArSMCs 
(Fgfr1: 0.892 ± 0.074 SMCGM vs 1.065 ± 0.065 neg Con, Pdgfrb: 0.890 ± 0.067 SMCGM vs 
1.008 ± 0.008 neg Con). Parallelly, treatment with the KCa3.1 channel blocker TRAM-34 had 
no significant effects on Fgfr1 and Pdgfrb expression compared to cells stimulated with 
SMCGM alone (Fgfr1: 0.892 ± 0.074 SMCGM vs 0.783 ± 0.034 TRAM-34, Pdgfrb: 0.890 ± 

















































blocker PAP-1 significantly repressed both, Fgfr1 0.62-fold as well as Pdgfrb with 0.58-fold 
compared to cells stimulated with SMCGM only (Fgfr1: 0.892 ± 0.074 SMCGM vs 0.557 ± 
0.035 PAP-1; Pdgfrb: 0.890 ± 0.067 SMCGM vs 0.520 ± 0.014 PAP-1) (Fig 3.11).  
Figure 3.11: Fgfr1 and Pdgfrb expression in MArSMCs under RTK stimulation 
Bar graph representing Fgfr1 and Pdgfrb expression values normalized to 18S rRNA, assessed by real 
time PCR. After serum starvation in 2 % FCS for 24h, cells were stimulated with SMCGM containing 
FGF-2 and EGF only or together with 100 nM TRAM-34 or 1 µM PAP-1 for 6h. One-way ANOVA 
and Holm-Sidak Post Hoc test, **p<0.01, n=3. 
3.5.2. Fgfr1 and Pdgfrb expression in collateral arteries 
Since KV1.3 blockade altered Fgfr1 and Pdgfrb expression in MArSMCs, the effects of channel 
blockade on the expression of both RTK 12h after FAL was investigated next.  
In control mice Fgfr1 and Pdgfrb were not differentially expressed, with occ-to-sham ratios of 
1.117 ± 0.103 for Fgfr1 and 1.036 ± 0.019 for Pdgfrb (Fig 3.12). In mice treated with the KCa3.1 
blocker TRAM-34, both genes were slightly depressed. However, this downregulation was not 
significant respect to controls for neither of the 2 genes (Fgfr1: 0.843 ± 0.175 vs 1.117 ± 0.103 
con, Pdgfrb: 0.744 ± 0.120 vs 1.036 ± 0.019). A much stronger and significant downregulation 
was evident under KV1.3 blockade with PAP-1 for both genes, Fgfr1: 0.608 ± 0.051 PAP-1 vs 










































Figure 3.12: Fgfr1 and Pdgfrb expression in collateral arteries 12h after femoral artery ligation 
Bar plot representing Fgfr1 and Pdgfrb gene expression as the ratio occ-to-sham collateral arteries in 
control, TRAM-34-treated and PAP-1-treated mice. One-way ANOVA and Holm-Sidak Post Hoc test, 
*p<0.05, n=3. 
3.6. Role of KV1.3 in receptor tyrosine kinase signalling 
So far, the data pointed to an important role of KV1.3 in SMC proliferation during arteriogenesis 
by regulating the expression of two important receptor tyrosine kinases involved in SMC 
proliferation: FGFR1 and PDGFR-ß. In this chapter, the role of KV1.3 in RTK signalling was 
investigated further.  
3.6.1. Effect of KV1.3 blockade on Egr1 expression in vitro and in vivo 
RTK activation signals among others through the MAPK/ ERK pathway. In arteriogenesis, 
MAPK/ ERK activation plays an important role in SMC proliferation by inducing the 
expression of the transcription factor EGR-1. Hence, Egr1 expression is upregulated 12h after 
FAL and in growing collaterals and EGR-1 controls SMC proliferation by regulating proteins 
involved in cell division as well as SMC phenotypic modulation (Pagel, Ziegelhoeffer et al. 
2012). 
To investigate the role of KV1.3 in RTK signalling, the expression of Egr1 in cultured 
MArSMCs under stimulation with RTK ligands as well as in collateral arteries 12h after FAL 
were assessed in the presence of the KV1.3 blocker PAP-1. 
MArSMCs stimulated with SMCGM containing FGF-2 and EGF slightly upregulated Egr1 
expression compared to cells cultured further in starvation medium (negative control) (0.501 ± 

































PAP-1, Egr1 expression was significantly downregulated 0.72-fold with respect to MArSMCs 
stimulated with SMCGM (0.359 ± 0.024 PAP-1 vs 0.501 ± 0.008 SMCGM), reaching values 
even lower than in negative control cells.  
As expected, 12h after FAL, a strong 1.879-fold upregulation of Egr1 expression in control 
mice was observed in collateral arteries of occluded hind-limb compared to their contralateral 
counterparts (1.162 ± 0.237 occ vs 0.646 ± 0.190 sham) (Fig 3.13, B). Analogous to in vitro 
data, KV1.3 blockade significantly repressed Egr1 expression 0.46-fold with respect to controls 
(0.860 ± 0.063 PAP-1 vs 1.879 ± 0.292 Con). Interestingly, this upregulation was not only 
truncated in mice treated with PAP-1 but was even slightly downregulated (0.906 ± 0.381 occ 
vs 1.109 ± 0.587 sham). 
Figure 3.13: Egr1 expression in cultured MArSMCs under RTK stimulation and in collateral 
arteries 12h after femoral artery ligation  
A. Egr1 expression values normalized to 18S rRNA in MArSMCs maintained in starvation medium and 
in MArSMCs stimulated with SMCGM containing FGF-2 and EGF for 6h, with or without 1 µM PAP-
1. One-way ANOVA and Holm-Sidak Post Hoc test. B. Egr1 expression 12h after FAL in collateral 
arteries of PAP-1-treated versus control mice, represented as ratio occluded- to sham-operated hind-









































































3.6.2. Effect of KV1.3 blockade on ERK1/2 phosphorylation under 
RTK stimulation in MArSMCs 
KV1.3 channel blockade resulted in downregulation of Egr1 expression. Since KV1.3 localizes 
at the cytoplasmic membrane and at the nuclear envelope, KV1.3-mediated Egr1 expression 
regulation could be effectuated at one of these two cellular levels. 
To investigate if KV1.3 channel blockade inhibits RTK activation at the cytoplasmic membrane, 
downstream phosphorylation of ERK by MEK was assessed via western blot in MArSMCs 
under treatment with two different KV1.3 channel blockers: PAP-1 and the membrane 
impermeable Margatoxin (MgTX). As a negative control for ERK phosphorylation, MArSMCs 
were treated with the specific MEK inhibitor UO126. 
In MArSMCs, ERK phosphorylation was strongly induced after stimulation with SMCGM 
containing FGF-2 and EGF for 5 min compared to MArSMCs cultured further in starvation 
medium (Fig 3.14). This increase was not due to higher ERK protein levels since ERK signals 
displayed similar intensities in both groups. As expected, addition of the MEK inhibitor UO126 
resulted in a reduced ERK phosphorylation, again without affecting ERK levels. In this setting, 
the presence of the KV1.3 channel blockers PAP-1 (1 µM) or MgTX (10 nM) did not influence 
ERK phosphorylation compared to MArSMCs stimulated with SMCGM alone. Total ERK 
levels were not affected neither. 
Figure 3.14: Analysis of ERK phosphorylation after RTK stimulation in MArSMCs 
Western blot with MArSMC lysates plotted against p-ERK and ERK, upper and middle panel 
respectively. Lower panel, Ponceau staining confirming equal loading. MArSMCs were stimulated with 
SMCGM containing FGF-2 and EGF for 5 min in the presence of 1 µM PAP-1 or 100 nM MgTX after 
a starvation period of 3 days in 0.5 % FCS. As a negative control, MArSMCs were incubated with the 













3.7. Role of Sp1 in KV1.3-mediated Fgfr1, Pdgfrb and Egr1 
expression regulation 
Fgfr1, Pdgfrb and Egr1 expression were downregulated under KV1.3 channel blockade both in 
MArSMCs cultured in vitro under RTK stimulation and during arteriogenesis. A literature 
research and an in silico analysis of transcription factor binding sites in the promoter sequences, 
revealed Specificity protein-1 (Sp1) as a common transcription factor for all three genes. In this 
section, its role in the expression regulation of the three genes was specifically assessed in 
MArSMCs. Furthermore, the effect of KV1.3 blockade on Sp1 expression was investigated in 
MArSMCs and in collateral arteries 12h after FAL.  
3.7.1. In silico analysis of Sp1 binding sites on Fgfr1, Pdgfrb and Egr1 
promoters 
The presence of Sp1 binding sites in Egr1 promoter has been reported elsewhere (Sakamoto, 
Bardeleben et al. 1991, Schwachtgen, Campbell et al. 2000). Moreover, Cao et al, demonstrated 
that Sp1 activates Egr1 expression in fibroblast in in vitro transfection studies (Cao, Mahendran 
et al. 1993). On the other hand, an Sp1-dependent regulation of Fgfr1 expression has been 
reported in myoblasts, chicken skeletal muscle and cardiomyocytes (Saito, Kouhara et al. 1992, 
Patel and DiMario 2001, Parakati and DiMario 2002, Seyed and Dimario 2007, Parakati and 
DiMario 2013). Pdgfrb expression regulation through Sp1 has also been reported in vitro in 
neuroblastoma cells (Molander, Hackzell et al. 2001, Kaneko, Yang et al. 2006). 
MatInspector software revealed two binding sites for Sp1 on Egr1 promoter, six binding sites 
on Fgfr1 promoter and two binding sites on Pdgfrb promoter (Table 3.1). 











Egr1 GXP_3614163 1 0.91 211 227 + ggttgGGGCgggggcaa 1.000 0.979 
2 0.91 578 594 - ggctgGGGCaggggccg 1.000 0.917 
Fgfr1 GXP_270509 1 0.88 284 300 - gggagGGGCgggtgcct 1.000 0.959 
2 0.91 580 596 + gctgcGGGCggcgcgga 1.000 0.921 
3 0.85 922 938 + accccGGGCggcggacc 1.000 0.854 
4 0.88 938 954 - cggggGGGAgggctcgg 0.807 0.891 
5 0.88 946 962 - aggcgGGGCggggggga 1.000 0.997 
6 0.91 986 1002 - agcccGGGCgggaacaa 1.000 0.932 
Pdgfrb GXP_423602 1 0.85 470 486 - cctgtGGGCggagttat 1.000 0.947 
2 0.88 483 499 - gttagGGGCgggccctg 1.000 0.969 
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In silico analysis of Sp1 binding sites in Egr1, Fgfr1 and Pdgfrb promoters performed with the 
MatInspector software. BS: binding sites, Opt: optimized, Core sim.: core similarity, Matrix sim.: matrix 
similarity. 
3.7.2. Effects of Sp1 DNA-binding blockade on Fgfr1, Pdgfrb and 
Egr1 expression in MArSMCs 
In order to investigate the specific role of Sp1 in the regulation of Fgfr1, Pdgfrb and Egr1 in 
SMCs specifically, their expressions were analyzed in MArSMCs in the presence of the Sp1-
specific blocker Mithramycin A.  
In MArSMCs, following three days in starvation medium, stimulation with SMCGM containing 
FGF-2 and EGF strongly induced Egr1 expression 4.65-fold (5.175 ± 0.159 SMCGM vs 1.112 
± 0.063 2 % FCS) (Fig 3.15). Addition of the Sp1 blocker Mithramycin A (MTM) resulted in 
a significant decrease of 0.84-fold in Egr1 mRNA levels compared to cells stimulated with 
SMCGM alone (5.175 ± 0.159 SMCGM vs 4.338 ± 0.195 MTM) (Fig 3.15, A). The same effect 
was observable on Fgfr1 expression. Stimulation with SMCGM resulted in an upregulation of 
Fgfr1 expression of 2.44-fold (0.562 ± 0.033 SMCGM vs 0.230 ± 0.013 2 % FCS) while 
treatment with MTM significantly repressed this upregulation 0.80-fold (0.448 ± 0.011 MTM 
vs 0.562 ± 0.033 SMCGM) (Fig 3.15, B). On the contrary, Pdgfrb was strongly downregulated 
1.80-fold after stimulation with SMCGM compared to starved MArSMCs (0.610 ± 0.054 
SMCGM vs 1.096 ± 0.048 2 % FCS). Treatment with MTM did not affect its expression 
compared to SMCGM stimulation alone (0.610 ± 0.054 SMCGM vs 0.577 ± 0.062 MTM). 
Figure 3.15: Effects of Sp1 binding blockade on Egr1, Fgfr1 and Pdgfrb expression in MArSMCs 
under RTK stimulation 
MArSMCs were stimulated with SMCGM containing FGF-2 and EGF for 6h after a starvation period 
of 3 days with 2 % FCS in the presence or not of the Sp1 blocker Mithramycin A (MTM) (20 µM). 
Expression of Egr1 (A) and the RTKs Fgfr1 and Pdgfrb (B) was analyzed by real time PCR. One-way 










































































3.7.3. Effects of KV1.3 blockade on Sp1 gene expression in MArSMCs 
and collateral arteries  
Since Sp1 regulates Egr1 and Fgfr1 expression in MArSMCs, a possible role of KV1.3 in Sp1 
transcription activity was investigated too. It has been reported that Sp1 transcription activity 
can be modulated not only through post-transcriptional modifications but also by protein 
abundance (Tapias, Ciudad et al. 2008). Therefore, Sp1 expression was assessed first in 
MArSMCs in the presence or not of the KV1.3 blocker PAP-1 following stimulation with 
SMCGM. Parallelly, Sp1 expression was determined in collateral arteries 12h after FAL of 
control and PAP-1-treated mice. 
In vitro stimulation of MArSMCs with SMCGM did not affect Sp1 mRNA levels compared to 
cells cultured in 2 % FCS (0.875 ± 0.052 SMCGM vs 0.894 ± 0.095 neg Con). However, 
MArSMCs stimulated with SMCGM in the presence of PAP-1 significantly downregulated Sp1 
expression 0.69-fold (0.605 ± 0.049 PAP-1 vs 0.875 ± 0.052 SMCGM) (Fig 3.16, A). 
Contrastingly, in collateral arteries 12h after FAL, treatment with the KV1.3 blocker PAP-1 did 
not influence Sp1 expression compared to control mice treated with vehicle only (1.192 ± 0.132 
Con vs 1.112 ± 0.165 PAP-1) (Fig 3.16, B).  
Figure 3.16: Sp1 gene expression in MArSMCs under RTK stimulation and in collateral arteries 
12h after femoral artery ligation  
A. Sp1 gene expression analysis represented as Sp1 values normalized to 18S in MArSMCs stimulated 
with SMCGM containing FGF-2 and EGF following a FCS-starvation period, in the presence or not of 
1 µM PAP-1. One-way ANOVA and Holm-Sidak Post Hoc test. B. Sp1 expression expressed as the 
ratio of collateral arteries in occluded- to collateral arteries in sham-operated hind-limbs of control and 








































































3.8. Effects of Sp1 DNA-binding blockade on Kcna3 expression 
Sp1 has been involved in Kcna3 (KV1.3 gene) expression regulation in carcinoma cells (Jang, 
Byun et al. 2015). To contrast these data in primary MArSMCs, cells were stimulated with RTK 
ligands in the presence of the Sp1-specific blocker MTM. Interestingly, Kcna3 expression was 
strongly induced in MArSMCs stimulated with SMCGM containing FGF-2 and EGF almost 2-
fold (1.886 ± 0.446 neg Con vs 3.756 ± 0.257 SMCGM) (Fig 3.17). However, KV1.3 mRNA 
levels were not affected with the addition of MTM under RTK stimulation (3.609 ± 0.625 MTM 
vs 3.756 ± 0.257 SMCGM). 
Figure 3.17: KV1.3 gene expression in MArSMCs under RTK stimulation and Sp1-DNA binding 
blockade 
KV1.3 gene (Kcna3) expression values normalized to 18S in MArSMCs stimulated with SMCGM 
containing FGF-2 and EGF for 6h were assessed with or without the Sp1-specific blocker MTM by real 
time PCR. Negative control, MArSMCs maintained in 2 % FCS. One-way ANOVA and Holm-Sidak 



























































4.1. Channel blockade versus channel-knockout mice 
To investigate the role of channels in vivo, two different strategies can be followed: the analysis 
of channel-specific knockout (KO) or the treatment of wild type mice with channel specific 
blockers (loss of function) or openers (gain of function).  
KV1.3 and KCa3.1 KO mice have been reported so far (Fadool, Tucker et al. 2004, Si, Heyken 
et al. 2006). However, both are constitutive KO mice, that is, gene expression is missing from 
the whole embryonic development and is deleted in all the tissues where the gene is expressed. 
In these mice, collaterogenesis, the formation of collateral arteries during embryogenesis, could 
be affected and influence the parameters used to evaluate arteriogenesis in adulthood. 
Moreover, it is well known that constitutive KO mice can develop compensation mechanisms 
by which the gene’s function is undertaken usually by high-conserved genes, unmasking any 
function (Sprossmann, Pankert et al. 2009). Hence, compensatory mechanisms have been 
detected in thymocytes of KV1.3-KO mice, by which a lack of voltage-gated K+ current is 
compensated by an increase in chloride currents (Koni, Khanna et al. 2003). On the other hand, 
while KCa3.1-KO exhibit a normal phenotype, a mild 7 mmHg increase in mean arterial blood 
pressure has been detected, probably due to interference with its EDHF function and other 
developmental compensations (Wulff and Castle 2010). To study the role of KV1.3 and KCa3.1 
channels in SMCs specifically, the best strategy would be the use of inducible SMC-specific 
KO mice. In these mice expression of the channel would be controlled temporally and spatially 
by using SMC-specific marker gene promoter (Kuhbandner, Brummer et al. 2000). The 
generation of these mouse models is however time-consuming and very expensive.  
Chemical inhibition with channel specific blockers neither affects embryonic development nor 
give place to compensation mechanisms, since the treatment starts shortly before the surgical 
procedure. Furthermore, treatment with channel blockers is quick, flexible and cheap. For all 
these reasons, the use of specific channel blockers was considered the best strategy in this study. 
However, chemical inhibition of channels presents some disadvantages to consider. As well as 
constitutive KO mice, the treatment with channel blockers is not cell type-specific: all cells 
expressing the channel will be affected. Furthermore, channel blockers must be tested for 
toxicity as any other drug and the dose used must be specific. Since family channels have highly 
conserved members, high concentrations of the channel blocker could act non-specifically over 
highly related-channels (Schmitz, Sankaranarayanan et al. 2005). 
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4.1.1. KV1.3 channel blocker PAP-1 
5-(4-Phenoxybutoxy)psoralen (PAP-1) is a membrane-permeable specific KV1.3-channel 
blocker, that is 23-fold selective over KV1.5 and 33- to 125-fold selective over other KV1-family 
channels (Schmitz, Sankaranarayanan et al. 2005). Furthermore, PAP-1 has been used in several 
in vivo studies in mice, rats and monkeys without toxic effects (Schmitz, Sankaranarayanan et 
al. 2005, Azam, Sankaranarayanan et al. 2007, Pereira, Villinger et al. 2007, Straub, Perez et 
al. 2011, Cidad, Novensa et al. 2014). In this study, the dose and administration route used, 40 
mg/kg/day i.p., is based on a rat study performed by Chen et al (Chen, Lam et al. 2013). To 
maintain a relative constant concentration of the blocker, the daily dose was administered in 
two injections with 10-12 h interval. In addition, special attention was paid to any manifestation 
of toxicity or any disease symptom. Since drugs were injected i.p., any signs of infection or 
inner organs damage were checked out during organ sampling or perfusion fixation. In PAP-1-
treated mice, drinking and eating behaviors, weight, feces and fur were as usual. 
4.1.2. KCa3.1 channel blocker TRAM-34 
TRAM-34 (1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole) is a membrane-permeable 
KCa3.1-specific blocker that has also been used in in vivo experiments with mice, rats and swine 
showing no toxicity so far (Kohler, Wulff et al. 2003, Tharp, Wamhoff et al. 2008). The dose 
and frequency used in this study, 120 mg/kg/d i.p., in two different injections with 10-12h 
interval were already reported in mice (Toyama, Wulff et al. 2008, Hua, Deuse et al. 2013) and 
rats (Kohler, Wulff et al. 2003, Grgic, Wulff et al. 2009).  
As in PAP-1-treated mice, treatment with TRAM-34 did not affect drinking and eating 
behaviors, weight, feces or fur. No symptoms were observed during the whole study. 
4.2. The role of KV1.3 in arteriogenesis and SMC proliferation 
4.2.1. KV1.3 is constantly expressed in collateral SMCs and ECs 
First, KV1.3 expression in collateral arteries of wild type mice undergoing FAL was confirmed 
through immunofluorescence histology. To further examine its expression regulation during 
collateral artery growth, immunofluorescence intensities were quantified in resting, two and 
seven day growing collateral arteries, corresponding to a highly proliferative and to a quiescent 
phase, respectively. Co-localization of KV1.3 with the SMC marker α-SMA and the EC marker 
CD31 revealed the expression of the channel in both cell types. Interestingly, quantification of 
Discussion 
83 
Kv1.3 immunofluorescence intensities in all time points investigated reflected no changes in 
KV1.3 protein levels, neither in SMCs nor in ECs.  
In contrast to this finding, two studies report an upregulation of the channel in proliferative 
versus contractile SMCs, albeit in models of  neointima hyperplasia, such as the murine femoral 
artery balloon injury model (Cidad, Moreno-Dominguez et al. 2010) or in human saphenous 
vein segments cultured ex vivo following endothelial damage (Cheong, Li et al. 2011). 
However, even if both arteriogenesis and neointima hyperplasia share a strong SMC 
proliferation, in neointima hyperplasia is characteristic an endothelial dysfunction occasioned 
by endothelium damage. During arteriogenesis, however, SMC proliferation induction follows 
a FSS-driven endothelial activation without endothelial damage or dysfunction (Hui 2008, 
Patel, Waltham et al. 2010). It is well known that the endothelium regulates SMC proliferation 
through several mechanisms. The endothelium acts as a barrier from continuous contact to GFs 
present in the vessel lumen and secrete products that directly inhibit SMCs proliferation, like 
nitric oxide (Feletou 2011, Napoli, Paolisso et al. 2013). Indeed, re-endothelization after 
vascular injury results in less neointima hyperplasia (Nugent, Rogers et al. 1999, Patel, 
Waltham et al. 2010, Adamo, Fishbein et al. 2016). Hence, the course of SMC proliferation 
during arteriogenesis may proceed to a different manner as the one in the pathological situation 
of neointima hyperplasia and explain the different KV1.3 expression regulation in proliferative 
SMCs in both models. 
Besides the regulation of protein abundance, channel function can also be modulated at the 
level of channel activity as well as subcellular localization. While KV1.3 channel gating occurs 
through membrane depolarization, mechanisms regulating channel gating have been reported 
such as post-translational modifications or modulation by auxiliary subunits (Cook and Fadool 
2002). The auxiliary subunit KCNE4 for example, strongly inhibits KV1.3 activation and 
increases its rate and extent of cumulative inactivation (Grunnet, Rasmussen et al. 2003, Sole, 
Roura-Ferrer et al. 2009). Auxiliary subunits also mediate channel sorting and trafficking. 
Hence, interaction with KCNE4 or the prodomain of the metalloproteinase 23 impair KV1.3 
targeting to the cell membrane and retains it in the endoplasmic reticulum (ER) (Sole, Roura-
Ferrer et al. 2009, Nguyen, Galea et al. 2013), while co-expression of Kv1.3 with the ß subunits 
KVß1 or KVß2 in oocytes results in increase channel localization and K+ currents at the cell 
membrane, without affecting its activation kinetic (McCormack, McCormack et al. 1999). 
KV1.3 has been found in different subcellular localizations such as nuclei and nuclear envelope 
as well as the mitochondrial membrane. Hence, as discussed in the next chapter, it may be 
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subject to recycling from the cell membrane to the nucleus (Gulbins, Sassi et al. 2010, Jang, 
Byun et al. 2015).  
In summary, KV1.3 might be regulated during arteriogenesis through channel activity and/or 
subcellular localization instead of protein abundance. Further investigations on channel 
subcellular localization, expression analysis of auxiliary subunits or KV1.3 post-translational 
modifications in collateral SMCs following FAL specifically will complement our knowledge 
on KV1.3 regulation in arteriogenesis.  
Along with its localization in SMCs, KV1.3 was strongly and constantly expressed in ECs. 
Interestingly, the fluorescence signal in ECs was stronger than in SMCs, reflecting higher KV1.3 
levels in ECs than in SMCs. A stronger expression of KV1.3 in ECs versus SMCs was also 
reported at the mRNA level by Fountain et al in mouse mesenteric arteries (Fountain, Cheong 
et al. 2004). The role of endothelial KV1.3, however, has not been investigated extensively. 
KV1.3 may mediate endothelial proliferation, since KV1.3 blockade with Margatoxin inhibited  
human umbilical vein ECs (HUVECs) proliferation in vitro, by interfering with VEGF-
mediated hyperpolarization and NO production, a well-known endothelial mitogenic factor 
(Erdogan, Schaefer et al. 2005). 
Based on cell morphology and localization, perivascular inflammatory cells and adventitial 
fibroblasts, in addition to skeletal muscle were also stained for KV1.3. Macrophages and T cells 
are recruited to collateral arteries where they foster collateral artery growth (Arras, Ito et al. 
1998, Scholz, Ito et al. 2000, Stabile, Kinnaird et al. 2006). In macrophages, KV1.3 plays a role 
in proliferation and migration (Vicente, Escalada et al. 2003, Kan, Gao et al. 2016). In T cells, 
KV1.3 is involved in T cell receptor-mediated activation and proliferation (Azam, 
Sankaranarayanan et al. 2007). While in fibroblasts, KV1.3 expression has not been described 
so far, in skeletal muscle KV1.3 has been involved in glucose uptake (Li, Wang et al. 2006). 
Due to the broad expression of KV1.3 in collateral arteries, results on the effects of channel 
blockade on SMC proliferation in vivo were analysed carefully and contrasted with in vitro 
experiments effectuated with primary MArSMCs. 
4.2.2. PAP-1 impaired arteriogenesis by inhibiting SMC PM and 
proliferation 
The expression of KV1.3 in resting and growing collateral SMCs, prompted us to investigate 
the impact of KV1.3 channel blockade on arteriogenesis and specially on SMC proliferation. 
Moreover, a first seven day follow up of the perfusion recovery of the hind-limb after femoral 
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artery ligation revealed an attenuation of the perfusion recovery on day three after FAL that 
became significant on day seven under KV1.3 channel blockade. To contrast LDI data, a more 
specific and detailed analysis of arterial morphometry was performed in collaterals of adductor 
samples of control and PAP-1-treated mice. Adductors were collected after maximal 
vasodilation and perfusion fixation with paraformaldehyde, seven days after ligation of the 
femoral artery. Histological cross-sections of the middle region were stained with Giemsa 
solution to delimitate vascular wall, and collaterals were compared between occluded- and 
sham-operated hind-limb and between groups. As expected, a strong increase in diameter and 
in medial thickness was detected in control mice between collaterals of the occluded hind-limb 
and their sham-operated counterpart. While collateral arteries in occluded hind-limb of PAP-1-
treated mice depicted similar diameters compared to control ones, a significant decrease was 
observed in collateral medial thickness and medial area. These results pointed to an inhibition 
of SMC proliferation by KV1.3 blockade with PAP-1 while EC proliferation remained 
unaffected. In order to verify this hypothesis, a quantitative analysis of proliferative SMCs and 
ECs was carried out in collateral cross-sections of occluded hind-limb of mice treated with the 
thymine substitute BrdU, seven days after occlusion of the femoral artery. Indeed, while BrdU+ 
ECs-to-total ECs ratios were similar in control versus PAP-1-treated mice, a strong reduction 
was observed in the BrdU+ SMCs-to-total SMCs ratio in collateral arteries under PAP-1 
treatment. Interestingly, an in vivo inhibition of SMC proliferation by PAP-1 has also been 
reported though in a murine model of hypertension-mediated neointima hyperplasia (Cidad, 
Novensa et al. 2014). 
Considering that collaterals luminal diameters in both PAP-1-treated and control mice were 
similar, it is at first glance surprising that channel blockade impaired blood perfusion recovery. 
However, as assessed by collateral morphometry and BrdU+ SMC counting in seven days 
growing collateral arteries, PAP-1 significantly decreased SMC numbers. Since SMCs play a 
crucial role in vascular tone regulation, collateral arteries of PAP-1-treated mice could be 
affected in their vasodilation function. Hence, during LDI measurement the mouse is placed in 
a warm chamber to induce a physiological vasodilation that could be hindered in the thinner 
collateral arteries of PAP-1-treated mice. In contrast, for collateral morphometry analysis, 
collaterals are externally vasodilated by perfusion fixation before sample collection, so that the 
same vasodilation is reached in all groups.  
In addition, an involvement of KV1.3 in vascular tone regulation cannot be excluded neither. 
Even though a direct role of KV1.3 in vascular tone regulation has not been reported yet, studies 
with isolated and endothelium-denuded mesenteric arteries have associated the highly-related 
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K+ channels KV1.2, KV1.4, KV1.5 and KV1.6 with tone regulation in terminal arterioles by 
employing KV1 inhibitors (Yuan, Wang et al. 1998, Cheong, Dedman et al. 2001, Plane, 
Johnson et al. 2005). Hence, KV1.3 blockade with PAP-1 could increase vascular tone and blood 
pressure, preventing so optimal vasodilation in the warm chamber during LDI measurements 
and giving misleading results. For instance, a similar situation was observed in endothelial nitric 
oxide synthase knockout mice (eNOS-KO). eNOS produces nitric oxide (NO) that diffuses 
towards the SMC layer inducing SMC relaxation and subsequent vasodilation. While eNOS-
KO mice have a very bad perfusion recovery measured with LDI compared to their wild type 
littermates, their collateral arteries have surprisingly normal diameters and wall thicknesses. 
The restoration to a normal perfusion recovery in eNOS-KO mice after injection of the NO-
donor S-Nitroso-N-Acetyl-D,L-Penicillamine (SNAP) just before LDI measurement, indicated 
that the low perfusion observed was due to an interference in the vasodilation induced in the 
warm chamber during LDI measurement and not to poorer collateral growth (Schaper and 
Schaper 2004). 
Unfortunately, no measurements of blood pressure in PAP-1-treated and control mice were 
performed in this study and reports characterizing KV1.3-KO mice did not assessed explicitly 
alterations in blood pressure and vascular tone neither (Xu, Koni et al. 2003, Fadool, Tucker et 
al. 2004). Therefore, it remains an open question if bad recovery in feet perfusion under KV1.3 
blockade was due to dysfunctional collateral arteries as a result of less SMC numbers and/or to 
a role of the channel in vascular tone regulation. 
In several studies, KV1.3 has been correlated with in vitro SMC proliferation too. To contrast 
our in vivo findings and the reported data, the inhibitory effects of PAP-1 on SMC mitogenesis 
were assessed in MArSMCs through a BrdU-based proliferation ELISA test.  
Indeed, MArSMCs proliferation was proportionally inhibited with increasing concentrations of 
PAP-1. This inhibition was already significant with 1 µM PAP-1, a dose reported to be non-
toxic in Jurkat T cells and in mouse erythroleukemia (MEL) cells treated for 48h and no 
mutagenic for Salmonella typhimurium in an Ames test (Schmitz, Sankaranarayanan et al. 
2005). PAP-1 has also been reported to inhibit SMCs as well as HEK-293 cell proliferation 
transfected with a KV1.3 plasmid in vitro (Cidad, Moreno-Dominguez et al. 2010, Cidad, 
Jimenez-Perez et al. 2012). 
Since PAP-1 is a membrane-permeable KV1.3 channel blocker, its effects on SMC proliferation, 
both in vitro and in in vivo, could be consequence of the blockade in both nuclear and cell 
membrane KV1.3 channels 
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According to the presence of KV1.3 in SMCs of resting collateral arteries and the inhibitory 
effect that KV1.3 channel blockade exerted on SMC proliferation, we raised the question if 
KV1.3 could mediate SMC PM soon after arteriogenesis induction. Since SMCs undergoing 
PM strongly downregulate the expression of the contractile marker α-SMA (Mack 2011), its 
expression was assessed in collateral arteries of mice treated with the channel blocker. A 
previous analysis of αSma expression at several time points after ligation of the femoral artery 
revealed a depression point 12h after FAL, while the expression recovered 24h after and was 
even upregulated from 36h on. This reflected a first SMC proliferation wave 12h after 
arteriogenesis induction. After proliferation, SMC differentiate again giving rise to a mixture 
of SMC populations in collateral arteries and explain the upregulation of α-SMA from 36h on. 
Supporting this finding, Pagel et al also detected a downregulation of aSma 12h after FAL 
(Pagel, Ziegelhoeffer et al. 2012). Interestingly, aSma was no more repressed when KV1.3 was 
blocked with PAP-1 compared to control mice treated with vehicle only. 
Despite the strong expression of KV1.3 in collateral ECs observed by immunofluorescence 
staining, the regular arterial diameters and BrdU+ ECs ratios of collateral arteries in occluded 
hind-limb of PAP-1 treated mice, made assume that in arteriogenesis endothelial KV1.3 
probably does not play a role in EC proliferation in contrast to what reported by Erdogan et al. 
in HUVECs (Erdogan, Schaefer et al. 2005).  
Altogether, in vivo findings point to a role of the Kv1.3 channel in the regulation of SMC 
proliferation during arteriogenesis and probably in the mediation of SMC PM soon after 
arteriogenesis induction. However, since the channel is also expressed in ECs and perivascular 
cells, known to foster collateral growth, blockade of the channel in these cells could influence 
SMC phenotype and proliferation too. To verify that the effects seen on SMC proliferation 
under PAP-1 treatment were indeed consequence of channel blockade on SMC themselves, in 
vitro experiments were performed in parallel with MArSMCs.  
4.2.3. KV1.3 localizes in the nucleus and could regulate gene 
expression 
The in vivo findings on KV1.3 expression in collateral SMCs and on SMC proliferation under 
channel blockade were contrasted with in vitro experiments performed with primary 
MArSMCs. Cells cultured in SMCGM containing the GFs EGF and FGF-2 were characterized 
by immunofluorescence cytochemistry. KV1.3 staining not only confirmed the expression of 
the channel but, moreover, it revealed an unexpected localization at the nucleus and ER, 
together with a much weaker signal in cytoplasm and cell membrane. Interestingly, the nuclear 
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localization of KV1.3 has been reported in several cancer cells, human brain tissue and Jurkat 
cells (Jang, Byun et al. 2015) but not in SMCs yet (Cidad, Moreno-Dominguez et al. 2010).  
How KV1.3 is transported to the nuclear envelope (NE) and/or into the nuclei and moreover, 
through which stimulus, is not well known. Nuclear proteins are transported to the nucleus 
usually through the recognition of a nuclear localization signal (NLS). Then, they cross the 
nuclear pore complexes (NPC) that connect the outer nuclear membrane (ONM) with the inner 
nuclear membrane (INM) together. However, KV1.3 protein has no conventional NLS in its 
sequence, and even if an atypical NLS cannot be discarded, its nuclear localization can be 
explained by other mechanisms (Jang, Byun et al. 2015). As other transmembrane proteins, 
KV1.3 channel may diffuse from the ER where it folders to the outer nuclear membrane (ONM), 
since both membranes are continuous. The channel, if located at the INM, could then be 
translocated from the ONM to the INM or to the nucleus through vesicular fusion or through 
peripheral channels present between the NPC core and the membrane (Zuleger, Korfali et al. 
2008, Ungricht and Kutay 2015). Interestingly, the voltage-gated K+ channel KV10.1 has been 
detected in the cell membrane but also in the INM of neurons, tumor cells and several cell lines 
(Chen, Sanchez et al. 2011). Even though KV10.1 contains a NLS, its translocation to the INM 
seems to precede channel recycling from the cell membrane via endocytosis and lysosomes 
sorting representing an alternative pathway to the NE, the so called retrograde pathway (Kohl, 
Lorinczi et al. 2011). Intriguingly, a recent publication reported the endocytosis of KV1.3 
following EGF-EGFR signalling in HEK-293 cells, targeting the channel to endosomes 
together with the EGFR, in an ERK1/2-dependent process (Martínez-Mármol, Comes et al. 
2016). Even if the authors found KV1.3 in lysosomes and concluded that the channel is finally 
degraded, a possible route from endosomes to the nucleus via the retrograde pathway, as 
described for KV1.10, cannot be excluded neither. Hence, the translocation from endosomes to 
the nucleus has also been described for EGFR itself, together with other RTKs such as FGFR-
1 (Wang, Yamaguchi et al. 2010). Moreover, since EGF is one of the GF present in the growth 
medium used in this study to culture MArSMCs, EGFR engagement might explain the different 
KV1.3 localization pattern observed in SMCs respect to other reports (Cidad, Moreno-
Dominguez et al. 2010). 
The NE is a permeable barrier to ions. The perinuclear space (NE lumen) acts as a Ca2+ store, 
with high [Ca2+] inside compared to cytoplasm and nucleoplasm. Inversely, [K+] in the 
perinuclear space is lower than outside (Garner 2002). The presence of intranuclear electrical 
charges (negatively charged DNA and positively charged histones) and the diffusion of ions 
across the NE through ion channels and along the NPCs generate a nuclear membrane electrical 
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potential difference (nmΔΨ). Thus, changes in the nuclear K+ channels activity alters K+ flux 
across the NE and affects nmΔΨ. Subsequently, changes in perinuclear [Ca2+] activates Ca2+-
regulated gene expression (Checchetto, Teardo et al. 2016). Hence, the blockade of the nuclear 
channels ATP-sensitive potassium channel (KATP) and KCa1.1 or activation of the nuclear 
inositol triphosphate receptor (InsP3R) trigger nuclear Ca2+ transients able to activate the 
transcription of the Ca2+-activated TF cAMP response element-binding (CREB) (Quesada, 
Rovira et al. 2002, Cardenas, Liberona et al. 2005, Li, Jie et al. 2014).  
Interestingly, Jang et al reported an increased phosphorylation and activation of CREB and an 
increased c-fos abundance under PAP-1 channel blockade and thus suggested a role for KV1.3 
in the regulation of gene expression. Accordingly, since Margatoxin induced hyperpolarization 
of the NE in isolated nuclei, this regulation may be permeation-dependent and Ca2+-mediated 
(Jang, Byun et al. 2015). Moreover, Klemm et al correlated high CREB levels with a lower 
SMC proliferation both in vivo and in vitro (Klemm, Watson et al. 2001).  
In addition, Jang et al demonstrated a direct interaction between KV1.3 and the TF Upstream 
binding transcription factor 1 (UBTF1), a TF that controls RNA polymerase I, responsible for 
the transcription of rRNA (Jang, Byun et al. 2015). rRNAs assemble with ribosomal proteins 
to form ribosomes, that in the cytoplasm, control mRNA translation to proteins. Both rRNA 
and the subsequent protein synthesis take place before mitosis and are crucial for successful 
cell proliferation. rRNA synthesis increases during the G1 phase and reach a maximum in G2 
phase (Hernandez-Verdun 2011). Interestingly, KV1.3 silencing in A549 lung adenocarcinoma 
cells resulted in anti-proliferative effects by affecting the G1 to S transition (Jang, Choi et al. 
2011).  
Furthermore, nuclear K+ ions can directly influence the physical structure of heterochromatin, 
regulating so transcription efficiency and splicing. K+ ions increase the stability of G-
quadruplex structures, inter or intramolecular non-Watson-Crick pairs in guanine-rich area, 
which can act as transcriptional repressor elements (Siddiqui-Jain, Grand et al. 2002). Chen et 
al postulated that KV10.1 could bind to heterochromatin since its localization correlated with 
the absence of Lamin A/C, compatible with heterochromatin (Chen, Sanchez et al. 2011). 
Interestingly, immunofluorescence staining of MArSMCs revealed KV1.3 signal surrounding 
pericentric heterochromatin stained with DAPI. 
In summary, the nuclear localization of KV1.3 in MArSMCs may be explained by recycling 
from the cell membrane following EGFR engagement and MAPK activation (Fig 4.1). In the 
nuclei or NE, KV1.3 may then influence gene transcription and subsequent SMC proliferation 
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through almost three different mechanisms: the regulation of TF activity/ abundance, rRNA 
synthesis and subsequent protein translation and/or by modifying heterochromatin structure and 
accessibility. 
Figure 4.1: Proposed model of nuclear KV1.3-mediated gene expression regulation 
EGFR engagement and MAPK activation leads to KV1.3 endocytosis from the cell membrane together 
with the EGFR (Martínez-Mármol, Comes et al. 2016). As described for KV10.1 and the EGFR itself, 
KV1.3 could be then recycled to the nucleus through the retrograde pathway (Wang, Yamaguchi et al. 
2010, Kohl, Lorinczi et al. 2011). In the nucleus, Kv1.3 might regulate gene expression by several 
mechanisms such as TF regulation, rRNA synthesis or heterochromatin stabilization (Siddiqui-Jain, 
Grand et al. 2002, Jang, Byun et al. 2015). 
4.2.4. Role of KV1.3 in RTK signalling 
GF signalling through RTK and downstream MAPK is a strong inducer of SMC proliferation 
(Mack 2011). In SMCs, engagement of FGFR-1, PDGFR-ß and other RTK leads to the 
activation of the MAPK kinase (MEK) that in turn phosphorylates ERK. ERK translocates to 
the nucleus and phosphorylates among others the transcription activator Elk-1. Finally, Elk-1 
binds to the TF SRF inducing the expression of early growth genes, such as the TF EGR-1 
(Santiago, Lowe et al. 1999, Hjoberg, Le et al. 2004, Vogel, Kubin et al. 2006).  
Hence, the influence of KV1.3 blockade on RTK and MAPK signalling was investigated next. 
First, the effect of channel blockade on the expression of the SMC mitogenic FGFR-1 and 
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PDGFR-ß receptors was analysed both in MArSMCs and in collateral arteries. Furthermore, 
we investigated the expression of the RTK downstream target EGR-1. Additionally, to elucidate 
if KV1.3 participates in RTK signalling at the cell membrane upstream ERK, ERK 
phosphorylation following RTK stimulation, was examined by western-blot in MArSMCs. 
PAP-1 repressed Fgfr1 and Pdgfrb expression in MArSMCs and in arteriogenesis 
Since FGFR-1 and PDGFR-ß gene expression is induced by FGF-2, MArSMCs were stimulated 
for 6h with SMCGM containing FGF-2 and EGF after a starvation period of 24h (Kano, 
Morishita et al. 2005). Compared to negative control cells cultured further in starvation 
medium, no significant up-regulation of Fgfr1 and Pdgfrb mRNA levels were observed under 
SMCGM stimulation. The absence of upregulation of the RTKs could be explained by the short 
starvation period (24h) in which SMCs could not have reached total quiescence and still express 
high amounts of RTKs. Nevertheless, an intriguing significant repression of Fgfr1 and Pdgfrb 
expression was manifested when MArSMCs were stimulated with SMCGM under KV1.3 
blockade.  
Likewise, gene expression analysis in collateral arteries 12h after FAL revealed a strong 
downregulation of Fgfr1 and Pdgfrb in mice treated with PAP-1. Since 12h after FAL is a very 
early time point and SMC proliferation reaches a peak three day after FAL, the lower levels of 
Fgfr1 and Pdgfrb detected under PAP-1 rather point to an involvement of KV1.3 in RTK 
signalling or Fgfr1 and Pdgfrb expression regulation directly and not to lower SMC numbers. 
In control mice, Fgfr1 and Pdgfrb were not differentially upregulated, presumably due to its 
earlier upregulation (Deindl, Hoefer et al. 2003). 
The relevance of FGFR-1 in arteriogenesis has been reported by Deindl et al. who not only 
detected an upregulation of the receptor in collateral arteries as early as 3h after FAL with a 
peak after 6h in the rabbit, but also a poor collateral growth under blockade of the binding of 
the receptor to its ligand with polyanetholesulfonic acid (PAS) (Deindl, Hoefer et al. 2003). 
FGF-2 in collateral arteries is secreted by recruited monocytes and tissue macrophages as well 
as mast cells (Arras, Ito et al. 1998, Scholz, Ito et al. 2000, Chillo, Kleinert et al. 2016). 
Likewise, tissue macrophages and mast cells release PDGF-BB in growing collaterals (Takeda, 
Costa et al. 2011, Chillo, Kleinert et al. 2016). The PDGF-BB-PDGFR-ß axis is well known 
for its mediation in SMC proliferation and migration also in arteriogenesis (Heldin and 
Westermark 1999, de Paula, Flores-Nascimento et al. 2009). 
Considering the important role of the RTK FGFR-1 and PDGFR-ß on SMC proliferation, it 
may well be that their soon downregulation under KV1.3 channel blockade observed in vivo, is 
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responsible, at least partially, for the reduced SMC proliferation detected in collateral arteries 
of mice treated with the KV1.3 channel blocker PAP-1. 
PAP-1 repressed the expression of the downstream transcription factor EGR-1 in 
MArSMCs and in arteriogenesis 
To induce Egr1 expression in vitro, MArSMCs were stimulated with SMCGM after 24h serum 
starvation. Egr1 was slightly upregulated after SMCGM stimulation compared to starved 
control cells, while, intriguingly, its expression was strongly downregulated when cells were 
given PAP-1 together with SMCGM.  
In vivo, analysis of Egr1 mRNA levels in collaterals of occluded- versus sham-operated hind-
limbs of control mice confirmed its already reported upregulation 12h after FAL (Pagel, 
Ziegelhoeffer et al. 2012). Moreover, and correlating with in vitro findings, Egr1 upregulation 
was significantly truncated in mice treated with the KV1.3 channel blocker.  
Besides Egr1 upregulation in collateral arteries 12h after FAL, Pagel et al also reported the 
involvement of EGR-1 in SMCs PM. Egr1-KO mice expressed higher α-SMA and splicing 
factor 1 (SF-1) levels compared to wild type mice, hallmarks of the SMC contractile phenotype. 
Moreover, the lack of Egr1 decreased the collateral expression of the proliferation marker Ki67 
and cyclin D, a cell cycle regulatory protein (Pagel, Ziegelhoeffer et al. 2012).  
Together with the expression repression of the RTK receptors FGFR-1 and PDGFR-ß, 
truncation of Egr1 upregulation may be responsible for the low SMC proliferation detected in 
growing collaterals of PAP-1 treated mice. Egr1 repression under KV1.3 channel blockade 
might be consequence of the downregulation of the upstream receptors FGFR-1 and PDGFR-ß 
themselves, but also to a role of KV1.3 in Egr1 expression regulation as postulated above. 
KV1.3 acts downstream ERK phosphorylation in MArSMCs 
KV1.3 channel current at the cell membrane is inhibited following EGFR engagement, in part 
through tyrosine phosphorylation by v-src tyrosine kinase (Holmes, Fadool et al. 1996, Bowlby, 
Fadool et al. 1997). Interestingly, v-src-mediated tyrosine phosphorylation of KV1.3 and current 
inhibition is reverted by the adaptor protein growth factor receptor-bound protein 10 (Grb10), 
a positive adaptor protein of RTK downstream signalling (Wang, Dai et al. 1999, Cook and 
Fadool 2002, Cailliau, Le Marcis et al. 2003).  
Hence, we asked if KV1.3 blockade at the cell membrane could inhibit downstream FGFR-1 
and EGFR signalling in MArSMCs. For this, ERK phosphorylation was assessed under 
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stimulation with SMCGM containing FGF-2 and EGF in the presence of two KV1.3 channel 
blockers, Margatoxin and PAP-1. As a negative control, cells were stimulated with SMCGM in 
the presence of the MEK inhibitor UO126. After five minutes stimulation with SMCGM, ERK 
phosphorylation by MEK was induced compared to cells maintained in starvation medium. 
Furthermore, treatment with UO126, strongly blocked ERK phosphorylation without affecting 
total ERK protein levels. However, neither Margatoxin nor PAP-1 could revert ERK 
phosphorylation, questioning a role of the channel upstream ERK.  
Interestingly, Jimenez-Perez et al. recently reported that KV1.3 conformational change 
following membrane depolarization leads to the exposure of a segment at the C-terminus of the 
channel that is subsequently phosphorylated by p-ERK increasing KV1.3 mitogenic effects 
(Jimenez-Perez, Cidad et al. 2016). In addition, EGF-mediated KV1.3 endocytosis from the cell 
membrane following EGFR engagement is also ERK1/2-dependent (Martínez-Mármol, Comes 
et al. 2016). Contrastingly, Kan et al. reported that KV1.3 downregulation via siRNA in cultured 
macrophages reduced ERK-phosphorylation and ERK-mediated migration, while UO126 
inhibited migration and increased ERK-phosphorylation induced by KV1.3 overexpression 
(Kan, Gao et al. 2016). 
This in vitro finding and the recent literature demonstrating a role of ERK in KV1.3 regulation 
and trafficking following RTK engagement point to a role of KV1.3 in RTK signalling 
downstream ERK. Furthermore, in view of the strong localization of the channel at the nuclei 
and nuclear envelope of MArSMCs cultured in SMCGM, a role of the nuclear KV1.3 in cell 
proliferation cannot been discarded neither. However, as reported for Kv1.3-mediated 
migration in macrophages, it cannot be excluded that KV1.3 also signals upstream ERK in other 
signalling pathways and functions such as migration. 
4.2.5. Sp1 could be involved in KV1.3-mediated gene regulation 
Considering the strong localization of KV1.3 in MArSMCs nuclei, we endeavored to define the 
role of the nuclear KV1.3 in RTK signalling. An intriguing role for KV1.3 in the activation of 
the TFs CREB and c-fos abundance in cancer cells has been reported, involving the channel in 
gene expression regulation (Jang, Byun et al. 2015). The authors detected an increased 
phosphorylation of CREB under PAP-1 treatment in lung adenocarcinoma cells. Interestingly, 
a correlation of increased CREB levels with downregulation of GFs and RTKs such as PDGFR-
α and Endothelin-1 receptor has been reported in SMCs (Klemm, Watson et al. 2001). One may 
hypothesize that the downregulation of Fgfr1, Pdgfrb and Egr1 observed under PAP-1 
treatment in MArSMCs and in collateral arteries could be mediated by an increased 
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phosphorylation of CREB. However, there is until now no evidence of a CREB-mediated 
downregulation of these genes following phosphorylation. Quite the contrary, a study in 
gonadotrophs described the binding of p-CREB to the Egr1 promoter and increased expression 
while a dominant negative mutant of CREB resulted in less Egr1 expression (Mayer, Willars et 
al. 2008). Hence, other TFs must be involved in the regulation of Fgfr1, Pdgfrb and Egr1 by 
KV1.3. Interestingly, a recent publication reported c-fos-dependent Fgfr1 transcription in 
osteosarcoma cells (Weekes, Kashima et al. 2016). Moreover, in arteriogenesis, activator 
protein-1 (AP-1), the heterodimer composed of c-fos and c-Jun, is activated 24h after FAL and 
regulates the transcription of MCP-1 in SMCs (Demicheva, Hecker et al. 2008). Since c-fos 
transcription is induced by MAPK signalling activation, it might also be involved in KV1.3-
mediated gene expression regulation of Fgfr1 (Karin 1995). 
Interestingly, Specificity protein 1 (Sp1), a member of the specificity protein/Krüppel-like 
factor (Sp/KLF) zinc finger family of transcription factors, regulates SMC PM and SMC 
proliferation (Andres, Urena et al. 2001, Deaton, Gan et al. 2009, Tang, Yu et al. 2017) and has 
been involved in the transcription of Fgfr1, Pdgfrb and Egr1 in different cell types, albeit not 
in SMCs specifically (Cao, Mahendran et al. 1993, Patel and DiMario 2001, Kaneko, Yang et 
al. 2006).  
Sp1-DNA binding blockade inhibits the expression of Fgfr1 and Egr1 in MArSMCs under 
RTK stimulation 
Since Sp1 transcription of Fgfr1, Pdgfrb and Egr1 has not been assessed in SMCs specifically, 
the effects of the Sp1-DNA binding blocker Mithramycin A (MTM) were investigated in 
MArSMCs via real time PCR. To induce Sp1 activation and transcription activity, MArSMCs 
were stimulated with SMCGM containing FGF-2 and EGF, as these GFs induce ERK-1/2-
dependent Sp1 phosphorylation and transcription activity in SMCs (Merchant, Du et al. 1999, 
Bonello and Khachigian 2004). 
After three days in starvation medium, MArSMCs stimulated with SMCGM for six hours 
significantly upregulated Fgfr1 and Egr1 expression. Addition of MTM significantly repressed 
this upregulation, even though both genes were still upregulated compared to negative controls. 
In contrast, Pdgfrb expression was strongly downregulated in MArSMCs following RTK 
stimulation independent on MTM treatment compared to cells in starvation medium. 
The partial repression of Fgfr1 and Egr1 upregulation indicated additional Sp1-independent 
transcription regulation mechanisms. Indeed, Fgfr1 gene expression is regulated by c-Fos/ AP-
1, the pRB/E2F pathway and by AP-2 in different cell types (Tashiro, Maruki et al. 2003, 
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Mitchell and DiMario 2010, Weekes, Kashima et al. 2016). Regarding Egr1, its expression is 
activated by Elk-1 following RTK engagement through binding with SRF among others (Gregg 
and Fraizer 2011). Regarding Pdgfrb regulation, a negative feedback loop in Pdgfrb expression 
has been reported in fibroblasts and in SMCs stimulated with FCS for a long period of time 
(Vaziri and Faller 1995, Kaplan-Albuquerque, Van Putten et al. 2005). Hence, 5 minutes 
stimulation with PDGF-BB resulted in a strong Pdgfrb upregulation and PDGFR-ß 
phosphorylation in SMCs, while six hours stimulation strongly repressed its expression 
(Kaplan-Albuquerque, Van Putten et al. 2005). In our setting, the strong downregulation 
observed under SMCGM stimulation could well be due to this negative feedback response.  
From these findings, it can be affirmed that indeed, Sp1 regulates the transcription of Fgfr1 and 
Egr1 under engagement of RTK in MArSMCs too, although other TFs may be involved. Hence, 
Sp1 could be the chain link between the nuclear KV1.3 and the downregulation of Fgfr1 and 
Egr1 observed under PAP-1 treatment. In addition, since Pdgfrb expression under MTM was 
performed in MArSMCs stimulated for six hours, which might have led to a negative feedback 
regulation, further experiments are needed to demonstrate an Sp1-mediated regulation of 
Pdgfrb expression following RTK engagement.  
KV1.3 blockade inhibits Sp1 expression in MArSMCs but not in whole collateral arteries 
Besides post-translational modifications and protein interactions influencing DNA binding 
and/or transactivation activity, Sp1 transcription activity can be modulated by Sp1 abundance 
(Bonello and Khachigian 2004, Tapias, Ciudad et al. 2008, Tan and Khachigian 2009, Azahri, 
Di Bartolo et al. 2012). Thus, the effect of KV1.3 blockade on Sp1 gene expression was analysed 
in vitro and in vivo.  
Interestingly, six hours stimulation with GFs-containing SMCGM following a starvation period 
did not influence Sp1 gene expression in MArSMCs, while KV1.3 blockade with PAP-1 
resulted in a significant decline of Sp1 mRNA levels. In contrast, channel blockade did not 
influence Sp1 expression in collateral arteries of occluded hind-limb 12h after FAL compared 
to their contralateral counterparts in control mice. Moreover, and in contrast to Egr1, Sp1 
mRNA levels in control mice were not differentially expressed at this time point neither.  
Sp1 plays an important role in cell cycle regulation and its Sp1 abundance is tiny regulated by 
cell cycle related proteins reaching a peak at the G1 phase (Tapias, Ciudad et al. 2008). Indeed, 
while ectopic expression of a truncated Sp1 mutant results in growth arrest at the S-phase, its 
overexpression in several cancer cells leads to an aberrant cell proliferation (Kumar and Butler 
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1998, Chen, Zhang et al. 2000, Wang, Wei et al. 2003). Expression of Sp1 is mainly regulated 
by Sp1 itself as well as by other Sp/KLF family members (Nicolas, Noe et al. 2003). 
Considering Sp1 downregulation by PAP-1 in MArSMCs, it is conceivable that KV1.3 channel 
influences Sp1 expression and subsequent transcriptional activity. However, this effect was not 
detectable in whole collateral artery samples, probably due to the ubiquitous expression of Sp1, 
unmasking any expression changes in collateral SMCs. Hence, further analysis of Sp1 
abundance in collateral SMCs through quantitative immunofluorescence histochemistry would 
complement in vitro data. In addition, Kv1.3 may influence Sp1 post-transcriptional 
modifications too as observed for p-CREB. Interestingly, post-translational induction of Sp1-
DNA binding and not Sp1 abundance induced SMC proliferation in a balloon angioplasty 




Figure 4.2: Proposed model of KV1.3-mediated transcription regulation of Fgfr1 and Egr1 through 
the regulation of Sp1 abundance in SMCs 
Following RTK engagement and MAPK signalling activation, KV1.3 channel is recycled to the nucleus 
and nuclear envelope. There, it might regulate Sp1 gene transcription since KV1.3 blockade repressed 
Sp1 expression. In addition, KV1.3 might also regulate Sp1 post-transcriptional regulation. As 
demonstrated with the Sp1 inhibitor Mithramycin A (MTM), Sp1 in turns regulates Fgfr1, Egr1 and 
probably Pdgfrb in SMCs, all three genes involved in SMC proliferation. The repression of the TF EGR-
1 would lead to the repression of early response genes regulating cell division while FGFR-1 and 
PDGFR-ß downregulation of the RTK would decline RTK signalling. Both situations would finally lead 
to less SMC proliferation. 
4.2.6. Sp1 does not regulate Kv1.3 expression in MArSMCs 
Besides Fgfr1, Pdgfrb and Egr1, Kv1.3 gene expression itself has been reported to be under the 
transcriptional activity of Sp1, albeit in cancer cells (Jang, Byun et al. 2015). Moreover, the 
expression of the KV1.3 highly related channel KV1.5 is also regulated by Sp1 (Fountain, 
Cheong et al. 2007). 
Interestingly, no effects on Kv1.3 mRNA levels were observed when MArSMCs were treated 
with MTM following RTK engagement, even if Kv1.3 expression was significantly upregulated 
following GF stimulation compared to cells cultured further in starvation medium.  
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This result denotes that KV1.3 gene expression is certainly regulated by TFs activated 
downstream RTK engagement. Interestingly, FGF-2 and PDGF-B upregulate KV1.3 expression 
and mitogenesis of cultured oligodendrocyte precursor cells (Chittajallu, Chen et al. 2002). So 
far, Sp1-mediated KV1.3 and KV1.5 expression regulation has been demonstrated through 
artificial in vitro systems (Fountain, Cheong et al. 2007, Jang, Byun et al. 2015). Thus, the 
stimulus inducing Sp1-mediated transcription of the KV1.3 gene is still unknown. 
4.3. The role of KCa3.1 in arteriogenesis 
Similar to KV1.3, the Ca2+-gated K+ channel KCa3.1 has been related to SMC proliferation in 
vitro and in vivo situations of intima hyperplasia. However, its specific role in arteriogenesis 
and in outward remodelling processes has not been investigated so far.  
4.3.1. KCa3.1 expression is induced in early arteriogenesis 
Immunofluorescence staining of collateral arteries sections demonstrated the presence of 
KCa3.1 in collateral SMCs, ECs and perivascular inflammatory cells. Interestingly, a rise in 
KCa3.1 level was observed in both SMCs and ECs two days after FAL, while seven days after 
ligation KCa3.1 levels returned to basal values in both cell types.  
In SMCs, expression of KCa3.1 was restricted to the proliferative phenotype. While in resting 
collateral arteries KCa3.1 protein level in SMCs was very low, two days after FAL an 
upregulation was evident although statistically insignificant. Moreover, KCa3.1 protein level 
was significantly restrained seven days compared to two days after FAL, time point by which 
most SMCs have reached again a differentiated phenotype. 
This in vivo induction of KCa3.1 expression has been reported in situations of neointima 
hyperplasia at both mRNA and protein levels too (Kohler, Wulff et al. 2003, Tharp, Wamhoff 
et al. 2008). However, the downregulation of KCa3.1 following a SMC mitogenic phase as 
observed in growing collaterals has never been described, again reflecting the different 
regulation mechanisms controlling neointima hyperplasia and arteriogenesis. 
KCa3.1 was also expressed in collateral ECs as detected by co-localization with the EC marker 
CD31. Again, its expression was stronger two days after FAL but very weak in resting and in 
seven day growing collaterals. Several studies report an upregulation of the channel in ECs 
when stimulated with the GFs FGF-2, VEGF and EGF. Moreover, through KCa3.1 blockade 
with TRAM-34, they confirmed a role of the channel in endothelial mitogenesis in vitro and in 
murine models of angiogenesis (Grgic, Eichler et al. 2005, Yang, Li et al. 2013). However, 
since in our in vivo findings, TRAM-34 did not influence ECs proliferation during 
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arteriogenesis (see below), its role in ECs may have more to do with its function in EDHF-
mediated vasodilation. Hence, KCa3.1 expression is induced in ECs exposed to FSS 
(Brakemeier, Kersten et al. 2003). Since increased FSS is the driving force for EC activation 
during early arteriogenesis, it might explain its upregulation soon after FAL. Interestingly, the 
Ca2+-channel transient receptor potential cation channel, subfamily V, member 4 (TRPV4) acts 
as an mechanotransducer of increased FSS in collateral arteries, being upregulated in ECs as 
early as 24h after FAL. Upon channel activation a first rise in intracellular Ca2+ concentration 
could lead to activation of KCa3.1 and EDHF-mediated vasodilation while a sustained increased 
in Ca2+ ions would activate Ca2+-dependent TFs (Troidl, Troidl et al. 2009, Troidl, Nef et al. 
2010) 
Besides SMCs and ECs, fibroblasts and perivascular inflammatory cells were also stained for 
KCa3.1. The channel has been correlated with migration in macrophages (Chung, Zelivyanskaya 
et al. 2002, Penna and Stutzin 2015), migration and degranulation in mast cells (Duffy, Cruse 
et al. 2005), T cell receptor-mediated activation and proliferation in T cells (Ghanshani, Wulff 
et al. 2000) and proliferation in fibroblasts (Pena and Rane 1999). Since KCa3.1 channel 
blockade in these cells could influence SMC proliferation, in vivo data were contrasted with 
cultured MArSMCs. 
4.3.2. KCa3.1 blockade by TRAM-34 has a mild effect on 
arteriogenesis 
The role of KCa3.1 in arteriogenesis and particularly in SMC proliferation was further 
investigated in the FAL model, under KCa3.1 blockade with TRAM-34. LDI revealed a 
tendency to lower perfusion recovery at day three that resulted in a significant impediment in 
perfusion recovery seven days after FAL in mice treated with the KCa3.1 channel blocker. In 
contrast, analysis of collateral artery lumen diameters and medial area displayed a regular 
collateral artery growth. To resolve this incongruency, quantification of SMCs proliferation 
under KCa3.1 blockade was performed in mice receiving the proliferation marker BrdU. Hence, 
and consolidating collateral morphometry data, no obvious decrease in medial BrdU+ SMCs 
numbers were detected in seven days growing collateral arteries when mice were given TRAM-
34. In ECs, KCa3.1 blockade had no inhibitory effect in their proliferation neither, since 
collateral diameters and BrdU+ ECs were normal or even higher than in control collaterals.  
The controversial data concerning perfusion recovery and collateral morphometry, might be 
explained by the well-known function of the KCa3.1 in EDHF-mediated vasodilation that could 
affect vascular tone (Eichler, Wibawa et al. 2003, Si, Heyken et al. 2006). Indeed, KCa3.1-KO 
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exhibit 7 mmHg increase in mean arterial blood pressure probably due to impediment of its 
EDHF-mediated function (Si, Heyken et al. 2006). The effect of endothelial KCa3.1 blockade 
could influence perfusion of the feet during LDI measurements under heat-induced vasodilation 
by an increased vascular tone compared to control mice. As mentioned above, a similar effect 
was observed in eNOS-KO mice (Schaper and Schaper 2004). 
In addition, to assess a role of KCa3.1 in PM and soon induction of SMC mitogenesis, gene 
expression analysis of the contractile marker α-SMA and the RTK FGFR-1 and PDGFR-ß were 
assessed in whole collateral arteries of mice treated with TRAM-34. 12h after FAL, aSma 
mRNA levels were downregulated in collateral arteries of the occluded hind-limb compared to 
their contralateral counterparts in both, control and TRAM-34-treated mice. Moreover, KCa3.1 
blockade did not affect the expression of the GF receptors Fgfr1 and Pdgfrb neither.  
Contrastingly, a downregulation of the contractile markers α-SMA, SMMHC and Smoothelin-
B together with a KCa3.1 upregulation has been reported in cultured SMCs under stimulation 
with PDGF-BB. Moreover, treatment with TRAM-34 was able to downregulate KCa3.1 channel 
expression and blocked repression of the above-mentioned contractile markers (Tharp, 
Wamhoff et al. 2006). Together with the later KCa3.1 expression induction following FAL, these 
findings questioned a role of the channel in the induction of SMC PM and early SMC 
proliferation during arteriogenesis. 
Considering the many reports linking the channel with SMC proliferation and the increased 
protein levels in collateral SMCs during the active proliferation phase, the low effect of TRAM-
34 treatment in arteriogenic SMC proliferation was unexpected. One hypothesis contemplates 
the absence of phenotype to a suboptimal channel blockade in vivo. However, given that the 
dose of 120 mg/Kg/day used has been reported to be effective in inhibiting SMC proliferation 
in several in vivo studies, this hypothesis seems unlikely. Hence, in a rat model of restenosis, 
the same dose of TRAM-34 reduced intima hyperplasia by 40 % (Kohler, Wulff et al. 2003), 
while in an atherogenic mouse model, it led to a significant SMCs inhibition in atherosclerotic 
lesions in aortic roots (Toyama, Wulff et al. 2008).  
Furthermore, KCa3.1 blockade with TRAM-34 did not inhibit EC proliferation neither, as has 
been reported elsewhere (Grgic, Eichler et al. 2005, Yang, Li et al. 2013). To the contrary, 
collateral artery diameters in TRAM-34 treated mice were similar or even slightly higher to 
those of control mice. Moreover, quantification of BrdU+ ECs in seven days growing collateral 
transversal sections were slightly increased compared to the control group. Interestingly, 
TRAM-34 has been shown to act as an agonist of the estrogen receptors α and ß and to potentiate 
Discussion 
101 
the estrogen-induced in vitro proliferation of breast cancer cells at concentrations of 3-10 µM 
(Roy, Cowley et al. 2010). Moreover, ECs express both receptors and their engagement, 
together with an eNOS activation and NO-dependent vasodilation, is responsible for estrogen-
induced EC proliferation and migration (Haynes, Sinha et al. 2000, Lu, Schnitzler et al. 2016). 
Contrastingly, estrogen has an inhibitory effect on SMCs migration and proliferation in vivo 
and in vitro (Dai-Do, Espinosa et al. 1996, Yue, Vickery-Clark et al. 2000, Pare, Krust et al. 
2002). 
At this stage, it can be concluded that KCa3.1 plays a mild if not irrelevant role in SMC 
proliferation during arteriogenesis. Its expression and upregulation in collateral endothelium 
two days after FAL may reflect a role of the channel in EDHF-mediated vasodilation in early 
arteriogenesis. In addition, besides its effects on KCa3.1 blockade, TRAM-34 could have act as 
an estrogen receptor agonist in ECs, slightly stimulating their proliferation and concurring with 
the reported inhibitory effect on KCa3.1-mediated ECs proliferation. 
KCa3.1 localizes in the cell membrane and nuclei of MArSMCs and its blockade inhibits 
MArSMCs proliferation 
Interestingly, KCa3.1 channel staining in MArSMCs depicted a strong localization surrounding 
the nuclei and at the nuclei together with a much weaker staining at the cytoplasm and cell 
membrane. 
The nuclear localization of KCa3.1 has been reported in airway SMC as well as in placental 
trophoblasts (Chachi, Shikotra et al. 2013, Diaz, Wood et al. 2014). In spite of the reported 
KCa3.1 localization at the NE, its function at the NE has not been investigated specifically. As 
mentioned above, KCa1.1 has also been found in the NE of neurones. Its role has been correlated 
with Ca2+ transients from the NE towards the nucleoplasm and subsequent Ca2+-mediated 
CREB transcription (Li, Jie et al. 2014). It is therefore possible that, KCa3.1 similar to KCa1.1 
influence Ca2+-mediated gene expression, albeit certainly with different activation and 
regulation mechanisms. Interestingly, Bi et al reported in whole cell lysates an increased 
phosphorylation of CREB levels and c-fos following stimulation of SMCs with PDGF that was 
repressed under TRAM-34 treatment or even enhanced in SMCs overexpressing the channel 
(Bi, Toyama et al. 2013). 
Since several studies involve KCa3.1 with SMC proliferation in vitro, a BrdU proliferation assay 
was performed with cultured MArSMCs. After a starvation period of 24h, cells were stimulated 
with 10% FCS-enriched basal medium in the presence of increasing doses of TRAM-34. 
Indeed, the specific dose of 100 nM significantly reduced proliferation more than 35 % respect 
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to control cells. The mitogenic inhibitory effect of 100 nM TRAM-34 in SMCs has also been 
observed in human coronary SMCs (Toyama, Wulff et al. 2008, Bi, Toyama et al. 2013) and in 
the cell line A7r5 derived from rat aortic vascular SMCs (Si, Grgic et al. 2006).  
Interestingly, since TRAM-34 is a membrane-permeable blocker, a role of the nuclear channel 
in SMC proliferation through gene expression regulation cannot been discarded. However, as 
observed in vivo, KCa3.1-mediated SMC proliferation seems to be independent of Fgfr1 and 
Pdgfrb expression regulation, since treatment with TRAM-34, in contrast to the KV1.3 channel 
blocker PAP-1, did not influence their mRNA levels neither in cultured MArSMCs nor in 
collateral arteries of mice treated with the channel blocker, 12h after FAL. Accordingly, neither 
Bi et al could observe any change on Pdgfrb expression in human coronary SMCs under KCa3.1 
blockade with TRAM-34 and PDGF stimulation. Moreover, as mentioned above KCa3.1-
mediated proliferation was dependent on intracellular Ca2+ concentrations and CREB, c-fos and 
neuron-derived orphan receptor 1 (NOR-1) activation (Bi, Toyama et al. 2013). 
In conclusion, KCa3.1 induced MArSMCs proliferation as shown be the inhibitory mitogenic 
effect of its blocker TRAM-34. Furthermore, the strong subcellular localization of the channel 
in MArSMCs cultured in a GF-enriched growth medium and literature reports make 
hypothesize that the channel might regulate SMC proliferation through Ca2+-mediated gene 
expression regulation, as described for the related channel KCa1.1. However, experiments 
performed in the murine FAL model under channel blockade revealed an irrelevant role of the 
channel on arteriogenic SMCs proliferation. However, its upregulation in endothelium two days 
















The present study demonstrates that the voltage-gated K+ channel KV1.3, but not the Ca2+-gated 
K+ channel KCa3.1, remarkably influences SMC proliferation during arteriogenesis. KV1.3 in 
vivo blockade with PAP-1 resulted in thinner collateral arteries and lower medial BrdU+ SMCs 
ratios. This restricted SMC proliferation is presumably consequence of an early repression of 
the receptor tyrosine kinases FGFR-1 and PDGFR-ß as well as the well-known pro-arteriogenic 
transcription factor EGR-1 observed under KV1.3 blockade.  
In MArSMCs, RTK downstream signalling was not affected by KV1.3 blockade as observed by 
normal ERK phosphorylation following growth factor (GF) stimulation. Together with the 
strong detection of KV1.3 at the nuclei of MArSMCs cultured in GF-enriched growth medium, 
these findings argue for a nuclear KV1.3-mediated gene expression regulation. The precise 
mechanism however remains to be elucidated. As reported in cancer cells, nuclear KV1.3 is able 
to regulate transcription factor activation and abundance. Sp1, a transcription factor influencing 
SMC PM and proliferation may mediate this effect. Hence, beside a downregulation of Fgfr1 
and Egr1 under Sp1 blockade, we detected an in vitro repression of Sp1 under treatment with 
the KV1.3 blocker PAP-1. 
These findings, on the one hand, add insight into the role of KV1.3 in SMC proliferation during 
collateral artery growth, and further support the nuclear localization of the channel as well as 
its control over gene expression regulation in SMCs. Future investigations on KV1.3 activation 
mechanisms during arteriogenesis and KV1.3 downstream targets might assist in the 
identification of new and specific targets for therapeutic arteriogenesis. On the other hand, since 
KCa3.1 blockade manifested a very mild effect on arteriogenesis, this study further supports 
















Arteriogenesis, i.e. the growth of collateral arteries forming physiological bypasses, represents 
a physiological alternative to vascular surgery in obstructive diseases, the leading cause of death 
worldwide. Collateral growth, however, is limited by genetic factors, age and physiological 
restrictions. Therefore, a better molecular knowledge is necessary in order to identify molecular 
targets to promote a faster and stronger growth of collateral arteries in patients. 
Proliferative smooth muscle cells (SMCs) are key players of collateral enlargement and wall 
remodelling, and thus interesting targets for therapeutic arteriogenesis. The induction of SMC 
de-differentiation towards proliferative SMCs is accompanied by changes in K+ channel 
composition and activity. The voltage-gated K+ channel KV1.3 and the Ca2+-gated K+ channel 
KCa3.1 are upregulated in cultured SMCs and in proliferative SMCs of neointima hyperplasia 
models. Moreover, their blockade impairs SMC proliferation. However, their role in 
arteriogenic SMC proliferation has not been investigated so far. Furthermore, the signalling 
pathways involved in KV1.3 and KCa3.1-mediated SMC proliferation are still under research. 
Using the murine femoral artery ligation (FAL) model of arteriogenesis, the expression of both 
channels in SMCs of resting and growing collateral arteries of wild type mice was first verified 
through histological analysis. The specific role of KV1.3 and KCa3.1 channel on arteriogenesis 
was then investigated employing pharmacological channel blockade with 5-(4-Phenoxybutoxy) 
psoralen (PAP-1) and TRAM-34 (1-[(2-chlorophenyl)diphenyl-methyl]-1H-pyrazole), 
respectively, giving a special focus on SMC proliferation. Furthermore, in vitro experiments 
with primary mouse artery SMCs (MArSMCs) were performed in parallel, so as to further 
investigate channel involvement in receptor tyrosine kinase engagement and downstream 
mitogen-activated protein kinase (MAPK) signalling pathway. 
The results showed that KCa3.1 blockade with TRAM-34 hindered MArSMCs proliferation in 
vitro but hold no significant effects on SMC proliferation in growing collateral arteries in vivo. 
Interestingly, its upregulation in endothelial cells two days after FAL may reflect a role of the 
channel in endothelial-derived hyperpolarization factor-mediated vasodilation. 
In contrast, an impairment on SMCs proliferation both in MArSMCs as well as in vivo was 
detected under KV1.3 blockade with PAP-1. Mice treated with PAP-1 displayed thinner 
collateral arteries and lower Bromodeoxyuridine (BrdU)+ SMCs ratios seven days after FAL, 
compared to control mice. Kv1.3 was constantly expressed in resting and growing collateral 
arteries, however, its function might be regulated at the level of channel activity or subcellular 
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localization. Moreover, since the channel is expressed in resting collateral arteries and channel 
blockade resulted in an absence of repression of the contractile marker alpha-smooth muscle 
actin (α-SMA) as early as 12h after FAL, a role of the channel in SMC phenotypic modulation 
was hypothesized. Interestingly, at the same time point, a repression at the mRNA level of the 
growth factor receptors fibroblast growth factor receptor 1 (FGFR-1) and platelet-derived 
growth factor receptor ß (PDGFR-ß) as well as the pro-mitogenic transcription factor early 
growth response protein 1 (EGR-1) was stated under KV1.3 blockade with PAP-1. Moreover, 
this repression was observed in MArSMCs too. Further in vitro experiments assessing the 
possible involvement of KV1.3 on receptor tyrosine kinase (RTK) signalling discarded a role of 
the channel upstream extracellular signal-regulated kinase (ERK) since ERK phosphorylation 
was not affected by KV1.3 blockade following stimulation with growth factors-enriched growth 
medium.  
Intriguingly, a strong detection at the nucleus beside its conventional cell membrane 
localization was noticed in MArSMCs cultured with growth factors-enriched growth medium. 
Since nuclear KV1.3 is able to regulate transcription factor activation and abundance in cancer 
cells, a role of the channel in nuclear gene expression regulation was ascribed in MArSMCs 
too. An in silico analysis and literature research revealed the transcription factor Sp1 as a 
common transcription factor for Fgfr1, Pdgfrb and Egr1. Moreover, Sp1 blockade with 
Mithramycin A indeed downregulated Fgfr1 and Egr1 in MArSMCs following stimulation with 
growth factors-enriched growth medium. Intriguingly, Kv1.3 blockade with PAP-1 repressed 
Sp1 expression in MArSMCs. Hence, the transcription factor Sp1 might be behind KV1.3-




Arteriogenese bezeichnet das Wachstum von Kollateralarterien zu physiologischen Bypässen 
und stellt eine natürliche Alternative zur Gefäßchirurgie bei obstruktiven Gefäßerkrankungen 
dar, die Haupttodesursache weltweit. Allerdings beeinträchtigen genetische Faktoren, Alter und 
physiologische Einschränkungen das Wachstum von Kollateralarterien in Patienten. Ein 
besseres molekulares Verständnis der Arteriogenese ist daher notwendig um neue molekulare 
Angriffspunkte zu identifizieren und ein schnelleres und ausgeprägteres Kollateralwachstum in 
Patienten zu fördern.  
Proliferierende glatte Gefäßmuskelzellen (smooth muscle cells, SMCs) spielen eine 
Schlüsselrolle bei der Erweiterung und dem Wandaufbau von Kollateralarterien und sind aus 
diesem Grunde ein interessanter Angriffspunkt für die therapeutische Arteriogenese. Die 
Induktion der SMC Dedifferenzierung zu proliferierenden SMCs wird unter anderem von 
Veränderungen in der K+-Kanalzusammensetzung und -Aktivität begleitet. Der 
spannungsgesteuerte K+-Kanal KV1.3 und der Ca2+-gesteuerte K+-Kanal KCa3.1 sind 
überexprimiert in kultivierten SMCs sowie in proliferierenden SMCs bei Neointima 
Hyperplasie Modellen. Ferner beeinträchtigt die Blockierung dieser Kanäle die Proliferation 
von SMCs. Nichtsdestotrotz wurde ihre Rolle bei der arteriogenen SMC Proliferation bis jetzt 
nicht erforscht. Des Weiteren sind die Signalwege, die an der KV1.3 and KCa3.1 gesteuerten 
SMC Proliferation beteiligt sind, noch Gegenstand der aktuellen Forschung. 
Unter Verwendung des Arteriogenese-Modells der murinen Femoralarterienligatur (FAL) 
wurde die Expression der beiden Kanäle in SMCs bei ruhenden und wachsenden 
Kollateralarterien von Wildtyp-Mäusen durch histologische Analyse überprüft. Die spezifische 
Rolle von KV1.3 and KCa3.1-Kanälen bei der Arteriogenese wurde dann mittels 
pharmakologischer Kanalblockierung unter Verwendung von 5-(4-Phenoxybutoxy) psoralen 
(PAP-1) beziehungsweise TRAM-34 (1-[(2-chlorophenyl)diphenyl-methyl]-1H-pyrazole) mit 
Fokus auf der SMC Proliferation untersucht. Des Weiteren wurden in vitro Experimente mit 
primären Mausarterien-SMCs (MArSMCs) parallel durchgeführt, um die Beteiligung der 
Kanäle an den Signalwegen der Tyrosin-Rezeptor-Kinase-Aktivierung (RTK) und der 
stromabwärts gelegenen Mitogen-aktivierten-Protein-Kinase (MAPK) zu untersuchen.  
Die Ergebnisse zeigten, dass obwohl eine KCa3.1 Blockierung mit TRAM-34 die Proliferation 
von MArSMCs in vitro behinderte, kein besonderer Effekt auf die in vivo SMC Proliferation 
bei wachsenden Kollateralarterien beobachtet werden konnte. Interessanterweise könnte die 
erhörte KCa3.1 Proteinmenge in Endothelzellen zwei Tage nach der FAL auf eine Rolle bei der 
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durch den endothelialen hyperpolarisierenden Faktor (endothelium-derived hyperpolarizing 
factor, EDHF) verursachten Vasodilatation hinweisen.  
Im Gegensatz dazu konnte eine gestörte SMC Proliferation sowohl in MArSMCs als auch in 
vivo bei der KV1.3 Blockierung mit PAP-1 nachgewiesen werden. Mäuse die mit PAP-1 
behandelt wurden zeigten gegenüber den Kontrollmäusen schmalere Kollateralarterien und 
niedrigere Bromodeoxyuridine (BrdU)+ SMC Verhältnisse sieben Tage nach der FAL. Obwohl 
KV1.3 in ruhenden und wachsenden Kollateralarterien konstant exprimiert ist, könnte seine 
Funktion jedoch auf der Ebene der Kanalaktivität oder subzellulärer Orte reguliert sein. Da der 
Kanal in ruhenden Kollateralarterien exprimiert ist und 12 Stunden nach der FAL die 
Kanalblockierung nicht zu einem Aussetzen der Repression des kontraktilen Markers alpha-
smooth-muscle Aktin (α-SMA) führte, wurde angenommen dass der Kanal bei der 
phänotypischen Modulation der SMCs eine Rolle spielt. Interessanterweise wurde zur gleichen 
Zeit eine Repression auf mRNA-Ebene des Fibroblast-Wachstumsfaktor-Rezeptors-1 (FGFR-
1) und Plättchen-gebundenen-Wachstumsfaktors-ß (PDGFR-ß) sowie des Pro-Mitogenetischen 
Transkriptionsfaktors Early Growth Factor 1 (EGR-1) bei einer KV1.3 Blockierung mit PAP-1 
festgestellt. Des Weiteren wurde diese Repression auch in MArSMCs beobachtet. Weitere in 
vitro Experimente, die die mögliche Beteiligung von KV1.3 beim Rezeptor-Tyrosin-Kinase 
(RTK)-Signalweg ermitteln sollten, schlossen eine Rolle der kanalaufwärts gelegenen 
Extrazellulären-signalregulierten-Kinase (ERK) aus, da die ERK-Phosphorylierung nach 
Stimulierung mit einem Wachstumsfaktoren-angereicherten Nährmedium durch eine Kv1.3 
Blockierung  nicht beeinträchtigt wurde. 
Faszinierenderweise konnte neben der konventionellen Zellmembranlokalisierung des Kv1.3 
dieser auch im Kern von MArSMCs, die mit Wachstumsfaktoren angereichertem Nährmedium 
kultiviert wurden, detektiert werden. Da KV1.3 im Zellkern in der Lage ist die Aktivierung und 
Menge von Transkriptionsfaktoren in Krebszellen zu regulieren, wurde dem Kanal auch eine 
Rolle bei der Kontrolle der nuklearen Genexpression in MArSMCs zugeschrieben. Eine in 
silico Analyse, sowie eine Literatur-Recherche zeigten, dass Specifity protein 1 (Sp1) ein 
gemeinsamer Transkriptionsfaktor für Fgfr1, Pdgfrb und Egr1 ist. Außerdem verhinderte eine 
Sp1 Inhibition mit Mithramyzin A tatsächlich Fgfr1 und Egr1 Expression in MArSMCs nach 
Stimulierung mit einem Wachstumsfaktoren-angereichertem Nährmedium. Zudem 
unterdrückte die KV1.3 Blockierung mit PAP-1 die Sp1 Expression in MArSMCs. Das heißt, 
dass der Transkriptionsfaktor Sp1 zumindest hinter der KV1.3 gesteuerten 
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FAL Femoral artery ligation 
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FN Fibronectin 
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MAPK Mitogen-activated protein kinase 
MArSMCs Mouse artery SMCs 
MCP-1 Monocyte chemoattractant protein 1 
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PFA Paraformaldehyde 
PM Phenotypic modulation 
qPCR Quantitative polymerase chain reaction 
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RTK Receptor tyrosine kinase  
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SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
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siRNA Small interference RNA 
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Sp1 Specificity protein 1 
SRF Serum response factor  
TBST Tris-buffered saline 1 % tween 20 
TCF Ternary complex factor  
TF Transcription factor 
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TRPV4 
Ca2+-channel transient receptor potential cation channel, subfamily V, 
member 4  
UBTF1 Upstream binding transcription factor 1 
VCAM-1 Vascular cell adhesion molecule 1  
VEGF-A Vascular endothelial growth factor  
VSD Voltage-sensing domain 





I am indebted to my supervisor PD Dr rer. nat. Elisabeth Deindl for giving me the chance to 
complete my PhD in such an exciting field of cardiovascular physiology. I appreciate her 
scientific advice and the freedom she gave me to pursue own ideas. I am also grateful for the 
helpful suggestions regarding the writing of this manuscript. 
I would like to thank Prof Dr Ulrich Pohl for his manifested interest in this project and for 
allowing me to perform the experiments at the Walter Brendel-Centre.  
To Prof Dr Klaus T. Preissner from the Justus-Liebig-University in Giessen for the financial 
support at the end of the experimental work. 
I would like to extend my gratitude to all my colleagues in the lab for the work together and the 
nice atmosphere these years! I thoroughly enjoyed learning from Dr Omary Chillo the femoral 
artery ligation model and LDI technique and passing this knowledge to the new PhD students. 
To Manuel Lasch, Thomas Lautz and Dr Eike Kleinert for offering assistance whenever needed 
it. I am also grateful to Christine Csapò for her technical assistance and for taking care of so 
many organization things. A special thanks to Dr Eike Kleinert for his encouragement and 
support. 
I strongly profited from the cooperative, friendly and international atmosphere at the WBC and 
I would like to say thank you to many people: Claudia Faney for her technical advices at the 
cell culture, Dr Michael Lorenz and Stefan Schmitt, for answering so many technical questions, 
Dr Julian Kirsch and Dr Holger Schneider for the scientific discussions and finally Dr Bettina 
Pitter, Dr Katharina Nekolla, Dr Sabine Sellner, Dr. Gabriele Zuchtriegel, Dr Louise Ince and 
Justin Chen for their help and encouragement. 
I am deeply grateful to Alba de Juan, not only for her help with fluorescence microscopy but 
even more for the many scientific discussions, for being there in the bad moments and enjoying 
the good results as if they were her own ones. For making Mondays more exciting and for the 
therapeutic swimming hours!  
Special thanks to Dr Xiaoling Liang for her personal support and encouragement before and 
during the thesis. For our cooking times together and long dinner conversations, and phone 
calls! I am indebted to her for the valuable suggestions regarding the writing of this thesis.  




Finally, I want to thank the most important people in my life, my family. A mis padres, hacia 
los que siento un inmenso agradecimiento por enseñarme, alentarme y apoyarme 
incondicionalmente. My parents, my siblings and brother’s family have always been a source 
of love, wellness and trust. Without this fortifying family entourage, I would not be where I am.  
My children have been a source of energy and inspiration during the writing of this thesis. But 
this end would not have been possible without the comprehension, generosity and love of my 
husband, Markus. To him, to our family, I dedicate this work. 
  
Acknowledgments 
137  
